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Abstract 
Jembrana disease is an acute and severe disease of Bali cattle (Bos javanicus) 
endemic in Indonesia that is caused by a bovine lentivirus designated Jembrana 
disease virus (JDV).  Previous studies have demonstrated that it is possible to 
induce a protective immunity against the disease by immunisation with a crude 
whole virus vaccine prepared from the tissues of infected cattle.  This vaccine has 
been demonstrated to ameliorate the clinical signs of disease resulting from 
exposure to virus infection but a safer vaccine amenable to commercial 
production techniques is required.  
JDV, like all lentiviruses, encodes a transcriptional trans-activator Tat protein that 
is encoded from one or both of two exons of the tat gene.  Tat is particularly 
essential for virus replication and it was hypothesised that the induction of an 
immune response in cattle against JDV Tat may effect protection against virus 
infection.  Investigations were therefore conducted on JDV Tat to provide basic 
information on the protein that would enable it to be further investigated as a 
potential immunogen for incorporation into vaccines for the control of Jembrana 
disease.  
Analysis of tat transcripts obtained from tissues of cattle infected with three 
strains of JDV suggested that, during the acute clinical disease, Tat produced at 
this stage of the disease process was translated from the first coding exon only.  
Nucleotide variation in this exon, which would have translated into amino acid 
variations in the Tat protein, was evident especially between strains from 
geographically different regions of Indonesia.  There was; however, conservation 
of the essential functional domains of cysteine-rich, core and basic regions, which 
suggested immunity to a single Tat protein might protect against infection by 
heterologous strains.  Subsequent studies on Tat reported in the thesis therefore 
concentrated on the protein encoded by tat exon 1 of a single strain of JDV. 
   ii 
The exon 1 of tat was cloned into the pGEX vector and recombinant Tat 
expressed in Escherichia coli.  Methods for the purification of the expressed 
protein were developed.  Immunogenicity of the recombinant protein was initially 
demonstrated by inoculation of the protein into a sheep which developed a high 
titred specific antibody response.  Antibodies induced by this recombinant protein 
recognised native Tat proteins produced by three JDV strains in Bali cattle and 
provided a valuable reagent for the subsequent detection of Tat in vitro and in 
vivo. 
Aspects of the antibody response to Tat were determined in cattle that had been 
infected naturally or experimentally with JDV, and compared with the levels of 
antibody to the immunodominant capsid protein.  Tat antibodies were detected in 
23 % of 128 Bali cattle from Jembrana disease-endemic areas of Indonesia; in all 
these cattle, evidence of previous virus infection had been demonstrated by 
detection of antibody to the JDV capsid protein by Western blot analysis.  In cattle 
experimentally infected with JDV, low levels of serum antibody to Tat were 
detected by Western blot in the first month post-infection but the levels of 
antibody then decreased; levels of antibody to the JDV capsid protein increased 
over the 6-month observation period following infection.  The detection of Tat-
antibody soon after the acute clinical disease suggested that this protein is 
secreted extracellularly during JDV infection in cattle.  In contrast to the antibody 
response to Tat in JDV-infected cattle, an apparently greater antibody response 
to Tat was induced by injection of recombinant Tat in Bali cattle.  The strong 
antibody response resulting from inoculation of the recombinant Tat and low 
levels of Tat antibody in animals that had been naturally or experimentally 
infected with virus suggested there might be a conformational difference in the 
recombinant and native Tat protein and that the native protein was a poor 
immunogen, or that the levels of Tat in infected cattle were too low to induce a 
strong antibody response.   
   iii 
As an alternative means of inducing an immune response to JDV Tat, perhaps 
one associated with a greater cell-mediated rather than an antibody response, a 
candidate tat DNA vaccine was produced by insertion of tat exon 1 into a DNA 
vaccine vector.  Transfection of this naked DNA plasmid into mammalian cells 
induced the expression of a functional Tat protein which maintained antigenicity.  
The results suggested this construct merits further animal studies attempting to 
induce a protective immune response against Jembrana disease in cattle.  A 
method of assaying the trans-acting function of Tat was also developed which will 
have application for quality control procedures for large-scale production of tat 
DNA vaccine.  iv 
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Chapter 1   
General Introduction 
Jembrana disease virus (JDV) is a member of the Lentivirus genus of the family 
Retroviridae, which causes an acute and severe infection in Bali cattle that is 
endemic in parts of Indonesia.  A high plasma viral load has been shown to 
coincide with the acute disease syndrome that occurs soon after infection.  An 
inactivated virus vaccine prepared from infected spleen extract has been 
produced and is used within Indonesia for the control of the disease (Hartaningsih 
et al., 2001) and shown to ameliorate the acute disease process.  Although this 
vaccine has many disadvantages its use has demonstrated that vaccination is a 
feasible method of control of the disease.  An alternative safer and higher quality 
vaccine is required, and the studies reported in this thesis were conducted in 
support of this objective. 
In addition to the gag, pol, and env genes characteristic of retroviruses, the 
lentiviruses encode several accessory and regulatory genes.  The tat gene 
encodes a regulatory protein Tat, a potent viral transcriptional trans-activator that 
is absolutely required for virus replication.  Because of its important biological and 
pathological roles in Human immunodeficiency virus (HIV) infection (Huigen et al., 
2004), the Tat protein has been considered as an attractive candidate protein for 
the development of Human immunodeficiency virus 1 (HIV-1) vaccines.  The 
principal aim of the investigations reported in this thesis was to investigate the 
potential of using JDV Tat as an immunogen for the control of Jembrana disease.  
This required preliminary in vitro investigation of the transcription and translation 
of tat and the construction of appropriate recombinant Tat proteins and naked tat 
DNA constructs that might be trialed as potential vaccines. 
Preliminary to this investigation, a review of the literature relating to the 
lentiviruses in general and particularly to bovine lentiviruses and their associated   2 
diseases was conducted and is provided in Chapter 2.  This provided background 
to the investigation and the relevance and direction of the research.  Features of 
the lentivirus genome, including the various gene products are described in the 
review, with particular emphasis on the role of tat and the encoded Tat in the 
pathogenesis of disease.  The potential use of Tat as a vaccine component is 
discussed with special reference to investigations that have been conducted with 
HIV-1.  These were reviewed as they provide an insight into the potential for 
induction of an immune response to JDV Tat as a means of controlling Jembrana 
disease in cattle. 
The mechanism of tat expression in infected animals was considered important in 
determining the probable characteristics of the expressed Tat protein, and in 
understanding the pathogenesis of Jembrana disease.  Investigations of tat 
transcription in animals with acute Jembrana disease were conducted and are 
reported in Chapter 3.  These studies included an investigation of possible tat 
sequence variation in 3 different JDV strains as this was considered important in 
defining possible antigenic variation in Tat. 
An antibody response in infected cattle has been demonstrated using whole virus 
as an antigen in serological assays (Hartaningsih et al., 1994); the antibodies 
detected were considered to be primarily those against the immunodominant 
capsid protein of JDV.  Evidence for the occurrence of antibodies in JDV-infected 
cattle that are reactive to Tat has not been reported.  To facilitate such 
investigations into the antibody response to Tat, and to provide a potential Tat 
immunogen for induction of a protective immunity against Jembrana disease in 
cattle, a bacterially expressed recombinant Tat fused to glutathione S-transferase 
was produced.  These studies on the immunogenicity and antigenicity of JDV Tat 
are reported in Chapter 4. 
DNA vaccines are thought to result in more efficient antigen presentation to the 
immune system and a greater T-cell-mediated (rather than antibody-mediated) 
immune response than protein-based vaccines. Hence a tat DNA construct was 
developed and investigations of its expression and function in vitro were   3 
conducted.  An assay to determine the functional activity of expressed Tat 
proteins was developed to facilitate these studies.  These preliminary studies on 
the development of a JDV tat DNA vaccine candidate are presented in Chapter 5 
A general discussion of the investigations conducted and the results obtained in 
Chapter 3, 4 and 5 is provided in Chapter 6.  4 
Chapter 2   
Review of the Literature 
This chapter reviews the characteristics of retroviruses with emphasis on 
lentiviruses, particularly the role of the transcriptional trans-activator protein (Tat) 
in lentivirus replication and pathogenesis of lentivirus-associated disease.  In 
addition, the literature describing the immune response to Tat and the use of Tat 
as a vaccine to control lentivirus infection are discussed with special reference to 
the Human immunodeficiency virus type-1 (HIV-1).   
The family Retroviridae 
Retroviruses comprise a large and diverse group of ribonucleic acid (RNA)-
containing viruses that infect primarily vertebrates (Coffin, 1992a).  The hallmark 
of the family is that replication involves an essential reverse transcription of the 
virus RNA into a linear double-stranded (ds) DNA and the subsequent integration 
of this dsDNA into the genome of the cell (Baltimore, 1970; Temin & Mizutani, 
1970; Temin, 1976).   
Typical retroviruses are enveloped particles ranging from 80 to 130 nm in 
diameter with an internal conical or spherical shaped core or capsid (CA) that is 
surrounded by matrix (MA) protein.  The core contains the viral RNA genome 
stabilised by a nucleocapsid (NC) protein, cellular tRNA primer and several viral 
encoded enzymes including reverse transcriptase (RT), integrase (IN) and 
protease (PR) (Vogt, 1997).  The envelope is a lipid bilayered membrane that is 
derived during maturation of the virus from the host cell membrane during a 
budding process, requiring modification of the cell membrane by insertion of two 
viral-coded glycoproteins, a surface (SU) glycoprotein and a trans-membrane 
(TM) glycoprotein.     5 
The retrovirus genome consists of two identical linear, positive-sense, single-
stranded (ss) RNA molecules non-covalently joined as a dimer at the 5` end, that 
are capped and polyadenylated like cellular mRNA (Berkowitz et al., 1996).  The 
genome of prototypical retroviruses contains the major genes, gag, pro, pol and 
env in that order, which encode for precursor polyproteins that are subsequently 
cleaved into the various structural and non-structural proteins of the virus.  In 
some retroviruses pro is part of either gag or pol.  Flanking the coding genes are 
untranslated redundant (R) sequences at both termini along with adjacent unique 
(U) sequences U5 and U3, positioned at the 5’ and 3’ ends of the RNA genome, 
respectively.  In the proviral (DNA) form the flanking regions are known as long 
terminal repeats (LTR), each composed of U3-R-U5 (Vogt, 1997). 
Retroviruses were originally classified into four morphologically distinct forms 
depending on the features of the core detected by electron microscopy, and were 
designated as types A, B, C and D (Coffin, 1992a; Luciw & Lesing, 1992).  
Viruses were also grouped according to differences in pathogenicity into three 
subfamilies: Oncovirinae, Lentivirinae and Spumavirinae (Matthews, 1982).  
However, more recent analysis of the genome has resulted in reclassification of 
the viruses into seven genera: Alpharetrovirus, Betaretrovirus, Gammaretrovirus, 
Deltaretrovirus, Epsilonretrovirus, Spumavirus and Lentivirus (van Regenmortel et 
al., 2000).   
The first five genera are often referred to as oncogenic retroviruses as they are 
associated with a variety of leukaemias and sarcomas in a wide variety of animal 
species.  The Spumaviruses, also known as “foamy” viruses, are highly cytopathic 
inducing marked syncytium formation and vacuolation in many types of cells in 
vitro and although they are known to cause persistent infection of several animal 
species they have not been definitively linked to any specific disease (Meiering & 
Maxine L. Linial, 2001; Rosenberg & Jolicoeur, 1997).  The several species of the 
genus Lentivirus cause a variety of syndromes including immunodeficiencies and 
neurological disorders in primates and feline species, chronic pneumonia, arthritis 
and encephalitis in goats and sheep, and anaemia in equine species (Desrosier, 
2001; Rosenberg & Jolicoeur, 1997).   6 
Characteristic of the genus Lentivirus 
The lentiviruses infect a diverse array of mammalian hosts, and can be 
categorised into five different groups accordingly: Primate lentivirus group 
(Human immunodeficiency virus [HIV-1 and -2] and Simian immunodeficiency 
virus [SIV]), Feline lentivirus group (Feline immunodeficiency virus [FIV] and 
Puma lentivirus [PLV]), Equine lentivirus group (Equine infectious anaemia virus 
[EIAV]), Bovine lentivirus group (Bovine immunodeficiency virus [BIV] and 
Jembrana disease virus [JDV]), Ovine/caprine lentivirus group (Maedi-visna virus 
[MVV] and Caprine arthritis-encephalitis virus [CAEV]).   The relationship between 
lentiviruses has been established molecularly by comparing the conserved pol 
gene particularly the RT coding region (Li et al., 1995b; Xiong & Eickbush, 1990).  
Figure 2.1 shows a phylogenetic relationship of several lentiviruses based on the 
analysis of their complete pol genes encompassing PR, RT and IN coding 
regions. 
Lentiviruses have a distinctive morphology.  Assembly of the lentivirus particles 
and budding occurs simultaneously at the plasma membrane of the infected host 
cell, similar to type C virion, leading to immature virions with hollow conical cores.  
The mature virion has an envelope with visible projections, and the capsid is 
arranged into a distinctive truncated cone-shaped rather than central and 
spherical as a C-type (Desrosier, 2001).  In addition, lentiviruses differ from the 
prototypic simple retroviruses in that their genome and replication cycle is more 
complex (Vogt, 1997).   
Genomic organisation and gene products of lentiviruses 
Lentiviruses have a similar genomic organisation that differentiates from that of 
other genera, but individual lentiviruses differ in the degree of complexity of the 
genome.  Illustrated schematically in Figure 2.2, the genome contains the three 
major open reading frames (ORFs) common to all retroviruses; gag, pol and env; 
pro is in-frame and contiguous with pol.  In addition, lentiviruses carry a variable 
number of distinctive regulatory and accessory genes, most of which are found    7 
 
Figure 2.1.  Phylogenetic tree of lentiviruses.  The genetic relationship of 
several lentiviruses was analysed based on complete pol gene sequences 
downloaded from GeneBank. The sequences were aligned and the tree 
was built using several programs accessible at ANGIS.  BIV, Bovine 
immunodeficiency virus; JDV, Jembrana disease virus; EIAV, Equine 
infectious anaemia virus; MVV, Maedi-visna virus; CAEV, Caprine arthritis 
encephalitis virus; FIV, Feline immunodeficiency virus; PLV, Puma 
lentivirus; HIV-1, Human immunodeficiency virus 1; HIV-2, Human 
immunodeficiency virus 2; SIVagm, Simian immunodeficiency virus 
(African green monkey isolate); SIVcpz, SIV (chimpanzee isolate); 
SIVmac, SIV (macaque isolate); SIVmnd, SIV (mandrill isolate); SIVsmm, 
SIV (sooty mangabey monkey isolate). 
   8 
 
 
Figure 2.2.  Genomic organisation of lentiviruses.  Lentiviruses are complex 
retroviruses with accessory and regulatory genes in addition to gag, pol, 
pro and env that form simple retroviruses such as murine leukemia virus 
(MuLV). The pro is not indicated as it is in frame with the pol gene. 
   9 
overlapping the central region between the end of pol and the beginning of env; 
and in several viruses also  post-env (Vogt, 1997). 
The most complex of the lentiviruses, HIV-1, contains tat and rev genes encoding 
viral proteins with regulatory functions and genes vif, vpu, vpr, and nef with 
accessory/auxiliary functions (Emerman & Malim, 1998; Frankel & Young, 1998; 
Freed & Martin, 2001; Piguet & Trono, 1999; Pollard & Malim, 1998).  The 
organisation of these regulatory and accessory genes of HIV-1 with the respective 
encoded proteins in the virion structure is depicted in Figure 2.3. 
 
 
Figure 2.3.  Genomic and structural organisation of HIV-1.  Positions of 
the major viral proteins, the lipid bilayered membrane, and the diploid 
genomic RNA are indicated. Reproduced from Frankel & Young (1998). 
 
The gag ORF encodes a 55 kilodalton (kDa) Gag (group-specific antigen) 
precursor polyprotein (Pr55
Gag) that is proteolytically cleaved into internal 
structural matrix protein of 17 kDa, the capsid protein of 24 kDa, the nucleocapsid 
protein of 7 kDa and the p6 (Swanstrom & Wills, 1997).  The MA protein is 
myristoylated at the N-terminus, which mediates the binding of the Pr55
Gag to the   10 
plasma membrane of the host cell giving it a key role in the assembly of infective 
virus (Freed, 1998).  Once cleaved, the MA protein is located in the matrix 
between the capsid and viral envelope.  The CA protein is the major structural 
protein of the virus; it forms the protein coat surrounding the genome and is an 
immunodominant viral protein (Coffin, 1992b).  The NC protein has an affinity for 
and is associated with the viral RNA genome and is required for packaging RNA 
into the virion.  The carboxyl-terminal p6 domain is required for virion release 
(Gottlinger et al., 1991; Huang et al., 1995) and for efficient incorporation of the 
viral accessory protein Vpr into virions (Kondo & Gottlinger, 1996). 
The pol region directs the synthesis of three virion-associated enzymatic proteins, 
the protease, reverse transcriptase and integrase enzymes, and is translated as 
an extended Gag-Pol polyprotein (Pr160
Gag-Pol) following a ribosomal frame-shift 
event (Vogt, 1997).  The PR, which is active in a homodimeric form (Navia et al., 
1989), is responsible for all the proteolytic cleavage of the precursor polyproteins, 
generating the mature Gag and Pol proteins during assembly and maturation of 
the viral particles (Mervis et al., 1988).  The RT has both RNA-dependent DNA 
polymerase and RNase H activities that are required to convert the ss viral RNA 
genome into dsDNA upon entry into host cells.  RT binds the tRNA primer 
(essential for initiation of DNA synthesis shortly after infection), and a separate 
domain on this protein functions as a ribonuclease specific for RNA-DNA hybrids 
(RNase H).  The biologically active form of HIV-1 RT is a heterodimer composed 
of a 51-kDa and a 66-kDa subunit (p51/p66).  RT is assembled into virions as part 
of a precursor Gag-Pol polyprotein which is generated during proteolytic cleavage 
by the pol-encoded protease (PR) (Katz & Skalka, 1994; Oroszlan & Luftig, 1990; 
Telesnitsky & Goff, 1997).  The p66 subunit contains the DNA polymerase and 
RNase H domains, while the p51 subunit lacks the RNase H domain (Hizi et al., 
1988; Prasad & Goff, 1989).  Each virion contains 10–20 molecules of RT which 
are loosely associated with the nucleoprotein core.  IN is a separate protein 
derived from the carboxyl terminus of the Gag-Pol polyprotein that catalysis the 
irreversible integration of the viral cDNA, generated by reverse transcription of the 
viral RNA genome, into host cell DNA (Coffin, 1979; Coffin, 1992b).     11 
The env ORF encodes a polyprotein, gp160, which is post-translationally modified 
in the endoplasmic reticulum via cleavage and glycosylation events mediated by 
cellular enzymes (Hallenberger et al., 1997) to produce two glycoprotein subunits, 
a surface (SU) gp120 molecule and trans-membrane (TM) gp41 (Coffin, 1992b).  
The SU is located on the external surface of the viral membrane and it is 
responsible for the binding of the virus to host cell receptors.  The TM is 
embedded into the lipid bilayer envelope and anchors the SU domain to the 
membrane and facilitates the fusion of viral and cell membranes during entry.  
These envelope glycoproteins are noncovalently linked as heterodimers that 
associate further into trimers (Weiss et al., 1990) to form the short spikes on the 
surface of the virion.  The glycoproteins are the primary targets of the neutralising 
antibody response and are the determinants of tropism and virulence (Coffin, 
1992a).  
The accessory proteins Vif, Vpr and Vpu appear to orchestrate a variety of 
functions.  They are not required for viral growth in vitro but are essential for
 viral 
replication and pathogenesis in vivo (Trono, 1995).  For example, infection of 
rhesus
 monkeys with a vpr- and vpx-defective SIV produced a low
 virus burden 
and they did not develop immunodeficiency disease (Gibbs et al., 1995).  The 
viral infectivity factor (Vif) of HIV-1 is encoded by an essential accessory gene 
that is conserved in all lentiviruses with the exception of EIAV (Oberste & Gonda, 
1992).  Vif enhances the infectivity of virus particles produced in non-permissive 
cells and the stability of viral DNA, and it also may play a role in virion assembly 
(Simon & Malim, 1996).  Vpr (viral protein R) assists in the transport of viral 
components into the nucleus promoting productive infection in non-dividing cells 
and it may induce an arrest of cell cycle progression in the G2 phase preventing 
the subsequent events of mitosis and division of HIV-1-infected cells, which 
provides a replication advantage for the virus (Cohen, 1996; Frankel & Young, 
1998).  Both Vif and Vpr are incorporated into the virion particles.  The Vpu is a 
small integral membrane protein that promotes degradation of intracellular CD4 
molecules, facilitating transfer of newly synthesised Env molecules to the cell   12 
membrane for virion assembly, and it can also down-regulate MHC class proteins 
and stimulate virion release (Frankel & Young, 1998). 
Nef (negative factor) is a protein unique to the primate lentiviruses that is 
incorporated into the virion core.  Nef is expressed rapidly and abundantly 
following infection in vitro and in vivo.  Nef is a major virulence factor in vivo: it 
down-regulates the CD4 receptor by binding to the cell surface, as well as MHC 
class I levels, which allows HIV-1 infected cells to escape from cytotoxic T-
lymphocyte-mediated lysis (Collins et al., 1998); extracellular Nef may also 
stimulate latently infected cells into productive HIV-1 infection. 
The regulatory genes tat and rev each consist of two exons generated by double 
or multiple splicing of viral RNA.  Rev is a small, 13-kDa sequence-specific RNA-
binding phosphoprotein that shuttles between the nucleus and the cytoplasm to 
promote transport of unspliced and singly spliced viral RNA from the nucleus to 
the cytoplasm.  It binds to the rev-responsive element (RRE), a cis-acting 
sequence within the env gene (Felber et al., 1990), permitting expression of viral 
structural proteins.  Tat activates the viral promoter at the 5’ LTR, leading to more 
efficient transcription of the proviral genome.  The Tat protein recruits cellular 
proteins and binds to the trans-acting response element (TAR), a cis-acting 
sequence in the LTR, to upregulate transcription (Arya et al., 1985).  The action of 
Tat thus forms a positive-feedback mechanism that greatly accelerates viral 
transcription once a threshold level has been reached.  Interaction of Tat with 
TAR is indispensable for viral replication.  The structure and functions of Tat was 
reviewed in more detail in separate sections. 
Bovine immunodeficiency virus  
In terms of genome organisation, BIV is the most complex non-primate lentivirus 
(Garvey et al., 1990; Gonda et al., 1994; Oberste et al., 1993).  Besides genes 
encoding obligate retrovirus Gag, Pol, and Env polyproteins, BIV has genes tat, 
rev, vif, vpw and vpy located in the central region of the genome, and tmx located 
in the 3’ end of env (Figure 2.2) that encode six accessory proteins, designated   13 
Tat, Rev, Vif, Vpw, Vpy, and Tmx, respectively.  These proteins play a critical role 
in the viral replication cycle and contribute significantly to the pathogenesis of 
BIV.   
BIV resembles HIV in its structural, genomic, antigenic, and biological 
characteristics. The predicted and/or known gene products of the accessory 
genes vif and tat, as well as those of the structural genes gag, pol and env have 
some sequence similarity to their counterparts in HIV-1 (Battles et al., 1992). 
Characterisation of the gag gene and the encoded 53 kDa precursor protein 
(Pr53
Gag) was reported by (Battles et al., 1992; Tobin et al., 1994).  The major BIV 
53 kDa precursor protein (Pr53
Gag) was cleaved into MA, CA, and NC gag 
proteins of p16, p26, and p13, respectively.  In addition to BIV Pr53gag, the major 
gag precursor, two other gag-related precursors of 170 and 49 kDa were 
identified, as were several alternative gag cleavage products.  Mono-specific 
antisera to HIV-1 CA (p24) and NC (p7) proteins cross-reacted with analogous 
BIV proteins which aided in the identification (Atkinson et al., 1992; Battles et al., 
1992). 
There are also significant differences in the genomes of the BIV and HIV.  In BIV, 
the genome locations and other conserved traits in the predicted products of rev 
and vpw and vpy ORFs suggest that they are probably analogous to rev and vpr, 
vpu, and vpx genes, respectively, in the primate lentiviruses.  The function of the 
BIV tmx gene is not known, but it resides in the 3' end of the genome in a position 
analogous to the nef gene of primate lentiviruses. 
Replication cycle of lentiviruses 
Unique among animal viruses, retroviral replication proceeds
 through an obligate 
recombination step with host cell DNA and the major steps are depicted 
schematically in Figure 2.4.  The early phase involves attachment of viruses via 
surface glycoproteins to the main cellular receptor CD4 followed by interaction 
with a co-receptor and subsequent fusion with the host cell.  The viral ssRNA    14 
 
Figure 2.4.  Major steps in the replication cycle of a typical retrovirus.  
Reproduced from Flügel (1993) 
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genome is subsequently converted into dsDNA by the viral enzyme reverse 
transcriptase and transported into the nucleus where the viral integrase mediates 
the integration of the viral DNA into the host genome.  In the late phase proviral 
DNA is transcribed by cellular enzymes to generate the spliced and unspliced 
viral mRNAs that are then translocated to the cytoplasm for translation.  The viral 
RNA and structural proteins are assembled into the immature virion core on the 
plasma membrane where it buds to form free virus and becomes mature. 
Attachment of virus to host cells and uncoating 
The attachment of the virion to the host cell receptor is the first step in the entire 
genetic delivery mediated by specific interactions between the envelope 
glycoprotein on the virion and one or more surface receptor molecules on the 
target cell.  This interaction is specific and selective for particular cells and 
therefore particular tissue types, and is associated with host cell specificity of the 
different species (Clapham & McKnight, 2002; Overbaugh et al., 2001). 
Attachment of HIV-1 to cells is mediated by the virion SU binding to CD4 
molecules, the major receptor on the surfaces of T-helper lymphocytes (T4-cells 
or CD4+ cells) and other antigen presenting cells such as macrophages, 
monocytes and dendritic cells.  This binding induces a conformational change that 
orientates the chemokine receptor-binding domains of SU into close proximity 
with the host cell chemokine receptors (CCR5 receptors on macrophages, 
CXCR4 receptors on T4-lymphocytes and CCR3 receptors on microglia cells of 
the brain).  In a subsequent conformational change, a previously buried portion of 
the TM protein gp41 is exposed, enabling the viral envelope to fuse with the host 
cell membrane (Sherman & Greene, 2002).  The fusion results in the release of 
the viral core molecule, containing the viral genome and enzymes, into the 
cytoplasm.  Alternatively, the virus might enter via endocytosis after which the 
envelope fuses with the endocytic vesicle releasing the genome-containing core 
into the cytoplasm.   16 
Reverse transcription of viral genome and its integration into cellular 
genome 
Upon entry into the cytoplasm, retroviruses are uncoated.  In the cytoplasm, the 
viral RNA is converted into dsDNA by the viral RT; the viral nucleic acids remain 
associated with a number
 of viral proteins throughout these steps.  The process of 
reverse transcription is a highly conserved function within the family Retroviridae, 
which occurs within the nucleoprotein complex and is initiated by the binding of 
cellular tRNA (tRNALys) to the primer binding site (PBS) located downstream to 
the 5’ LTR of the viral genomic plus-stranded RNA (Gerdts et al., 1997).  The 
minus-stranded DNA complementary to the 5’ U5 and R region is then 
synthesised and the complementary RNA template is partially degraded by the 
ribonuclease H (RNAse H) activity of the reverse transcriptase.  The synthesised 
minus-stranded DNA is thereafter transferred to the 3’ end of the RNA, where its 
R sequence hybridises with the plus-stranded 3’ R sequence.  The minus-
stranded DNA is extended, and most of the plus-stranded RNA is digested except 
the polypurine tracts (PPT) that serve as a primer for the synthesis of the 3’ part 
of the complementary strand of DNA (plus-stranded DNA).  The PPT RNA 
sequences are then removed by RNAse H and a second strand transfer of the 
minus-stranded DNA allows the hybridisation of the PBS sequences of both DNA 
strands.  This process provides free 3’ ends for completion of the synthesis of 
both plus and minus strands of DNA, generating the ds linear DNA ready for 
integration.  The viral DNA is contained in a protein-DNA complex known as
 the 
pre-integration complex (PIC) (Bowerman et al., 1989; Miller et al., 1997). 
How the PIC enters the nucleus remains unclear (Depienne et al., 2001; Devroe 
et al., 2003).  In the simple retroviruses, nuclear localisation
 of the PIC requires 
cell division (Lewis & Emerman, 1994; Miller et al., 1990; Roe et al., 1993), while 
for the
 lentiviruses, nuclear importation of PIC can occur even in non-dividing 
cells
 (Lewis et al., 1992).  Once inside the nucleus, the linear DNA serves as the 
immediate precursor for the formation of
 the integrated virus dsDNA or “provirus” 
(Brown, 1997).  The integration reaction requires
 three discrete steps: assembly 
of a stable pre-integration complex
 at the termini of the viral DNA, and two 
sequential transesterification
 reactions.  In the 3’-processing reaction,   17 
endonucleolytic
 cleavage of the two 3' nucleotides at each DNA end generates
 3'-
hydroxyl group that provides the site for joining with the 5’-ends of the target host 
DNA in the strand transfer reaction.  The product of integration is a gapped 
intermediate in which the non-joined 5’-viral DNA ends are flanked by short 
single-stranded gaps in the host DNA.  Removal of mispaired nucleotides and 
gap repair are carried out by cellular enzymes (Engelman, 2003). 
Once integrated, the HIV proviral DNA exists in either a latent or productive state, 
determined by genetic factors dependent on the virus strain, the type of cell 
infected and the production of specific host cell proteins.  The majority of proviral 
DNA is integrated into the chromosome of active T4-lymphocytes.  These 
generally comprise 93–95 % of infected cells and are productively infected.  A 
small percentage of HIV-infected memory T4-lymphocytes persist in a resting 
stage due to a latent provirus.  These, along with infected monocytes, 
macrophages and dendritic cells, provide reservoirs of HIV capable of escaping 
host defences and antiretroviral therapy (Blankson et al., 2002; Zhang et al., 
1999). 
Circular forms of viral DNA containing either one
 or two copies of the LTR can be 
found in the nucleus (Hindmarsh & Leis, 1999; Lobel et al., 1989).  These viral 
DNAs are generally believed to be transcriptionally silent remnants of dsDNA that 
fail
 to integrate (Sakai et al., 1993).  It has been reported; however, that in certain 
mutants defective in integrase function these are capable of limited viral gene 
expression including expression of Tat (Stevenson et al., 1992; Wiskerchen & 
Muesing, 1995).  Integrated provirus is essential for HIV-1 replication (Englund et 
al., 1995; Goff, 1992; Whitcomb & Hughes, 1992) but during the asymptomatic 
phase the most prevalent form of HIV-1 DNA in resting and activated CD4+ T 
cells is a full-length, linear, unintegrated form that is not replication competent 
(Chun et al., 1997). 
Integrated proviral DNA maintained within host chromosomal DNA is an active 
template for the expression of retroviral gene products.  The proviral DNA serves
 
as a single expression unit, where a single primary mRNA is transcribed from the   18 
5’ long terminal repeat (LTR) promoter, and is terminated at the 3’LTR, which also 
provides the polyadenylation signal for cellular RNA polymerase
 II (Goff, 2001).   
Transcription of mRNA 
Splicing plays a key role in the production of mRNA for the retroviral
 proteins and 
a summary of the events involved is shown in Figure 2.5.  More than 30 different 
mRNA transcripts generated through alternative splicing of the
 precursor RNA 
have been observed in HIV-1 infected cells, and these can be grouped into three 
classes: the unspliced primary
 transcript ( 9 kb), singly spliced RNAs ( 4 kb) 
lacking
 the gag–pol coding region, and multiply spliced
 RNAs ( 2 kb) lacking the 
env coding region (Purcell & Martin, 1993; Schwartz et al., 1990).  Approximately 
half of the HIV-1 RNA transcripts are unspliced
 and are used as message for gag 
and pol gene products.  The unspliced
 RNA also serves as viral RNA, which is 
packaged in progeny virions.  The singly spliced mRNAs encode the Env proteins
 
and the viral regulatory proteins Vif, Vpr, Vpu and one-exon Tat, while Tat,
 Rev 
and Nef are produced from RNAs spliced at multiple sites (Purcell & Martin, 
1993).  The full-length RNA genome and all subgenomic messages have a 
common 5' methylated cap leader sequence and 3' terminal poly (A) tracts similar 
to eukaryotic mRNA. 
Equilibrium between
 spliced and unspliced transcripts is critical for retrovirus 
replication.  The splicing  processes are regulated by suboptimal splice site 
sequences that differ to a certain extent from the optimal consensus splicing 
signal (Dyhr-Mikkelsen & Kjems, 1995; O'Reilly et al., 1995; Staffa & Cochrane, 
1994) 
 and splicing regulatory elements (Amendt et al., 1995; Staffa & Cochrane, 1995).  
For example, the splicing of the first tat intron is down-regulated by an exon 
splicing silencer (ESS) located in the second tat exon. 
Spliced as well as full length viral RNA molecules are transported to the 
cytoplasm and are translated into structural proteins, glycoproteins and enzymes 
by the host cell metabolic machinery.  The multiply spliced mRNA lacks the RRE   19 
and their transportation into the cytoplasm is Rev-independent, while unspliced 
and singly spliced transcripts are dependent on the viral protein Rev for 
transportation to the cytoplasm.  In the early phase of HIV-1 gene expression, 
only completely (multiply) spliced mRNAs are exported to the cytoplasm, and 
these give rise to
 the Tat, Rev and Nef proteins.  In the late phase of replication, 
Rev protein binds to the RRE sequence located in the env gene present on 
unspliced
 and partially spliced mRNA (Daly et al., 1989; Hope, 1999) and 
mediates their nuclear export
 by delivering them into the Crm1-dependent export 
pathway (Fischer et al., 1995; Fornerod et al., 1997). 
 
Successful infection and production of new infectious viruses
 requires the 
balanced expression of all viral genes, which is
 accomplished by a combination of 
alternative splicing, intron
 retention and regulated nuclear export of the primary 
Figure 2.5.  Genomic organisation of HIV-1 and splicing pattern of viral 
mRNAs.  In the early stage of transcription, multiply spliced mRNAs 
encoding regulatory proteins are produced and their nuclear export is Rev 
independent.  The unspliced and singly spliced transcripts are produced in 
the late stage and Rev is needed for their transport to cytoplasm.  
Reproduced from Bohne et al. (2005).   20 
transcript
 reviewed in (Coffin et al., 1997; Frankel & Young, 1998; Pollard & 
Malim, 1998) 
Assembly and budding  
Virion assembly and release from the host cell are the last stages in the retroviral 
replicative cycle.  The structural proteins are expressed in the late phase of 
transcription when progeny RNA is formed also.  Translation of singly-spliced env 
mRNA result in polyprotein that undergoes posttranslational modification and 
cleavage in the endoplasmic reticulum into an external glycoprotein (SU) and a 
trans-membrane (TM) protein inserted into the host cell cytoplasmic membrane.  
Gag and Pol are initially translated as a single fusion polyprotein, which is self-
cleaved by the viral PR into the components of Gag (CA, MA and NC) and the 
components of Pol (RT, PR and IN).  Gag and Gag-Pol polyprotein precursors 
assemble in the cytoplasm beneath the host-cell membrane and interact with the 
viral RNA genome forming immature virus particles close to the host cell 
membrane into which TM and SU are inserted.   
By budding through the cell plasma membrane these particles acquire a lipid- 
bilayered membrane displaying Env glycoproteins.  Final maturation steps in 
newly released extracellular virus particles involves processing of assembled Gag 
and Gag-Pol polyproteins by the viral protease to yield fully infectious virions. 
The pathogenesis of lentivirus diseases depends on persistent viral replication in 
the presence of an anti-viral immune response.  Two basic mechanisms are 
involved in this persistence: antigenic variation and restriction of viral gene 
expression (Cheevers & McGuire, 1988). 
Genetic variation of lentiviruses 
Of the three different polymerases involved in retrovirus replication, namely RT, 
DNA polymerase, and RNA polymerase II (Pathak & Temin, 1990), it is RT 
involved in the process of reverse transcription that generates the majority of the 
variation in the retroviral genome (Temin, 1993).  The viral RT is very error-prone 
and lacks proof-reading ability (Preston et al., 1988; Roberts et al., 1988), which   21 
results in an error frequency that has been estimated to 3x10
-5 during the reverse 
transcription process (Mansky, 1998). 
The other most important mechanism involved in the generation of variation is 
recombination (Hu et al., 2003; Jung et al., 2002; Robertson et al., 1995; Temin, 
1991).  Recombination is believed to occur during reverse transcription as a result
 
of the RT switching templates between co-packaged heterogeneous RNA 
molecules during viral DNA synthesis (Hu & Temin, 1990).  It results in vast 
genetic alterations within the viral genome to
 increase the diversity of the viral 
population, which can improve
 the probability of the survival of the viral population 
in a
 changing environment (Coffin, 1979; Temin, 1991).  
High virus production rate of 10
8 to 10
9 virions per day (Ho et al., 1995; Wei et al., 
1995) and large numbers
 of infected cells of 10
7 to 10
8 (Offermanns et al., 1997) 
have been reported.  This continual increase in genetic diversity enables HIV-1 to 
rapidly adapt to a variety of selection pressures.  Examples include escape from 
the humoral (Richman et al., 2003; Wei et al., 2003) and cytotoxic-T-lymphocyte 
(CTL) (Borrow et al., 1997; Cao et al., 2003; Draenert et al., 2004; Price et al., 
1997) immune responses, as well as resistance to antiretroviral drugs (Johnson et 
al., 2003). 
In BIV the RT gene is quite conserved, with 89 % nucleotide (89 % amino acid) or 
greater identity, in contrast to the variable SU, with 45 % or greater nucleotide 
identity (51 % or greater amino acid similarity) among BIV isolates in pair-wise 
comparisons.  The SU gene may also vary greatly in size among different viral 
isolates and even within viruses isolated from the same animal (Suarez & 
Whetstone, 1995,  1997). 
The trans-activator of transcription, Tat 
All lentiviruses encode Tat, a small RNA-binding protein which regulates the 
transcription of the viral genome from the LTR promoter (Tang et al., 1999).  
Multiply spliced tat transcripts were produced in the early stage of HIV-1 infection   22 
(Malim et al., 1988; Purcell & Martin, 1993) even before integration (Wu & Marsh, 
2003; Wu, 2004).  These transcripts lead to the synthesis of a few Tat molecules 
sufficient to stimulate HIV transcription, leading to the production of additional tat 
transcripts and Tat protein.  In HIV-1, this nuclear protein is indispensable for 
virus replication (Dayton et al., 1986; Fisher et al., 1986).  Tat acts as an 
elongation factor of transcription through binding to TAR (Kao et al., 1987); 
without Tat, HIV transcriptional elongation is inefficient and results in abortive 
transcripts that can not support viral replication (Kao et al., 1987; Toohey & 
Jones, 1989). 
There are several forms of the Tat protein.  In most wild type isolates of HIV-1, 
Tat comprises 101 amino acids, the first 72 of amino acids encoded by tat exon-1 
and amino acids 73–101 encoded by tat exon-2.  Some laboratory-passaged 
strains, like LAI and HXB2 from HIV-1 group M, produce an 86 amino acid form.  
Since most wild-type strains produce the 101 amino acid form, it has been 
suggested that the 86 amino acid variant represents a truncated non-natural form 
of the protein resulting from a single nucleotide change from G to A in amino acid 
87; this nucleotide change appears to generate a stop codon leading to the 
expression of a truncated Tat of 86 amino acids (Jeang et al., 1999; Neuveut & 
Jeang, 1996).  The preservation of residues 87–101 in wild-type isolates hints at 
some biological importance of this region, even if the region is not required for ex 
vivo propagation of the virus, and its importance is supported by the apparent 
importance of exon 2 in several biological assays (Col et al., 2002; Jeang et al., 
1999; Neuveut & Jeang, 1996; Verhoef et al., 1998). 
Domains and functions of Tat 
Tat protein can roughly be divided into several domains or regions, each having 
specific biochemical and functional characteristics (Kuppuswamy et al., 1989).   
Tat consists of five different domains, or dominant functional regions: the N-
terminal domain, the cysteine-rich domain, the core, the basic domain and the C-
terminal domain (Figure 2.6).  The basic and core regions are
 conserved among 
lentiviruses (Rana & Jeang, 1999).       23 
An acidic N-terminal domain (amino acids 1–20) forms a stable structure that 
contains both hydrophilic and hydrophobic amino acids arranged in a serial 
fashion, and in the majority of variants has five prolines which form a conserved 
motif (x)2P(x)2P(x)3P(x)3P(x)3; the high concentration of proline in this region may 
be able to prevent the degradation of Tat by proteases (Jeang et al., 1999; Loret 
et al., 1991).  The role of this domain in trans-activation has not yet been clearly 
defined.  Introduction of mutations and deletions in this domain have given rise to 
contradictory results.  In one study, this domain was shown to be essential and 
the deletion of the domain led to a loss of trans-activating properties 
(Kuppuswamy et al., 1989).  In another study, deletion of the domain failed to 
prevent trans-activation of the HIV genes (Sadaie et al., 1988). 
 
Figure 2.6.  Schematic diagram of HIV-1 Tat structure.  Tat protein can be 
divided into five physical domains; N-terminal (N-TERM), cysteine-rich 
(CYS-RICH), core, basic, and C-terminal (C-TERM) domains.  Motifs of the 
functionally important domains are indicated.  Adapted from Freed & 
Martin (2001). 
 
The Cys-rich domain (amino acids 21–37) contains seven highly conserved 
cysteine residues, most of which are essential for the trans-activational activity of 
Tat and virus replication (Sadaie et al., 1990).  This region is responsible for the 
intramolecular disulfide bond formation of Tat (Koken et al., 1994), and it induces 
HIV replication and participates in TAR-dependent trans-activation (Boykins et al., 
1999).  Deletion of this domain, or induction of point mutations of certain cysteine   24 
residues, leads to a loss in its ability to trans-activate HIV-1 genes (Kuppuswamy 
et al., 1989; Rice & Carlotti, 1990; Ruben et al., 1989).  While it is evident that the 
integrity of this cysteine rich domain plays an important role in the activation of 
HIV-1 genes, in some studies Tat lacking both domains 1 and 2 was found to 
have the same level of trans-activating activity as the whole protein (Green & 
Loewenstein, 1988).  It is probable that this domain is involved in a number of 
interactions with cellular- transcriptional co-activator that interacts with a number
 
of DNA-binding proteins and cofactor proteins involved in the
 regulation of 
transcription (Fridell et al., 1995; Hottiger & Nabel, 1998; Kamine et al., 1996) 
The core domain or region (amino acids 38–48) consists of a conserved and rigid 
α-helical structure shown to enhance the binding of Tat to TAR; it seems to be 
required for the specific recognition of Tat with the hairpin loop of TAR, which is 
formed at the start of the viral mRNA.(Bayer et al., 1995; Churcher et al., 1993).  
It has been suggested that together with the Cys-rich domain, it circumscribes the 
minimal activation domain of Tat (Carroll et al., 1991; Derse et al., 1991).  Lysine 
41 may be of particular importance in the trans-activation of HIV-1 genes, as point 
mutations of this have led to a dramatic diminution or loss of trans-activating 
capability (Kuppuswamy et al., 1989).   
The basic domain (amino acids 49–59) is also highly conserved and contains an 
RKKRRQRRR motif required for binding to TAR (Frankel & Clarke, 2000; Karn, 
1999).  It also functions as a nuclear localisation signal (NLS) by binding with 
importin β (Truant & Cullen, 1999).  Mutations in this area lead to a loss of trans-
activating activity (Hauber et al., 1989).  This is one of the domains that affixes to 
the hairpin loop of TAR (Aboul-ela et al., 1995; Loret et al., 1992; Puglisi et al., 
1992) and peptides that correspond to this area are capable of binding to TAR 
with almost the same affinity as the entire Tat protein (Calnan et al., 1991; Loret 
et al., 1992; Tao & Frankel, 1992).  However, residues flanking this basic domain 
have been shown to significantly influence the specificity of the interaction 
between Tat and TAR (Karn, 1999), and this may be the case for both the 
glutamine rich (C terminal) and the core domain as well which are all necessary 
for transcriptional function of Tat.  Lysine residues at positions 50 and 51 are   25 
thought to be major substrates for acetylation (Kiernan et al., 1999); a process 
necessary for Tat trans-activation of the LTR promoter.  Acetylation might 
modulate Tat binding affinity for either TAR or other interacting transcription 
factors (Deng et al., 2000; Kiernan et al., 1999; Ott et al., 1999).  Prevention of 
acetylation by substitution of lysines 50 and 51 to alanines strongly reduced 
trans-activation (Deng et al., 2000; Dorr et al., 2002; Kiernan et al., 1999), while a 
more conservative substitution with arginines exhibited a more modest effect 
(Pantano et al., 2002).  Computational analysis revealed correlation between 
protein structure, which was profoundly disturbed in the alanine substitutions in 
contrast to the highly maintained Tat conformation in lysines to arginines 
substitution, with the trans-activation activity (Mujtaba et al., 2002; Pantano et al., 
2002).  
The C terminal domain contains glutamine-rich pattern (amino acids 60–76) that 
forms a rigid structure that pairs with three nucleotides in the TAR loop, thus 
providing an additional motif in Tat able to recognise TAR RNA (Loret et al., 
1992).  In the highly virulent subtype of HIV-1 Tat this motif forms an α-helical 
structure (Gregoire et al., 2001) which brings the cys-rich and basic domains into 
close proximity during Tat-TAR binding.  The rest of the domain is encoded by the 
second tat exon, the function of which is less characterised.  However, mutations 
in this coding exon produce a virus that replicates poorly in vivo (Smith et al., 
2003). 
Alignment of Tat proteins of HIV-1, HIV-2, SIVs, JDV, BIV, EIAV, CAEV, MVV, 
and Orf-A of FIV is shown in Figure 2.7, which allows their structural identification 
deduced from the pattern of conserved amino acids.  It was demonstrated that 
Tat proteins of BIV and JDV display structural homology with their primate 
counterparts; they contain all 5 physical domains and share high conservation in 
Cys-rich and core domains.  Considerable similarity was also shown by the EIAV 
Tat, which shares the 4 domains with a highly conserved core region, but lack of 
Cys-rich domain (Dorn et al., 1990).      26 
On the contrary, Tat proteins of CEAV and MVV, and Orf-A of FIV have different 
structural organisation; amino acid alignments denote a similar organisation of 
putative physical domains of an N-term acidic and hydrophobic, a central leucine-
rich, and a C-term cysteine-rich (Tomonaga & Mikami, 1996; Villet et al., 2003a), 
and they do not contain the core and basic domains.  The N-term domain was 
proposed as the trans-activation domain, the central region involved in the 
recruitment of Fos and Jun to the Ap1 sites in the LTR and the C-term region 
involved in protein dimerisation and localisation to the nucleus (Villet et al., 
2003b)  MVV and CAEV show high homology in the central and C-termi regions 
but the trans-activation domains are divergent. 
Interaction of Tat with TAR 
The replication cycle of lentiviruses consists of defined steps requiring several cis 
and trans genetic elements.  Regulation of HIV gene expression involves a 
complex interplay between chromatin-associated proviral DNA, cellular 
transcription factors and the viral encoded trans-activator of transcription, Tat.   
The viral core or basal promoter (nt –78 to –1) contains a TATAA box and three 
consensus SP1 binding sites.  The enhancer (nt –105 to –79) carries a 
duplication of the 10-bp NF-kB binding sites. 
The LTR promoter of HIV represents a most interesting example of molecular 
adaptation of a virus to the host cellular environment.  The activity of the promoter 
is dependent on the viral trans-activator Tat (Berkhout et al., 1989; Jeang et al., 
1999) and a variety of cellular transcription factors have been proposed to interact 
with the LTR in a cell-specific and cell activation-dependent manner (Gaynor, 
1992; Pereira et al., 2000).  The 5’ LTR is particularly important as it contains the 
promoter region, indispensable for the initiation of transcription. 
The 5’ LTR can be sub-divided into three regions: U3, R and U5.  The promoter is 
situated in the U3 region, which contains a nucleotide sequence that is 
recognised by a number of cellular transcription factors: NF-κB, Sp1, the basal 
promoter TATA box and AP1.  The R region contains regulatory elements such as  
2
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Figure 2.7.  Alignment of the amino acid sequences of lentivirus Tat proteins. The deduced amino acid sequences for the Tat 
exon 1 are shown for HIV-1 (K03455), SIVcpz (X52154), HIV-2 (M30502), SIVmac (M19499), SIVmnd (M27470) and 
SIVagm (M29975).  The putative N-terminal (N-TERM), cysteine-rich (CYS-RICH), core, basic, and C-terminal (C-TERM) 
domains of Tat are indicated.  Highly conserved core domain and cysteine residues of CYS-RICH are shaded; dashes 
represent gaps introduced to align sequences.  The GeneBank accession number of each sequence is given in brackets. 
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the trans-acting responsive element (TAR), which once translated into mRNA, 
folds into a specific stem-loop structure (Figure 2.8) which allows it to be 
recognised by Tat (Feng & Holland, 1988; Rosen et al., 1985).  The TAR stem 
contains a three-nucleotide bulge structure recognised by the arginine-rich motif 
(ARM) in Tat basic domain (Churcher et al., 1993).  This configuration is essential 
for trans-activation; mutations destabilising the TAR stem abolish Tat-stimulated 
transcription (Selby et al., 1989).  The loop region of TAR (nucleotides 30–35) is 
required for in vivo trans-activation but is not involved in binding to Tat (Dingwall 
et al., 1990). 
 
 
Figure 2.8.  Tat responsive element stem-loop structure.  The important 
site for Tat binding, U-rich bulge, and essential region for activation, the 
loop, are indicated. Adapted from Freed & Martin (2001) 
 
Tat binds
 to the 5' end of the newly transcribed TAR RNA and promotes the 
assembly of transcriptionally active complexes at the LTR and increases the rate   29 
of elongation by RNA polymerase II which results in the augmentation of viral 
gene transcription (Jones & Peterlin, 1994; Rana & Jeang, 1999).  The binding 
requires CyclinT1 (CycT1), a cofactor that is part of the cellular-positive acting 
transcription elongation factor (P-TEFb), a component of pre-initiation 
transcription complexes which stimulates RNA polymerase II (pol II) elongation 
(Marshall & Price, 1995).  Tat- CycT1 interaction is highly cooperative.  CycT1 
binds with both Tat via the cysteine-rich and core domains and the TAR terminal 
loop sequences, and remodels the structure of Tat to enhance its affinity for TAR 
RNA, and that TAR RNA further enhances the interaction between Tat and CycT1 
(Bieniasz et al., 1998; Wei et al., 1998; Zhang et al., 2000).  CycT1 forms a 
heterodimer with the cyclin-dependent kinase 9 (CDK9), and recruitment of this 
heterodimer to the transcription initiation site leads to the hyper-phosphorylation 
of the carboxyl terminal domain (CTD) of the largest subunit of pol II, which 
potentially enhances the processivity of the pol II (Bieniasz et al., 1999c; Isel & 
Karn, 1999; Ping & Rana, 1999).  Similar mechanism was shared by SIV and 
EIAV Tat proteins, which demonstrate dependency on CycT1 for both TAR 
interaction and transcription elongation (Bieniasz et al., 1999b,  1999c).   The 
mechanism of Tat trans-activation is illustrated schematically in Figure 2.9. 
Not all lentiviruses utilise a Tat-TAR interaction for transcription activation.  In 
MVV, CAEV and FIV, there is no stem-loop structure within the LTR analogous to 
the TAR sequences.  The Tat protein of MVV, and presumably that of CAEV, 
stimulates viral gene expression indirectly by interacting with cellular transcription
 
factors Fos and Jun, which target the resulting complex to an AP-1
 site located  
within the viral LTR, proximal to the transcription start site (Carruth et al., 1996; 
Neuveut et al., 1993).  Once targeted to the AP-1 site,
 Tat recruits the TATA box 
binding protein (TBP) which results
 in enhanced transcription initiation (Morse et 
al., 1999).  This model of transcription activation is consistent
 with the observation 
that replication of MVV is enhanced in activated monocytes (macrophages) 
concordant with increased
 levels of Fos and Jun  (Morse et al., 1999; Shih et al., 
1992). 
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Likewise, the target of the FIV Tat-like protein encoded by the orf-A gene appears 
to be AP-1, cEBP, and ATF
 sites within the viral LTR (Chatterji et al., 2002).  
Gemeniano et al. (2003) suggested that the orf-A is required for optimal viral 
replication and pathogenicity, but it is not critical for viral replication, as is the tat 
gene of CAEV and MVV (Villet et al., 2003b); they have only mild trans-activating 
activity.  The Tat proteins of CAEV and MVV are apparently incorporated into 
virions, localised in the nucleus and induced cell cycle arrest in the G2 phase of 
replication typical function of HIV-1 Vpr (Villet et al., 2003a).  Evidence of a 
similar function for the Orf-A of FIV has also been demonstrated by Gemeniano et 
al. (2004), which led to the proposal that the tat gene of CAEV and MVV, FIV orf-
A code for a Vpr-like accessory protein. 
Tat and reverse transcription 
In addition to the trans-activation ability, Tat has been implicated to have an 
important role in the activity of reverse transcriptase.  It has been observed that 
HIV-1 lacking a functional Tat protein (HIV-1Δtat) was unable to efficiently 
generate proviral DNA following infection (Harrich et al., 1997; Ulich et al., 1999).  
This defect could be trans-complemented by co-expressing the Tat protein of not 
only HIV-1, but also JDV and EIAV suggesting that the reverse transcription 
function of Tat is conserved within lentiviruses (Harrich & Hooker, 2002).  Apolloni 
et al. (2003) postulated that PR cleaved form of Tat is present in the virion and 
exerts a direct effect on efficient reverse transcription although the precise 
mechanism has yet to be investigated.  On the other hand, another group argued 
that Tat increases overall reverse transcription activity by promoting annealing of 
the tRNALys  onto primer binding site of viral RNA but not DNA polymerisation 
(Kameoka et al., 2001; 2002; Liang & Wainberg, 2002).  They reasoned that the 
interference of Tat on RT elongation might blockade premature DNA synthesis, 
which could be beneficial for packaging the RNA genome into the progeny virion 
and subsequent maturation.     31 
 
Figure 2.9.  Schematic diagram illustrating Tat transactivation.  Tat first 
recruits P-TEFb composed of CycT1-CDK9 heterodimer and binds TAR on 
viral transcripts.  Subsequently, CDK9 stimulates the phosphorylation (P) 
of the C-terminal domain of RNA polymerase II (Pol II) and transcription 
elongation proceeds.  Adapted from Price (2000). 
Tat protein of BIV  
BIV tat produces two mRNA species in vivo, coding for phosphorylated proteins 
103 (Tat
103) and 108 (Tat
108) amino acids in length due to alternative splicing 
patterns (Fong et al., 1997).  BIV Tat contains five functionally conserved 
domains, a amino-terminus, cysteine-rich, conserved core, basic and carboxyl-  
 
 
Figure 2.10.  Representation of BIV Tat-TAR and P-TEFb complex.  
Reproduced from Barboric et al. (2000).  
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terminus domains similar to HIV (Chen & Frankel, 1994; Fong et al., 1997).  
Functional differences have been found in the two BIV Tat species.  Tat
108 
induces moderately stronger trans-activation of the BIV LTR than Tat
103 (Fong et 
al., 1997), mainly due to the presence of carboxyl-terminal regions which have 
been shown to increase trans-activation in other lentiviruses such as HIV-1 and 
SIV (Viglianti & Mullins, 1988). 
An interesting feature of BIV Tat is that the arginine-rich RNA-binding motif (ARM) 
of basic
 domain is fully capable for binding with high affinity and specificity to the 
stem and bulge in its homologous TAR, and the central loop is apparently not 
essential for its trans-activating function (Chen & Frankel, 1994; Harada et al., 
1996; Tan et al., 1993).  BIV Tat-TAR has been recognised as a "primordial" 
lentivirus interaction, where only basic interaction and function exists (Lim & 
Barton, 1997; Moras & Poterszman, 1996; Srinivasan et al., 1996; Ye et al., 
1995).  This interaction does not use cellular proteins to stabilise the Tat-TAR 
complex and is more specific for its homologous TAR, unlike the HIV, SIV, EIAV 
Tat-TAR complex which necessitates Cyc-T1 (Bieniasz et al., 1999b,  1999c; 
Gold et al., 1998).  Consequently, BIV Tat is able to trans-activate HIV-1 LTR, 
initiating and up-regulating viral gene expression whereas HIV-1 Tat is a poor 
trans-activator of BIV LTR (Bogerd et al., 2000; Chen & Frankel, 1994).   
Although Cyc-T1 does not appear to participate directly in BIV TAR recognition, it 
probably still interacts with the Tat activation domain, allowing Cdk9 recruitment, 
transcriptional activation, and replication (Figure 2.10) (Barboric et al., 2000; 
Bogerd et al., 2000).  It has been shown that BIV Tat upregulates gene 
expression 15-80-fold in a TAR-dependent manner and 2.5-fold in a TAR-
independent manner (Fong et al., 1995; Pallansch et al., 1992). 
Association of Tat with pathological properties of lentiviruses 
A multiplicity of functions has been ascribed to the Tat protein (Rubartelli et al., 
1998).  Despite the lack of a signal sequence, Tat is released by infected
 cells 
and is found in detectable levels (0.01–0.1 nM)
 in the culture supernatants of cells   33 
infected with HIV-1 (Chang et al., 1997; Ensoli et al., 1990; 1993; Westendorp et 
al., 1994).  Biologically significant amount of Tat have also been detected in the 
sera of HIV-1 infected individuals (Westendorp et al., 1995; Xiao et al., 2000).  
Tat is efficiently
 taken up by a variety of cells (Chang et al., 1997; Ensoli et al., 
1993; Fawell et al., 1994; Frankel & Pabo, 1988) and may
 enter T-cells by 
endocytosis (Vendeville et al., 2004); this may lead to trans-activation of various 
cellular genes (Demirhan et al., 1999b; Frankel & Pabo, 1988).   
The production and release of Tat from the infected cell may activate or repress 
cytokines and genes that control the cell cycle in uninfected cells (Chang et al., 
1995).  This deregulation of cellular gene expression and function by Tat cause 
abnormalities which may participate in AIDS pathogenesis.  It is thought that Tat 
can affect cellular gene expression in two ways (Ensoli et al., 1993; Frankel & 
Pabo, 1988; Tyagi et al., 2001): intracellularly by direct contact with components 
of the transcriptional machinery; extracellularly through receptors on the surface 
of the cell triggering signalling pathways that will lead to a change in cell 
function/cellular gene expression.  The extracellular Tat enters infected and 
uninfected bystander cells through interaction with cell membrane heparan sulfate 
proteoglycans (Tyagi et al., 2001). 
Extracellular Tat binds to chemokine receptors, integrins or CD26
 to induce 
cellular signalling (Noonan & Albini, 2000).  The binding of extracellular Tat to the 
T-cell activation marker CD26 has been suggested to inhibit its dipeptidyl 
peptidase IV activity, which is thought to mediate immunosuppressive activity 
(Gutheil et al., 1994; Wrenger et al., 1997) and induce immune cells to produce 
several cytokines which could lead to a dysregulation of the immune response 
(Nath et al., 1999).  In addition, Tat has been shown to induce 
immunosuppression by inhibiting antigen- and mitogen-induced proliferation of 
PBMC and T-cell clones, and by inducing immunosuppressive protein IFNα 
causing impairment of T-cell functions in HIV-infected individuals (Ensoli et al., 
1992; Viscidi et al., 1989; Zagury et al., 1998a).  Tat has also been associated 
with increased IL-2 secretion in response to co-stimulation with CD3 plus CD28 in   34 
HIV-1 infected patients which induce T-cell activation or immune hyperactivation 
(Ott et al., 1997; Secchiero et al., 2000; Westendorp et al., 1994).    
The expression of several cellular genes, including cytokines and their receptors, 
is modulated by Tat (Buonaguro et al., 1992; de Paulis et al., 2000; Sharma et al., 
1995), whereas levels of MIP1-α, an inflammatory response modulator, and IL-12 
are down-regulated (Ito et al., 1998; Sharma et al., 1996).  In microglia and 
astrocytes, dysregulation of chemokine and chemokine receptor expression 
together with the secretion of inflammatory cytokines from infected monocytes is 
toxic to the cells of the central nervous system and could lead to encephalitis and 
dementia (Conant et al., 1998; McManus et al., 2000). 
The depletion of CD4+ T cells is the most characteristic trait of HIV infection and 
there can be loss of these cells in the absence of their infection, which has been 
ascribed to apoptosis induced by Tat (McCloskey et al., 1997; Purvis et al., 1995; 
Westendorp et al., 1995).  The rate of apoptosis was slightly enhanced in HIV-1 
productively infected cells in comparison with uninfected or bystander cells (Azad, 
2000; Bahbouhi et al., 2004; Bolton et al., 2002).  This relatively low level of 
apoptosis in HIV productively infected cells has been linked to the ability of Tat 
with potent up-regulation of the anti-apoptotic protein Bcl2 and IL-2 (Andreas 
Ehret, 2001; Bahbouhi et al., 2004; Bennaser & Bahroui, 2002; Buonaguro et al., 
1992; Ndolo et al., 2002; Ott et al., 1997; Scala et al., 1994; Vacca A. et al., 1994; 
Westendorp et al., 1994; Zauli et al., 1995a). 
Tat is also responsible for the spread of infection; several postulated mechanisms 
have been correlated with this property.  One method is its function as a chemo-
attractant involving several different cell types of the immune system (Benelli et 
al., 2000).  By moving into the area of a cell productively infected with HIV, these 
attracted cells are more easily infected.  Tat also stimulates dendritic
 cell (DC) 
maturation and induces expression of chemokines that contribute to the 
recruitment of activated T cells and
 macrophages, the targets of HIV-1 infection 
(Izmailova et al., 2003).  In addition, Tat has been implicated in up-regulating
  the 
expression of chemokine receptors such as CCR5 and CXCR4 that serve as HIV   35 
co-receptors on lymphocytes or monocytes/macrophages, thus rendering 
bystander cells more susceptible to infection with M- or T-tropic viruses (Huang et 
al., 1998; Secchiero et al., 1999).  And recently (Marchio et al., 2005) showed that 
Tat segregated on the cell membrane interacts with gp120 facilitating virus 
attachment and entry into cells.  
Tat has also been associated with the development of Kaposi's sarcoma (KS) in 
HIV-infected individuals.  Tat promotes the growth of activated vascular and 
lymphatic endothelial cells, and also their migration, invasion and adhesion.  It 
has been reported that Tat and basic fibroblast growth factor (bFGF) act 
synergistically in angiogenesis, inducing the growth of KS cells (Albini et al., 
1994; Ensoli et al., 1990).  Extracellular Tat induces cytokine production such as 
angiogenic factors in macrophages.  This means that the presence of Tat leads to 
a production of blood vessels, which may promote the development of tumours.  
Extra-cellular Tat stimulates the growth of cells stemming from KS in individuals 
infected by HIV-1 promoting the growth and invasiveness of KS cells (Barillari & 
Ensoli, 2002; Cantaluppi et al., 2001; Ensoli et al., 1994). 
Immune response to Tat 
An immune response to Tat has been detected in HIV-1 infected humans and 
animals, as well as in animals vaccinated with Tat.  Tat is not immunodominant in 
natural
 HIV
 infections and in HIV-infected patients the prevalence of Tat 
antibodies varies from less than 15 % to 35 %, and longitudinal studies have 
indicated that while antibody is sometimes constantly detectable it is in other 
patients only occasionally detectable (Krone et al., 1988; Lamhamedi-Cherradi et 
al., 1992; Lieberman et al., 1997; Reiss et al., 1990; Wieland et al., 1990).  
Interestingly, a significant lower prevalence of Tat antibodies has been detected 
in patients with KS (Demirhan et al., 1999a), and there is a low or absent antibody 
response to Tat in patients with p24 antigenaemia and those that have 
progressed to develop AIDS (Re et al., 1995).   36 
During in vitro infection, relatively low levels of anti-Tat antibodies clearly inhibit 
Tat-mediated trans-activation of HIV-1 LTR or intracellular trafficking of Tat 
(Cruikshank et al., 1997; Mhashilkar et al., 1995; Poznansky et al., 1998), and 
HIV-1 replication in various cell lines and in PBMC cultures in a concentration-
dependent manner (Re et al., 1995; Steinaa et al., 1994; Tosi et al., 2000). 
Induction of Tat antibody has been associated with HIV-1 induced 
immunosuppression of T cells, as well as HIV-1 induced generation of suppressor 
T cells (Lachgar et al., 1996).  Induction of Tat-specific antibody in vaccinated 
rhesus macaques was also associated with minimisation of chronic plasma 
viraemia (Goldstein et al., 2000).  Thus, extracellular Tat-antibodies may inhibit 
the paracrine activation pathway shown to be one feature of extracellular Tat 
protein (Ensoli et al., 1993).   
Two major domains have been associated with the immunogenicity of Tat and are 
most often recognised by specific antibodies (Figure 2.11) (Belliard et al., 2003; 
Moreau et al., 2004; Noonan et al., 2003).  Monoclonal antibodies raised against 
the N-terminal sequence of Tat were shown to completely inhibit Tat trans-
activation (Demirhan et al., 1999a) and to delay HIV-1 replication in PBMCs (Zauli 
et al., 1995b).  The second major immunogenic region is found in the basic 
domain of Tat (Goldstein, 1996) which is recognised by antibody from infected 
individuals (Demirhan et al., 1999a; Re et al., 2001a; Rodman et al., 1999; 
Tahtinen et al., 1997) and vaccinated macaque or mice (Marinaro et al., 2003; 
Tikhonov et al., 2003).  Antibodies to this domain have been associated with 
neutralising activity in vitro, inhibition of extracellular Tat-dependent trans-
activation, reduction of HIV-1 replication in acutely infected T cells, inhibition of 
reactivation of virus replicating at low levels in chronically infected cells (Moreau 
et al., 2004), and neutralisation of the apoptotic effect (Belliard et al., 2003).   
Belliard et al. (2005) demonstrated that the epitopes involved displayed limited 
polymorphism among HIV strains, but that the neutralising activity of induced Tat 
antibodies failed to protect against challenge in rhesus macaques.   37 
Another interesting function of Tat
 is its apparent role as a T-cell adjuvant 
preferentially stimulating a Th1-type
 response (Fanales-Belasio et al., 2002a; 
2002b; Ramakrishna et al., 2004).  Gavioli et al. (2004) suggests that the Tat is 
involved in optimising and modulating the generation of CTL epitopes that benefit 
Th1 response.  However, contrary evidence has been presented that the role of 
Tat in antigen-specific immunosuppression is by a directly modulation of T-cell 
function (Cohen et al., 1999; Viscidi et al., 1989; Zagury et al., 1998a). 
In HIV-1 infected individuals, CTL precursors (CTLp) against Tat correlate 
inversely with rapid disease progression to AIDS (Froebel et al., 1994; van 
Baalen et al., 1997; Venet et al., 1992).  Studies of a group of Gambian women 
who remained seronegative for HIV-1 infection despite exposure, revealed high 
levels of Tat-specific CTL considered to contribute to resistance of infection 
(Rowland-Jones et al., 1995).  The possibility that a CTL response against early 
regulatory proteins was effective in controlling lentivirus infection was also 
recently supported by studies on SIV infection in macaques (Pauza et al., 2000; 
Walker & Goulder, 2000).  Allen et al. (2000) reported that a Tat-specific CTL 
response induced after SIV infection in rhesus macaques was able to control 
primary infection, and demonstrated there was immune pressure on the Tat CTL 
Figure 2.11.  B-cell epitopes of HIV-1 Tat stimulating an antibody response.  
From the HIV Molecular Immunology Database (http://www.hiv.lanl.gov/ 
content/immunology/index).    38 
epitope leading
 to the selection of slowly replicating and apparently less
 
pathogenic escape mutants.   
Tat vaccines and vaccination 
Subunit and DNA vaccines 
Vaccination remains the most effective method to control viral diseases, and 
there have been considerable recent advances in the development of vaccines.  
The first generation of viral vaccines were mainly based on the use of live 
attenuated virus or inactivated whole virions (Plotkin et al., 2004) but the recent 
advent of recombinant technology has accelerated vaccine development.  It is 
now possible to use only small, well-defined immunogenic parts of pathogens, or 
DNA plasmids containing genes that will express proteins of interest as vaccines 
to induce immune responses, with the added benefit of a marked increase in 
vaccine safety. 
The first subunit protein vaccine used was a Hepatitis B vaccine consisting of 
purified hepatitis B surface antigen (HBsAg) extracted from human plasma.  
However, identification and isolation of the gene encoding this HBsAg enabled it 
to be produced using recombinant DNA technology in yeast (Hilleman, 2003) 
replacing the plasma derived hepatitis B vaccine in human use.   
The basics of recombinant DNA technology are to transfer a gene encoding an 
antigen, responsible for inducing immune responses sufficient for protection, to a 
non-pathogenic host, thereby making the production of the antigen safer and 
generally more efficient (Makela, 2000).  Protein expression can be optimised by 
many methods, for example truncation of the gene may remove sequences 
encoding toxic peptides (Dertzbaugh, 1998), codon usage may be modified for 
optimal expression of the protein in the expression system such as E. coli 
(Hannig & Makrides, 1998), and the recombinant construct can be designed 
either for secretion or for intracellular expression of the protein.  Intracellular 
expression in E. coli often leads to the formation of inclusion bodies, which may   39 
be advantageous in that the product normally is protected from proteolytic 
degradation, and they are often associated with high yields of the recombinant 
protein.  Although recombinant protein immunogens offer several advantages, 
they are generally poor immunogens when administered alone, and safe immune 
adjuvants might be needed. 
The choice of expression system used will be dependent of the characteristics of 
the protein to be expressed, and the host used may affect the immunogenicity 
and protective efficacy of the product.  For example, if a post-translationally 
modified antigen is required, a bacterial expression system is not the right choice 
despite the promise of a high yield (Dertzbaugh, 1998).  Common major host cell 
systems used to produce recombinant proteins include bacteria, yeast, insect 
cells, and mammalian cells. 
Another method of vaccination, so called DNA vaccination, has promised much 
but as yet no commercial DNA vaccine has been licensed for use in animals or 
humans.  The technology is a relatively new strategy in which DNA encoding a 
protein of interest is incorporated into a vector and administered into a host in 
order to get expression of the protein by host cells with consequent induction of 
an immune response to the encoded antigen.  Wolff et al. (1990) were the first to 
demonstrate that non-replicating DNA expression vectors could be taken up by 
muscle cells with in vivo expression of protein from the recombinant gene.  Tang 
et al. (1992) demonstrated that specific antibodies were elicited following injection 
of plasmids encoding human growth hormone into mice.  Similar studies have 
been repeated many times.  Influenza nucleocapsid DNA vaccines primed 
cytotoxic T-cells (CTL) and resulted in protection from influenza challenge (Ulmer 
et al., 1993).  Other DNA vaccines have since then been reported to generate 
immune responses against various antigens, and also protective immunity in 
several diseases in animal species ranging from mice to humans (Liljeqvist & 
Stahl, 1999; Liu & Ulmer, 2000).   
Most DNA vaccines incorporate a gene of interest into plasmid DNA of bacterial 
origin.  The plasmids are engineered to contain a strong promoter mostly derived   40 
from cytomegalovirus (CMV) or simian virus 40 (SV40) for optimal expression in 
eukaryotic cells (Gurunathan et al., 2000).  A polyadenylation signal (Poly-A) is 
also incorporated to stabilise mRNA transcripts, and translation initiation can be 
optimised by incorporation of a ”Kozak” translation initiation region (An et al., 
2000).  The plasmid encodes an origin of replication which allows for growth in 
bacteria, and an antibiotic resistance gene for selective growth conditions.  DNA 
vaccines thus utilise the transcriptional and translational machinery of the host 
cells allowing for the proper processing of the gene product that is then presented 
to the immune system of the host. 
When administered intramuscularly, myocytes are less likely to be the primary 
inducers of immune responses as they lack co-stimulatory molecules (Donnelly et 
al., 1997).  DNA vaccines are thought to prime and cross-prime professional 
antigen presenting cells (APC), mainly dendritic cells (DC), to present the 
encoded antigen (Corr et al., 1996; Corr et al., 1999; Fu et al., 1997; Ulmer et al., 
1996).  These can be accomplished by direct transfection of APC or uptake of 
soluble antigen that has been secreted or released by transfected myocytes as 
illustrated in Figure 2.12. Priming or cross-priming of DCs will induce up-
regulation of the co-stimulatory molecules that enable the DCs to process the 
antigen for both MHC class I and class II association for presentation to both 
CTLs and T helper cells (Liu, 2003).   
Certain immunostimulatory motifs have been mapped in bacterial DNA to the 
unmethylated CpG dinucleotides flanked by two 5' purines and two 3' pyrimidines 
that are able to stimulate the innate immunity of the host.  This sequence was 
shown to induce polyclonal B cell activation, maturation or activation of DCs and 
induction of T helper-1 (Th1) responses (Klinman et al., 2004). 
Immunisation with DNA vaccines offers several advantages.  DNA vaccines are 
easy to manipulate, combination vaccines can easily be made because all 
components can be purified by the same procedure, endogenous antigen 
production can provide appropriate tertiary structure for the induction of 
conformationally specific antibodies and facilitate the induction of a cellular    41 
immune response.  The same vector can also be used for subsequent 
immunisation since no immune response is elicited against the vector itself, in 
contrast to vaccinia and other live virus vectors.  Moreover, sufficient quantities of 
plasmid DNA can be produced by simple bacterial fermentation and purification 
techniques, avoiding many of the complications and expense associated with the 
production of purified recombinant proteins.  In addition, induction of immune 
tolerance or of autoimmunity has not generally been seen during DNA vaccination 
and preclinical animal studies suggest that induction of anti-DNA antibodies is 
unlikely (Donnelly et al., 1997). 
Despite the advantages, there are areas of concern with regard to DNA 
vaccination and it is noted that no DNA vaccine has yet been licensed for use.  A 
major issue involved the possible integration of injected plasmid DNA into the 
host cell genome, and this has to be examined carefully, although it is considered 
 
Figure 2.12.  Schematic representation of the mechanism of T-cell 
activation by DNA vaccines.  Reproduced from Liu (2003). 
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by some not to pose a significant safety concern (Ledwith et al., 2000; Martin et 
al., 1999).   
Vaccination against Tat 
In the extensive studies toward the control of HIV 1 infection, Tat is one of the 
proteins that have been considered for therapeutic intervention, including its use 
as an immunogen for anti-HIV-1 vaccination.  There are several reasons for 
targeting Tat.  It is produced
 early during the virus life cycle and is indispensable 
for efficient
 virus replication (Adams et al., 1988; Arya et al., 1985; Dayton et al., 
1986): various tat transcripts have been detected before viral genomic integration 
(Wu & Marsh, 2003; Wu, 2004).  Regulatory genes including tat are genetically 
more conserved than other genes such as env.  Tat is also antigenically 
conserved, and anti-Tat IgG reacts with all the functional domains of Tat 
(Demirhan et al., 1999a; 2000).  Tat is immunogenic and anti-Tat antibodies have 
been correlated with low plasma viral load and delayed disease progression in 
HIV-infected subjects (Re et al., 2001b; Reiss et al., 1990; Zagury et al., 1998b).  
It is reasonable to presume that an immune response directed against this protein 
might prevent later steps in the virus life cycle and inhibit the release of progeny 
virus particles.   
Candidate Tat antigens have been produced in several formats as potential 
vaccines, including as a peptide (Boykins et al., 2000; Goldstein et al., 2000), a 
protein (Ensoli & Cafaro, 2000), a toxoid (Goldstein et al., 2000; Pauza et al., 
2000), a DNA vaccine (Allen et al., 2002; Cafaro et al., 2001; Caselli et al., 1999; 
Hinkula et al., 1997), and a recombinant virus (Allen et al., 2002; Hel et al., 2002).   
Although the results of these studies have not been uniformly promising, some 
have, and the importance of anti-Tat immune responses as a correlate of 
protection has been established.  Vaccination experiments using active or 
inactive Tat in animal models were shown to induce specific immune responses 
and confer protection against disease progression (Agwale et al., 2002; Barillari 
et al., 1999; Pauza et al., 2000).     43 
Tat-antibodies have been produced in the sera of immunised animals and these 
antibodies were capable of neutralising the effect of extracellular Tat on HIV-1 
replication (Cafaro et al., 1999; Caselli et al., 1999).  A significant attenuation of 
disease, lower viral load, plasma p24 levels, higher CD4 count, was detected in 
rhesus macaques immunised with chemically modified, immunogenic Tat 
preparation (Tat toxoid) (Pauza et al., 2000).  Tat toxoid was also used to 
immunise seronegative individuals that demonstrated a 3-fold to more than a 10-
fold increase in circulating antibodies against Tat, and positive delayed type 
hypersensitivity skin tests and increased lymphoproliferative responses to Tat in 
vitro (Gringeri et al., 1999).  Low level T-cell proliferative responses to Tat has 
been detected in humans (Calarota et al., 1999; Gringeri et al., 1999), monkeys 
(Cafaro et al., 1999; Pauza et al., 2000; Putkonen et al., 1998) or mice (Caselli et 
al., 1999) immunised either with Tat protein or plasmid DNA.   
The immunological responses needed for protection are still unclear.  Some 
studies showed that both the humoral and cell-mediated responses were needed 
for attenuation of infection (Pauza et al., 2000).  Others have reported that 
neutralisation titres do not correlate with protection (Belliard et al., 2005).  A 
cellular immune response to the regulatory proteins of HIV-1, especially Tat, is 
considered important for protection against disease progression (Allen et al., 
2000; van Baalen et al., 1997).   
Various DNA vaccines have also been tested for the purpose of inducing cellular 
immune response.  These vaccines shown to induced potent T-cell proliferative 
responses in monkeys (Cafaro et al., 2001; Fanales-Belasio et al., 2002b), mice 
and human (Hinkula et al., 1997), and strong antibody response when combined 
with protein booster (Hinkula et al., 1997; Putkonen et al., 1998; Reiss et al., 
1990).   
Jembrana disease 
In 1964 an epidemic of an infectious disease affecting Bali cattle (Bos javanicus) 
was first reported in the Jembrana district on the island of Bali in Indonesia   44 
(Adiwinata, 1967).  The disease spread rapidly throughout Bali and within twelve 
months an estimated 60,000 deaths from a total population of 300,000 (20 %) 
occurred (Pranoto & Pudjiastono, 1967; Wilcox et al., 1995).   
After many years of investigation, the causative agent, which was originally 
believed to be rickettsia (Ressang et al., 1985), has been characterised as a 
lentivirus, closely related to Bovine immunodeficiency virus (BIV), based on the 
antigenic cross-reactivity of CA and genomic sequence analysis (Chadwick et al., 
1995a; Kertayadnya et al., 1993; Wilcox et al., 1992), and named Jembrana 
disease virus (JDV).  It causes an acute and severe clinical and pathological 
manifestation unique to Bali cattle (Chadwick et al., 1995b; Dharma et al., 1991; 
Kertayadnya et al., 1993; Soesanto et al., 1990; Wilcox et al., 1995). 
The acute nature of JD, with 100 % morbidity and 20 % fatality rates, is atypical of 
nearly all other lentivirus infections.  After a short incubation period of 4–12 days 
(d), infected cattle develop consistent clinical signs of fever, anorexia, lethargy, 
nasal discharge, diarrhoea and lymphadenopathy that persist for about 12 d 
(Soesanto et al., 1990).  At this acute clinical stage high titres of virus of up to10
8 
infectious units/mLcan be found in the plasma (Soeharsono et al., 1990).  The 
major haematological changes include leukopenia, lymphopenia, eosinopenia and 
a slight neutropenia, a mild thrombocytopenia, a normocytic normochromic 
anaemia, uraemia and hypoproteinaemia (Soesanto et al., 1990).   
Pathological changes reflect a rapid, intense proliferative disorder of blastic 
lymphocytes in the parafollicular regions of lymphoid tissues in the spleen, lymph 
nodes and other organs, particularly the gut.  Spleen is congested and enlarged.  
Marked enlargement of the spleen, to 3 to 4 times normal size, and a generalised 
enlargement of lymph nodes was observed frequently (Budiarso & Hardjosworo, 
1976; Pranoto & Pudjiastono, 1967). 
The typical development of pathological changes following JDV infection can be 
divided into three distinguishable phases (Dharma et al., 1991).  Phase one 
changes consist of a generalised lymphoreticular reaction, which occurs during 
the first week post-infection (p.i.), prior to the development of clinical signs.    45 
During the second phase, from one to five weeks p.i., the spleen and lymph 
nodes become markedly enlarged, petechial haemorrhages may occur on serosal 
surfaces, and ulcerations are sometimes found on oral and intestinal mucosae.  
Histopathological analysis demonstrates an intense non-follicular 
lymphoproliferative disorder in which pleomorphic lymphoblastoid cells come to 
predominate throughout parafollicular areas of the spleen and lymph nodes, 
causing total destruction of the normal follicular architecture.  A similar 
proliferative cellular infiltrate is also seen in the parenchyma of the lungs, liver 
and kidneys and other organs, and unusual lesions containing proliferative 
macrophage-like cells are seen within small vessels in the lung (Budiarso & 
Rikihisa, 1992; Dharma et al., 1991).  This multi-system involvement contributes 
to the mortality rate of about 20 %, although earlier outbreaks often had higher 
mortalities (Dharma et al., 1991; Teuscher et al., 1981).  In non-fatal infections, 
phase three changes represent regression of lesions and commence about five 
weeks p.i.  These changes consist of a progressive decline in the parafollicular 
reaction and a marked increase in follicular development and plasma cell 
formation.  In animals that survive the acute phase, remission of signs coincides 
with both a reduction in the viraemia and the appearance of anti-viral antibodies, 
which occurs after about 8 weeks (Hartaningsih et al., 1994).   
The host range of lentiviruses is normally very restricted and is limited to the 
natural host and closely related species.  Since the initial outbreak of Jembrana 
disease in 1964, there has been general agreement amongst JDV investigators 
that the disease has attenuated somewhat, although this impression is difficult to 
substantiate (Wilcox et al., 1995).  Although some buffalo (Bubalis bubalis) were 
reportedly affected in an early outbreak (Pranoto & Pudjiastono, 1967), the 
severe effects of experimental JDV infection have been specific to Bali cattle, 
which are a unique species of cattle descended from wild banteng of Java 
(Soeharsono et al., 1990; 1995).  Infection of buffalo, Ongole cattle (Bos indicus), 
Friesian cattle (Bos taurus) and crossbred Bali cattle (Bos javanicus x Bos 
indicus) with the Tabanan/87 strain of JDV resulted in a transient fever and 
viraemia, but only a mild clinical disease.   46 
JDV and the Tat protein 
Sequencing of the complete genome confirmed that JDV is genetically closely 
related but distinct to BIV (Chadwick et al., 1995b).  The CA protein of both 
viruses share 75 % homology (Chadwick et al., 1995b), cross react antigenically 
(Kertayadnya et al., 1993), and no truncated recombinant proteins derived from 
gag were able to differentiate this two viruses (Desport et al., 2005).  With the 
viral genome size of 7.7 kb, JDV is a lentivirus with the smallest genome 
identified thus far.  The genomic organisation is simpler than BIV (Figure 2.13); it 
contains three obligatory retroviral coding regions of gag, pol, and env, flanked by 
two long LTRs containing transcriptional regulatory elements (Chadwick et al., 
1995b).  In addition, JDV possesses a number of accessory and regulatory genes 
tat, rev, vif and tmx. 
Figure 2.13.  Schematic organisation of the DNA proviral genome of bovine 
lentiviruses. 
 
Like the other lentiviruses, JDV encodes a Tat protein and sequence analysis has 
predicted that JDV Tat is translated from two separate tat coding exons by 
splicing (Chadwick et al., 1995b).  Alignment of the amino acid sequence 
encoded by tat exon 1 with those of BIV and the primate lentiviruses identifies the   47 
presence of five common structural domains: acidic amino-terminal, cysteine-rich, 
conserved core, basic, and carboxyl-terminal (Chadwick et al., 1995b; Chen et 
al., 1999).  Chen et al. (1999) demonstrated that the first coding exon is sufficient 
to generate a functional Tat, which strongly trans-activates the viral promoter to 
drive high viral gene expression that would be expected to result in the high-level 
viraemia seen in the disease.  This activation was mediated
 by TAR-like elements 
located in the LTR, and the loop region in
 the TAR seemed to be less critical.  The 
JDV Tat can not only
 stimulate its own LTR significantly but also stimulates BIV 
and HIV LTR-directed
 CAT expression to high levels, equivalent to those obtained 
with their homologous Tat proteins (Chen et al., 1999).  Subsequent study 
showed that JDV Tat trans-activated the HIV LTR in a partially-TAR-dependent 
manner (Chen et al., 2000). 
Similar to BIV Tat, the JDV Tat uses ARM domain to recognise its TAR sites, and 
adopts a ß-hairpin conformation upon TAR binding and utilise several side chains 
other than arginine for specific RNA recognition (Chen & Frankel, 1994,  1995; 
Puglisi et al., 1995; Smith et al., 2000; Ye et al., 1995).  In this situation, cyclin T1 
is not required to form stable, high-affinity RNA complex and the loops do not 
contribute to recognition, which is in contrast to the HIV Tat-TAR interaction 
(Barboric et al., 2000; Bogerd et al., 2000; Chen et al., 2000; Chen & Frankel, 
1994; Smith et al., 2000).  Despite the structural similarity of the TAR sites (Smith 
et al., 1998), BIV Tat binds HIV TAR only weakly and cannot use cyclin T1 as a 
cofactor to bind TAR.  Interestingly however, the JDV Tat ARM can flexibly bind 
heterologous RNAs with high affinity in two distinct binding modes, by using a 
cyclin T1-independent, ß-hairpin conformation to bind BIV TAR and a cyclin T1-
dependent, extended conformation to bind HIV TAR, utilising one arginine for 
specific recognition (Smith et al., 2000). 
The host immune responses against JDV infection 
In JDV-infected cattle, an antibody response is not usually detectable until at 
least eight weeks p.i., which is probably a consequence of the absence of a   48 
significant follicular B-cell response until the recovery phase (Hartaningsih et al., 
1994).  Recovered animals do not develop any further JDV-associated clinical 
disease, but remain persistently infected with the virus.   
The development of an antibody response to JDV was investigated in 19 cattle 
recovered from an experimental infection over the period of 59 weeks after 
infection (Hartaningsih et al., 1994).  An ELISA was employed to detect the 
antibody, using a sucrose gradient purified virus antigen prepared from the 
plasma of acutely infected animals.  Antibody was not detected until 
approximately 6 weeks after infection and was present in all cattle only after 11 
weeks p.i., peaked at 23-33 weeks p.i.  and persisted during the observation 
period.  The principal serological response to JDV proteins was against the p26 
CA (Kertayadnya et al., 1993), typical of other lentivirus infections (Battles et al., 
1992; Grund et al., 1994; Sheppard et al., 1991).  An antibody response to other 
higher and lower molecular weight virus proteins was demonstrated by Western 
immunoblotting (Kertayadnya et al., 1993), which could have been SU and TM 
glycoproteins, unprocessed Gag and other viral protein such as MA and NC as 
previously demonstrated in BIV infections (Whetstone et al., 1990).   
In another experiment, Wareing et al. (1999) demonstrated that JDV-infected 
calves gave a delayed and significantly lower antibody response when they were 
inoculated 3 weeks p.i. with Brucella abortus Strain 19.  Similarly, compared with 
controls, antibody to chicken ovalbumin (cOVA) was also delayed in the JDV-
infected calves.   
Histopathological examination revealed atrophy of follicular (B-cell) areas and 
marked proliferation of lymphoblastoid cells in parafollicular (T-cell) areas, of 
lymph nodes and spleen (Dharma et al., 1991).  A scarcity of plasma cells and a 
significant decrease in CD4/CD8 ratio during acute phase to weeks 3 p.i.  were 
also reported (Dharma et al., 1994).  After approximately 5 weeks there is a 
decrease in the parafollicular proliferation, regeneration of follicular cells, and 
increased plasma cell formation.  A concurrent Pasteurella pneumonia is 
commonly detected in animals which die during or following the acute phase of   49 
Jembrana disease (Dharma et al., 1991).  The histological changes and the 
delayed antibody response suggest JDV infection results in impairment of 
humoral immune function, which is a common aspect of the pathogenesis of 
disease associated with lentivirus infections, in both man and animals (Haffer et 
al., 1990; Newman et al., 1991). 
The production of virus neutralising antibodies has been shown to limit virus 
replication and expression in many lentivirus infections (Cao et al., 1995; 
Clements & Zink, 1996).  However, there is only limited information on the 
presence of neutralising antibody in JDV-infected cattle (Hartaningsih et al., 2001) 
but animals that survive the initial infection develop immunity, exhibit a minimal 
viraemia, and are resistant to re-infection (Soeharsono et al., 1990) and there 
have been no reports of recurrence of disease in cattle that have survived the 
initial acute febrile disease.  It is possible that cell mediated immune response 
may contribute in this resolution.  This feature provides a prominent example on 
the success of immune response in controlling lentivirus infection. 
Vaccination against JDV 
Control Jembrana disease has been attempted utilising inactivated virus 
preparation prepared from spleen tissue of acutely affected cattle (Hartaningsih et 
al., 2001).  The vaccination procedure suppressed the duration and alleviated the 
severity of the disease but did not completely prevent the development of disease 
in animals challenged with 100 infectious doses of virus (ID50).  Vaccination in 
field conditions is restricted to endemic areas, due to concerns with the safety of 
the inactivated vaccine but its use has demonstrated that vaccination is feasible.  
There is an urgent need for a safer and more effective vaccine, and approaches 
using recombinant proteins and DNA vaccines should be considered using a 
variety of virus structural proteins and glycoproteins, and also regulatory proteins 
such as Tat.  50 
Chapter 3   
Jembrana disease virus tat gene: 
identification of transcript and sequence 
variation in infected Bali cattle 
Summary 
Transcription and sequence variation of JDV trans-activator gene (tat) was 
investigated in 3 strains of JDV.  tat cDNA was cloned from spleens and PBMCs 
from experimentally-infected cattle during the peak period of viraemia associated 
with the acute disease syndrome characteristic of Jembrana disease.  RT-PCR 
examination using a set of 7 different primers distinguished 4 predominant tat 
mRNAs expressed in similar patterns by the 3 virus strains.  Nucleotide sequence 
analysis revealed that the transcripts were generated by multiple splicing events 
involving 2 potential coding exons, in the presence or the absence of noncoding 
exons between the major splice donor (SD) downstream from the LTR and the 
splice acceptor (SA) at the first tat exon (tat-1).  The use of a SD downstream of 
tat-1 was common which suggests that a Tat protein of 97 amino acids specified 
by tat-1 is translated in the viraemic phase.  Nucleotide sequence analysis of tat-1 
identified limited variation; the strains from the same geographical areas shared a 
96.6 and 100 % homology, but there was a lower of 89.1 % between strains from 
geographically different areas of Indonesia.     51 
Introduction  
Genetic organisation of lentiviruses and including the bovine lentiviruses 
Jembrana disease virus (JDV) and Bovine immunodeficiency virus (BIV) is 
characterised by the presence of retroviral obligatory genes gag, pol and env, 
along with regulatory and accessory genes (Coffin et al., 1997).  Lentiviruses 
encode transcriptional trans-activator (Tat) proteins that potently upregulate the 
level of gene expression from their cognate long terminal repeat (LTR) promoters 
(Cullen, 1991; Jones & Peterlin, 1994; Jones, 1997).  They use a complex 
splicing strategy to generate different species of viral mRNA for protein 
production.  The Tat protein is derived from multiply spliced mRNAs involving 2 
coding exons; composition of the encoded protein depends on the splicing 
patterns between the coding exons (Fong et al., 1997; Unger et al., 1991).  In 
JDV, 2 separate tat exons have been identified (Chadwick et al., 1995b).  The 
first exon encoded a cysteine-rich region, a core region, and a downstream basic
 
domain that was found in the Tat proteins of most lentiviruses,
 including BIV 
(Garvey et al., 1990).   
JDV infection causes an acute disease syndrome in Bali cattle with a case fatality 
rate of approximately 20 %.  Jembrana disease is endemic in Indonesia.  
Vaccination using a detergent-inactivated virus preparation prepared from tissues 
of acutely affected cattle has been shown to induce a protective immune 
response (Hartaningsih et al., 2001).  Use of this vaccine is limited to areas where 
the disease is endemic because of uncertainty about complete inactivation of the 
virus (Dr Nining Hartaningsih, Personal Communication) and a safer vaccine is 
needed.   
Attempts to control lentivirus infections in other animal systems have involved a 
number of approaches, including Tat vaccines.  Vaccination with HIV-1 Tat in 
animal models has been shown to induce a protective immunity against disease 
progression (Agwale et al., 2002; Cafaro et al., 1999; Pauza et al., 2000; 
Stittelaar et al., 2002).  Tat is also a potential immunogen for the control of   52 
Jembrana disease and there is no information available on the genetic variability 
of tat that might lead to variation in antigenicity of the encoded protein.   
Preliminary to an investigation of Tat as a potential immunogen for the control of 
Jembrana disease, further characterisation of Tat was considered necessary and 
is reported in this Chapter.  The investigations reported include the mechanism of 
tat transcription in acutely infected animals, whether both or only one of the 2 tat 
exons was involved in the translation of the encoded Tat protein.  Splice donor 
and SA sites were also examined in subgenomic tat mRNA.  The variability of tat 
was investigated by an examination of proviral DNA extracted from tissues of 
affected animals in different regions of Indonesia and in different time periods.   
Materials and methods 
Isolation of nucleic acid  
Extraction of total RNA from tissues 
Total RNA was extracted from spleen tissues and PBMCs using a Totally RNA
TM 
kit (Ambion), which is based on a method described by Chomczynski and Sacchi 
(1987), according to the manufacturer’s instructions.  Briefly, cells or tissues were 
homogenised with 10 volumes of Denaturation Solution, lysates were transferred 
into a fresh tube (referred to as the Starting Volume).  The lysate was pipetted up 
and down to help solubilise the RNA, and then an equal volume of 
Phenol:Chloroform:IAA was added.  The mixture was vigorously shaken for 1 min 
and then kept on ice for 5-10 min and subsequently centrifuged (12,000 g, 10 
min, 4°C).  The resulting aqueous phase was transferred to a fresh tube and 
mixed with 1/10 volume of 5 M sodium acetate.  One Starting Volume of Acid-
Phenol:Chloroform was added followed by vigorous shaking for 1 min.  
Preparations were kept on ice and centrifuged as before.  The aqueous phase 
was placed in a fresh tube, mixed with an equal volume of isopropanol and kept 
at –20°C for 1 h.  After centrifugation (12,000 g, 15-20 min), the RNA pellet was 
washed with 70 % ethanol and resuspended in 0.5-1 mLof RNase-free dH2O.  To   53 
remove residual genomic DNA, a 1/10 volume of DNase Reaction Buffer and 1 µl 
of RNase-free DNase I per 100 µl RNA were added, and mixed gently.  Following 
incubation for 30 min at 37°C, a 1/10 volume DNase Inactivation Reagent was 
added, mixed, and incubated for 2 min at room temperature.  The mixture was 
centrifuged (10,000 g, 1 min) and the supernatant transferred into a new tube and 
stored at -70°C until needed. 
Preparation of genomic DNA 
Genomic DNA was prepared by a technique similar to that for RNA except that 
Acid-Phenol:Chloroform was replaced with Tris-buffered Phenol:Chloroform and 
the resulting DNA pellet was dissolved in TE buffer (10 mM Tris, 0.1 mM EDTA 
pH 8).   
Plasmid purification 
Qiagen Miniprep kits were used for purifying plasmid DNA for subsequent 
sequence analysis.  Briefly, 1.5 mLof an overnight bacterial culture was 
centrifuged (14,000 g, 20 seconds) and the pellet resuspended in 250 µl of buffer 
P1.  The cells were lysed with 250 µl buffer P2, neutralised with 250 µl buffer P3 
followed by gentle inversion until a precipitate formed.  The mixture was 
centrifuged (14,000 g, 10 min) to remove cell debris, and the supernatant 
containing the plasmid DNA was applied to a QIAprep column (Qiagen).  After 
centrifugation (14,000 g, 30 seconds), the flow through was discarded and the 
column was washed twice with 500 µl buffer PE by centrifugation (14,000 g for 30 
s and then 2 min).  Finally 60 µl of warm distilled H2O was added, centrifuged 
(14,000 g, 1 min) and the supernate containing DNA stored at –20°C.  Aliquots 
were subjected to agarose gel to check integrity and were also quantified 
fluorometrically. 
Recovery of DNA from agarose gels   
Following agarose gel electrophoresis, DNA fragments (bands) of interest were 
recovered from 0.8 % gels using QIAquick Gel Extraction Kit (Qiagen) according 
to the protocol of the manufacturer.  Each band was excised from the gel using a   54 
clean sharp scalpel and transferred to an eppendorf tube.  Two times the gel 
volume of buffer QE was added and incubated at 50°C for 5 min to dissolve the 
gel.  After complete solubilisation, the mixture was passed through the spin 
column by centrifugation and washed once with 750 µl buffer PE.  The DNA was 
eluted from the membrane by adding 30 µl of warm 10 mM Tris-HCl, pH 7.5, and 
then centrifuged (14,000 g, 1 min).   
Agarose gel electrophoresis  
Agarose gel electrophoresis was used to fractionate DNA molecules to enable 
analysis of PCR products and restriction enzyme digests, to determine plasmid 
integrity, and estimate DNA concentration.  Prior to loading, DNA samples were 
mixed with 6X tracking dye (0.25 % bromophenol blue, 0.25 % xylene cyanol FF 
and 10 % glycerol) and electrophoresed on 0.8 to 2 % agarose gels containing 
0.1 µg/mLethidium bromide.  Size markers (100 bp or 1 kb plus DNA ladders; 
Gibco) were added to separate lanes.  Electrophoresis was carried out in TAE 
buffer (40 mM Tris, 20 mM sodium acetate, 2 mM Na2EDTA, and glacial acetic 
acid to pH 8.3) at a constant voltage of 40–100 kV for 40 min to 3 h depending on 
the resolution required.  Sometimes, variations in the gel percentage, voltage and 
run times were used to obtain better separation of products, especially when 
multiple products were expected.  Gels were examined with an ultraviolet 
transilluminator to visualise DNA bands. 
Estimation of nucleic acid concentration 
The amount of RNA in samples was estimated photometrically by measuring 
absorption of the samples at 260 nm.  An OD260 of 1 was considered to indicate 
40 µg/mLof single-stranded RNA.  The purity was determined by the OD260/ OD280 
ratio: ratios of less than 2.0 were considered to indicate the present of 
contaminants. 
The concentration of DNA was determined by fluorometric analysis in a 
DYNAQuant 200 Fluorometer (Hoefer-Pharmacia).  DNA samples were mixed   55 
with 2 mLfluorometer working solution (0.1 mg/mLfluorochrome [Hoechst 33258] 
in 10 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, pH 7.4.  The dye binds to DNA 
and fluoresces at 460 nm relative to the DNA concentration standardised with a 
known concentration of calf thymus DNA (Promega). 
Oligonucleotide primers 
The oligonucleotide primers in this study were designed based on the genomic 
RNA sequence of the Tabanan/87 reference strain of JDV (Chadwick et al., 
1995b).  Primers were obtained from Invitrogen and dissolved in water to a final 
concentration of 200 µM.  The sequence and annealing positions of the primers 
used are indicated in Table 3.1.  The location of primers used for cDNA synthesis 
and detection is depicted in Figure 3.5. 
Reverse transcription 
cDNA was synthesised with Moloney murine leukaemia virus reverse 
transcriptase (MLV RT) SuperscriptII RNAseH
– (Invitrogen) with an antisense 
primer j7730/3’ (Table 3.2) following the protocol recommended by the 
manufacturer.  Briefly, total RNA (4µg) was mixed with 4 pmol primer and 10 µmol 
DNTP mix in a total volume of 10 µl.  To disrupt the secondary structure of the 
RNA, the mixture was heated at 65°C for 10 min, then quickly chilled on ice for 1 
min.  After brief centrifugation, the following components were added: 2 µl 10X 
RT buffer, 2 µl 0.1 M DTT, 4 µl 25 mM MgCl2 and 1 µl RNaseOUT (40 U/ µl).  The 
content of the tube was mixed gently and incubated at 42°C for 2 min.  One µl of 
reverse transcriptase (50 units) was added, and further incubated for 40 min.  The 
reaction was terminated by heating at 70°C for 15 min, then chilled on ice for 2 
min, and finally treated with 1 µl RNase H at 37°C for 20 min to degrade the RNA 
template.  The reaction was stored at –70°C until needed.   
Polymerase chain reaction (PCR) 
PCR was employed to detect tat sequences in cDNA and proviral DNA, and for 
detection of recombinant plasmids.  
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Table 3.1.  Oligonucleotide primers used for the detection of tat transcripts (Primers 1-7) and proviral DNA (Primers 
8 -10).   
Genomic positions
1  Primer  Sequence (5’ to 3’) 
Nucleotide   Region 
j129/5’ TGTCTCCTCGACCCGAAC  129–146 U5-LTR 
j5047/5’ GGCACAATGGAGGATTT  5047–5063  5’  tat 1 
j7069/3’  TTTGAGCGCCCAAGTTTG  7069–7052 middle tat 2 
j7730/3’ CCGAAAGCCAAACGACCTT  7730–7712 R-LTR 
Tab_Pulj3’
2= CACTGGAGGAC^CGTGATC 7043–7033^5335–5329  3’  tat splice junction 
Kalj1/3’
2= ACTGGAGGAC^CGTTATCCT 7042–7033^5335–5327  3’  tat splice junction 
Kalj2/3’
2= TGAGGATAAG^TCTGGAGTAGAT 6967–6958^5278–5267  3’  tat splice junction 
j4938  GGGAAGGAGCCAACGATTC 4938–4956  upstream tat 1 
j5338 CACCGTGATCTTCCAGGGT  5338–5320 downstream tat 1 
jK5337
3= ACCGTTATCCTCCAGGACCCA  5337–5317 downstream tat 1 
1 The position was based on JDV Tabanan/87 genomic RNA sequences (Chadwick et al., 1995b). 
2 Primers were designed following sequence identification of splicing junction between the two tat exons.  Sequences and numbers are 
separated by a carat (^) to indicate fusion of two separate regions of the viral genome. 
3 Primer was designed based on the Kalimantan sequences identified from the transcripts  57 
PCR using proof-reading polymerase 
Expand 
TM High Fidelity PCR System (Roche) a blend of Taq and Pfu proof 
reading polymerases was used for cloning.  PCR reactions were performed in a 
20 µl volume containing 200–600 µM dNTPs, 5–20 pmol primers depending on 
the template (Table 3.2), 2.0 µl of PCR buffer with 15 mM MgCl2, 2 U Expand
 TM 
and 1–2 µl template.  Amplification was performed in a
 PE2400 automatic 
thermocycler (Perkin-Elmer Cetus) under the conditions described in Table 3.3. 
Table 3.2.  Various PCR reaction mixes used for the detection of tat. 
Volume (µl) 
Expand
TM system 
Ingredient 
cDNA Proviral  DNA 
Dynazyme 
system 
10X buffer with MgCl2 2  2  2 
dNTP mix (2 mM)  6  2  2 
Forward primer (20 µM)  1  0.25  0.25 
Reverse primer (20µM)  1  0.25  0.25 
Polymerase   0.75  0.75  0.25 
Template 2  1–2  2 
Ultrapure H2O  Up to 20 µl  Up to 20 µl  Up to 20 µl 
 
PCR for screening of recombinant plasmids 
PCR was conducted with a Dynazyme (Finnzyme) system summarised in Table 
3.2 using 5 pmol of each vector-specific M13/F (5’GTAAAACGACGGCCAGT 3’) 
and M13/R (5’AACAGCTATGACCATG 3’) or gene specific primers (Table 3.1), 
and subjected to similar condition to the Expand 
TM system but with modified 
annealing, at 56°C for M13 or 60°C for gene-specific primers, and elongation for 
40 sec (Table 3.3).     58 
Table 3.3.  Various thermocycling conditions used for the detection of 
tat. 
Duration 
Expand
TM system 
Step Temp 
 (°C) 
cDNA Proviral  DNA 
Dynazyme 
system 
Cycles 
 
Initial denaturation  95  5 min  5 min  5 min  1 
Denaturation   95  40 sec  40 sec  40 sec 
60  Annealing  
56 or 60
1 
30 sec  30 sec   
30 sec 
Elongation   72  1.5–3 min  1.5 min  40 sec 
 
Final elongation  72  7 min  7 min  7 min  1 
1 Varied depending on the primers used in the reaction. 
 
Cloning of PCR products 
Taq polymerase has a terminal transferase activity that results in the non-
templated addition of a single nucleotide to the 3'-ends of PCR products.  In the 
presence of all 4 dNTPs, dA is added preferentially.  This terminal transferase 
activity is the basis of the TA-cloning strategy, which in the current study was 
conducted using pDrive (Qiagen) or pCR2.1 (Invitrogen) cloning vectors 
according to the protocol provided by the manufacturers.  Reaction mixtures 
(Table 3.4) of 10 µl containing 30–50 ng of DNA, 50 ng vector, ligase and dH2O 
were mixed gently and incubated at 14°C for 2 h (pDrive) or 14 h (pCR2.1). 
Table 3.4.  Quantities of reagents incorporated into TA-cloning reactions. 
Volume 
Ingredient  
pCR2.1 pDrive 
Vector (50 ng/µl)  1 µl  1 µl 
PCR product  30–50 ng  30–50 ng 
Buffer  1 µl  5 µl 
T4 DNA Ligase  1 µl  - 
Ultrapure dH2O  Up to 10 µl  Up to 10 µl 
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Transformation of plasmids into Escherichia coli 
The Escherichia coli Top10F’ [F´{lacI
q Tn10(Tet
R)} mcrA D(mrr-hsdRMS-mcrBC) 
f80lacZDM15 DlacX74 deoR recA1 araD139 D(ara-leu)7697 galU galK rpsL (Str
R) 
endA1 nupG ] (Invitrogen) was used in these experiments.  Transformation was 
conducted by gently mixing 25 µl TOP 10F’ one shot competent cells (Invitrogen) 
with 2 µl ligation mixture, followed by incubation on ice for 30 min.  The cells were 
then heated at 42°C for 30 sec and kept on ice for a further 2 min before adding 
125 µl of SOC medium.  The cells were incubated at 37°C for 1 h to allow 
antibiotic resistance expression and then spread on Luria-Bertani (LB) plates (1 
% Bacto-tryptone, 0.5 % yeast extract, 1 % NaCl and 1 % agar) containing 100 
µg/mLampicillin, 50 µM isopropyl
 β-D-thiogalactopyranoside (IPTG) and 0.4 % X-
Gal for “blue-white” screening.  The plates were incubated at 37°C for at least 18 
h and then kept 2 h at 4°C before further screening.   
Screening for recombinant plasmids 
For each cloned PCR product, 25 white colonies were randomly picked and each 
was diluted with 20 μl of 0.1 % Triton-X in TE buffer, and boiled for 5 min.  After 
centrifugation at 14,000 g for 5 min, 2 ul of supernatant was used as a template 
for PCR with Dynazyme (Finnzyme) as detailed above. 
Sequencing 
Nucleotide sequencing was conducted by a dideoxy-chain termination method as 
described by Sanger et al. (Sanger et al., 1977) in an ABI377A fluorescence 
automated sequencing apparatus.  Half sequencing reactions were prepared for 
both anti-sense and sense strands using universal M13 primers in ABI PRISM
TM 
Big Dye Terminator version 3.1 ready reaction kit with Amplitaq DNA polymerase 
(Perkin-Elmer, Applied Biosystems).  In brief, 10 µl reactions containing 500 ng 
plasmid DNA, 4 µl Terminator Ready Reaction mix and 3.2 pmol of M13/F or R 
primer were subjected to amplification conditions of 96°C for 2 min; followed by 
30 cycles of 96°C/10 sec, 55°C/5 sec and 65°C/4 min, with a 14°C final hold.  
DNA was precipitated by adding 25 µl of 95 % ethanol, 1 µl of 125 mM EDTA and   60 
1 µl of 3 M Na-acetate (pH 4.6) on ice for 20 min before centrifugation at 14,000 g 
for 30 min at room temperature.  Pellets were washed with 70 % ethanol, 
vacuum-dried briefly, and submitted for sequencing.  SeqEd
TM version 1.0.3 
(Applied Biosystem Inc.) was used to display and edit raw sequence data. 
Isolation and identification of tat transcripts  
Virus strains used for characterisation of tat transcripts 
Three JDV strains were used in this study.  All originated from Indonesia, two 
from Bali and one from Kalimantan.  The 2 Bali strains included the prototype 
strain, Tabanan/87 isolated during 1987 from an affected animal in the Tabanan 
district, for which complete sequence data was available (Chadwick et al., 
1995b).  The second Bali strain (Pulukan/00) was from an affected animal in the 
Pulukan subdistrict in 2000.  The Kal/00 strain was obtained from an affected 
animal during an outbreak in the Tanah Laut district in mid-2000.  The JDV 
strains were maintained by passage of spleen tissue in the natural host as 
described by Soeharsono et al.  (1990).  Information on the number of passages 
of each strain prior to the collection of tissues used in these current experiments 
was not available but was estimated at less than five. 
Animal infection and processing of tissues 
To enable the collection of tissues from infected animals, the 3 strains were each 
inoculated into a single Bali animal of approximately 18 months age at the 
Disease Investigation Centre in Denpasar, using procedures similar to those 
described by Soeharsono et al. (1990).  Rectal temperature, total leukocyte 
counts and enlargement of the superficial lymph nodes were monitored.  A rectal 
temperature in excess of 39.5°C for 2 or more days, in conjunction with 
leukopenia and enlargement of the superficial lymph nodes was used as an index 
of the occurrence of Jembrana disease.  To collect peripheral blood mononuclear 
cells (PBMCs), heparinised whole blood was obtained and the cells separated 
using Ficol-paque (Gibco-BRL), then washed in phosphate-buffered saline (PBS) 
and pelleted by centrifugation (3,000 g, 5 min).  The animals were killed on the   61 
second day of the febrile period following infection, and spleen tissue was 
collected.  Spleen tissue was examined histologically following necropsies to 
verify the animals were affected with Jembrana disease (Dharma et al., 1991).  
Aliquots of the spleen tissue were washed with PBS and stored in liquid nitrogen 
pending further examination.  In addition to the samples from experimentally 
infected cattle, one additional sample (Kal/03) of spleen tissue was obtained from 
an infected Bali animal during an outbreak in the Tanah Laut district of 
Kalimantan in 2003. 
RT PCR 
Total cellular RNA was extracted from 1 g of spleen or 50 µl of PBMC suspension 
using a Totally RNA
TM kit as detailed previously.  Four microgram of RNA were 
reverse transcribed at 47°C for 40 min using primer j7730/3’ which corresponds to 
the transcription termination region.  For the detection of tat transcripts, 2 µl of RT 
product was used as a template for PCR containing 200 µM dNTPs, 20 pmol 
primers, 2.0 µl of PCR buffer with 15 mM MgCl2 (Roche), and 0.75 µl of Expand
TM 
system (Roche).  Primer pair j5047/5’ and j7069/3’ located in tat exons 1 and 2, 
respectively, were selected to determine the junction region.  To characterise the 
5’ region of the transcripts following the identification of the junction sequences, 
junction primers Tab_Pulj3’ specific for Tabanan/87 and Pulukan/00 strains, and 
Kalj1/3’ and Kalj2/3’ for Kal/00 strain, were designed and used in combination 
with j129/5’ situated downstream the transcription start site. 
Amplified PCR products were extracted after agarose gel electrophoresis and TA-
cloned as described above.  The cloned DNA was subjected to automated 
sequencing
 using universal M13 primers in both orientations. 
Cloning of tat DNA and nucleotide sequence analysis  
Total DNA was prepared from PBMCs and/or spleen tissues of experimentally 
and naturally infected cattle as described previously.  The tat exon 1 was 
amplified from 300 ng of total DNA using oligonucleotide primers (Table 3.1) 
j4938/j5338 for Tabanan/87 and Pulukan/00, or j4938/jK5337 for Kal/00 DNA   62 
templates in conjunction with the Expand
TM system.  The reaction mixtures were 
prepared as detailed in Table 3.2 and subjected to 30 cycles of melting at 94°C 
for 30 seconds, annealing at 60°C with a 1.5 min extension at 72°C.  PCR 
products were separated on 0.8 % agarose gels and purified with a QIAquick gel 
extraction kit (Quiagen).  The resulting DNA fragments were TA cloned and 
sequenced using universal M13 primers as described earlier.  Sequences were 
aligned with PileUp program of the Genetics Computer Group (GCG) (Wisconsin 
package) and displayed by Pretty program provided by ANGIS (Australian 
Genomic Information Services). 
 
Table 3.5.  Rectal temperatures at intervals after cattle were infected 
with 3 JDV strains.  A rectal temperature in excess of 39.5°C was 
indicative of the onset of the acute phase of Jembrana disease.  The 
animals were killed on the second day of the febrile reaction.  Samples 
collected from the animals for subsequent analysis are indicated. 
Temperature (°C)  Samples collected for analysis  Days after 
infection 
Tab  Pul Kal Tab  Pul  Kal 
1  38.0 38.6 38.2 –  –  – 
2 –  38.8  –  –  –  – 
3  38.3 38.9 38.4 –-  PBMCs  – 
4  38.0 38.7 38.3 PBMCs  –  PBMCs 
5  38.0 38.5 38.2 –  PBMCs  – 
6  38.3 39.9 38.6 –  –  – 
7 39.2  †  38.3  PBMCs  Spleen, 
PBMCs 
PBMCs 
8 39.9    39.3  –  –  – 
9 †    39.9  Spleen, 
PBMCs 
– – 
10    †  –  –  Spleen, 
PBMCs 
    † denotes the animal was killed.   63 
Results 
Isolation and identification cDNAs representing 3’ end of tat 
transcripts 
Genomic sequence analysis has predicted that JDV tat is encoded by 2 exons 
(Figure 3.5A).  The first is located downstream of the vif and overlapped at half 3’ 
end with env from nt 5010 to 5303, and the second is encoded by an exon 
located within the envelope gene from nt 7057 to 7087.  In order to identify 
splicing patterns between the 2 coding exons, 3 different primers were used to 
amplify spleen and PBMC mRNAs from experimentally infected cattle.  Primer 
j5047/5’ was complementary to 5' to the first tat exon, and the second primer, 
j7069/3’ was homologous to the predicted second exon.  Primer, j7730/3’ was 
used in place of j7069/3’ to hybridise at the poly(A) tail located at the LTR.  
Clones were generated either with the first (j5047/5’and j7069/3’) or the second 
(j5047/5’and j7730/3’) pair of primers.  Products greater than 300 bp were 
amplified with the first primer pair (Figure 3.1A), while the second primer set 
allowed amplification of 3’ end transcripts of approximately 1,000 bp size (Figure 
3.1B).  Productive amplification was detected only from spleen and PBMCs 
collected on the second day of fever.  No amplicon was obtained from PBMCs 
collected before fever.  To resolve nt sequence of this region, the PCR products 
were TA-cloned; 25 clones were randomly selected from each amplification 
reaction and screened by PCR using j5047/5’– j7069/3’ primer pair.  In 300 white 
colonies, 2 different PCR products were detected (Figure 3.1, A and B), the 
predominant product from both spleen and PBMC cDNA of the 3 JDV strains were 
clones that produced band of approximately 300 bp as shown in Figure 3.2.  One 
band migrating slightly above the major band was detected from Kal/00 sample 
(Figure 3.2C lane 6).  Subsequent nucleotide sequencing confirmed the size of 
the bands, which were 327 bp for the predominant band and 345 bp for the other.  
Both incorporated coding exons 1 and 2 but displayed different splice sites 
between these 2 exons.  The majority of transcripts demonstrated the splice 
junction generated by joining the SD downstream of coding exon 1 at nt position 
5335 and the SA at the start of exon 2 at nt position 7033; these were conserved   64 
among the 3 strains despite nt substitutions detected in the Kal/00 strain (Figure 
3.7).  The only transcript detected from the Kal/00 strain utilised a SD upstream 
the stop codon of exon 1 at nt 5268 and a SA upstream of the second exon at nt 
6947.  Amplification with the second primer set in all clones also demonstrated 
the extension of the second coding exon to the 3' end of the JDV genome, right 
through the polyadenylation site at nt 7730. 
 
Figure 3.1.  PCR amplification of tat cDNA.  To identify 3’ regions of mRNA 
and the splice patterns between the 2 coding exons, cDNA was amplified 
using primer sets (A) j5047/5’ and j7069/3’ and (B) j5047/5’ and j7730/3’, 
which detected products of approximately 300 bp and 1000 bp, respectively.  
Each PCR product was subsequently TA-cloned and sequenced.  Lanes 1-3, 
Tabanan/87, Pulukan/00 and Kal/00 strains, respectively.  Lane 4, control 
without DNA.  Lane M, 1 Kb Plus DNA ladder (Invitrogen). 
Isolation and identification of 5’ end of transcripts 
Following identification of splicing sites between the 2 tat exons, three 3’ 
“junction” primers were designed.  These were Tab_Pulj3’, Kalj1/3’ and Kalj2/3’, 
the sequences of which spanned the splice junctions created by joining the SD at 
nt position 5335 and SA at position 7033 (5335^7033) with Tabanan/87 and 
Pulukan/00 strains, and 5335 to 7033 (5335^7033) and 5278 to 6967   65 
(5278^6967) with the Kal/00 strain.  A 5’ primer (j129) homologous to the U5 
region of the LTR and each of junction primers mentioned above was used to 
synthesise single-stranded cDNA from RNA extracted from tissues of the JDV-
infected cattle.  In combination with primers complementary to the common splice 
sites 5335^7033, 6 products varying from 490 to 706 bp were amplified, whose 
separation was achieved through electrophoresis in 2 % agarose gels at 40 V for 
4–5 h as shown in Figure 3.3A.  In contrast, combination of j129 and a primer 
homologous to the second junction sequence (5278^6967) of Kal/00 amplified a 
different region of the genome.  Sequence analysis of this product (Figure 3.3, 
Panel B) showed there was considerable homology between the junction primer 
and 5’ region of the genome (Figure 3.3, Panel C).  Attempts to increase the 
specificity of the reaction by using higher annealing temperature did not result in 
amplification of the expected product. 
 
PCR products generated with the first primer set were TA-cloned and screened by 
PCR with the same primers used for cDNA amplification.  In 300 randomly 
selected clones, 6 types of PCR product were detected (Figure 3.4).  The 
predominant types were 583 (type III), 553 (type IV), 515 (type V) and 490 (type 
VI) bp as shown in Figure 3.3, Panel A).  Larger 706 (type I) and 638 bp (type II) 
products (Figure 3.3, Panel A) were detected but at a considerably lower 
frequency than the smaller transcripts and they were detected only in the tissues 
of animals infected with the Pulukan/00 strain (Fig 3.4, Panel B, lanes 1–3 and 
17).  The various transcripts differed in SA sites used (nt 4938 in types I, II IV and 
VI; nt 4894 with types III and V) upstream of the first coding exon, and in the 
presence (nt 4014–4081 in types I, III and IV; nt 4663–4808 in types I and II) or 
absence (types V and VI) of non coding exons between the first major splice site 
at nt 204 and the first tat exon, as illustrated in Figure 3.5, Panel B.  Evidence of 
splicing between the LTR region and tat-1 of a truncated tat transcript (type VII) 
detected in Kal/00 was not obtained.  The SD and SA sites utilised to generate 
the different tat transcripts are shown in Table 3.6. 
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Figure 3.2.  PCR using primer pair j5046 and j7069 for the detection of clones containing 3' end transcripts.  Results of 
only representative clones are shown.  The products were dominated by a 327 bp product in Tabanan/87 (Panel A), 
Pulukan/00 (Panel B) and Kal/00 (Panel C) strains of JDV.  One clone from the Kal/00 strain produced a slightly larger 
product of 345 bp (Panel C, lane 6).  Lane M, 100 bp (Panel C) and 1 Kb Plus (Panels A and B) DNA ladders 
(Invitrogen). 
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Figure 3.3.  RT-PCR analysis of the 5’ end of tat mRNA in tissues of Bali 
cattle experimentally infected with virus strains Tabanan/87 (Lane 2), 
Pulukan/00 (Lane 3) or Kal/00 (Lane 4); Lane 1, negative control; Lane 
M, 100 bp DNA marker (Invitrogen).  Panel A.  Amplification with j129 
and junction primers for the predominant splicing junction j5335^j7033 
(shown in Table 3.1) revealed tat mRNA of various sizes (types I–VI).  
The composition of each transcript is illustrated in Figure 3.5, Panel B.  
Panel B.  When a 3' primer homologous to the second splicing junction 
found in the Kal/00 strain (Figure 3.2C, lane 6) was used a product was 
amplified from a different region of JDV.  Sequence analysis identified the 
product as an unspliced RNA which was amplified as a result of the 
considerable sequence homology between the junction primer and the 
region of gag as shown in Panel C  
6
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Figure 3.4.  PCR screening using j129 and junction primers homologous to the 5335^7033 sequence for the detection of 
clones containing 5' end transcripts.  Representative clones from Tabanan/87 (Panel A), Pulukan/00 (Panel B) and 
Kal/00 (Panel C) strains are shown.  The products obtained were predominantly the smaller products of 490 bp (type 
VI), 515 bp (type V), 553 bp (type IV) and 583 bp (type III).  The frequency of the larger 638 bp (type II) and 706 bp 
(type I) products (Panel B, lanes 1–3 and 17) detected only in the Pulukan/00 strain, was much less.  Sequence 
analysis of representative clones revealed the presence and absence of non coding exons between the major splice site 
at nt 204 and tat-1, illustrated in Figure 3.5.  The products shown in Panel B, lanes 4 and 5, and Panel C, lanes 9 and 22, 
were determined by sequence analysis to be not of JDV origin.  Lane M, 100 bp (Panel C) and 1 Kb Plus (Panels A and 
B) DNA ladders (Invitrogen).   69 
Table 3.6.  Splice sites used to generate tat mRNA transcripts identified 
in Bali cattle experimentally infected with 3 JDV strains. 
Nt position
1  Sequence Notes 
204
1  UGAG/GUGAGUAC major  SD 
4081  UUAU/GUAAGUAU  non coding exon SD 
4808  AGUG/GUGAGCCA  non coding exon SD 
5268
2  ACAG/AGAGCGGU  tat exon 1 SD
2 
5335
1 CACG/GUGAGAUC  major tat exon 1 SD 
     
4014 AAUGCUCGUAUACAG/GUAC  non coding exon SA 
4663 UGAUGACACCCGCAG/GAAC  non coding exon SA 
4894 GCUGGUAUCCGGUAG/GGAC  tat exon 1 SA 
4939
1 UGCAUUUUACAACAG/GGAA  tat exon 1 SA 
6947
2  UCCGAUACUUGGCAG/ACUU  tat exon 2 SA
2 
7033
1 UAUUUUGCAUUUAAG/GUCC  major  tat exon 2 SA 
1 Nt position previously predicted from sequence analysis by Chadwick et al.  (1995). 
2 These splice sites were identified in only one transcript in animal infected with Kal/00 
strain of JDV. 
 
 
Comparison of nucleotide sequence of different strains 
In addition to the 3 strains of JDV (Tabanan/87, Pulukan/00 and Kal/00) the 
samples analysed included material present in spleen from an animal with 
Jembrana disease in Kalimantan in 2003 (Kal/03), the same region from where 
the Kal/00 strain was obtained 3 years previously.  Amplification of Kal/03 using 
primer pairs j4938 and j5338 for Tabanan/87and Pulukan/00 strains, and j4938 
and jK5337 for Kal/00 and Kal/03 strains yielded bands of 400 bp (Figure 3.6).  
Products of similar size were also amplified from PBMCs of cattle experimentally 
infected with Tabanan/87, Pulukan/00 and Kal/00. 
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Figure 3.5.  .  Amplification strategy for the identification of JDV tat transcripts.  (A) The JDV genome is flanked by LTRs 
where start (broken arrow) and termination (pA) sites of transcription are located; boxes represent the viral open 
reading frames including tat-1 and -2 (black filled).  Arrow heads indicate the position and orientation of 
oligonucleotide primers used for cDNA detection (as shown in Table.3.1); “junc” refers to primers that were 
complementary to the sequence of splicing junction between the 2 tat exons.  (B) Multiply-spliced transcripts (I-VI) 
detected which contained discrete exons (black boxes) by the removal of introns (horizontal broken line); the SD and 
SA nt positions are shown by the numbers at the top right and left of the exons, respectively.  Splicing between tat-1 
and tat-2 in transcript types I-VI was taken place 34 bases downstream the TGA stop codon at nt 5301 of tat-1 and nt 
7033 of tat-2.  A truncated tat transcript (type VII) detected in one transcript from Kal/00 contained a SD pstream of 
the end of tat-1 (nt 5278) and spliced to a SA in env (nt 6958).  71 
 
 
Figure 3.6.  Amplification of tat exon 1 proviral DNA.  Total DNA isolated 
from 4 spleen samples was subjected to PCR using primer pairs j4938 
and j5338 for Tabanan/87 (Lane 1) and Pulukan/00 (Lane 2), and j4938 
and jK5337 for Kal/00 (Lane 3) and Kal/03 (Lane 4).  Lane M, 100 bp 
ladder.  Products of the appropriate size were detected from all strains.   
 
Analysis of nt sequences of the two tat exons identified variation in exon 1 and 
conservation in exon 2 (Figure 3.7).  The tat exon 1 of all strains was 294 nt in 
size, corresponding to nt 5010–5303 of the genome; the sequence of Tabanan/87 
was identical to that reported previously by Chadwick et al (1995b).  The two 
Kalimantan isolates (Kal/00 and Kal/03) obtained from cattle during outbreaks in 
the same district but 3 years apart, were identical.  Less than 5 % variation was 
detected between the Tabanan/87 and Pulukan/00 strains obtained from cattle in 
Bali 13 years apart.  Nucleotide identity with reference to the Tabanan/87 strain 
was 89.1 % and 96.6 % for Kal/00 and Pulukan/00, respectively (Table 3.7).  
Nucleotide identity between Pulukan/00 and Kal/00 was 89.5 %.  Alignment of the 
deduced Tat-1 amino acid sequences illustrated in Figure 3.8 showed identity of 
83.5 % (Kal/00), 93.8 % (Pulukan/00) to the Tabanan/87 and 84.5 % between    72 
 
Figure 3.7.  Nucleotide sequence alignment of the two tat coding exon from the 
spliced transcripts of 3 JDV strains Tabanan/87 (Tab), Pulukan/00 (Pul) and 
Kalimantan/00 (Kal).  Dashes and lower case denote nt identity and 
substitution, respectively.  Variation was evident in the first tat exon up to the 
junction (nt 5010–5335); some substitutions were silent (boxed).  There was 
only limited variation between strains from the same geographical area.  There 
was little variation in the nt sequence of exon 2 (shaded) in the 3 strains.  ^ 
indicates the fusion of 2 discontiguous regions of the viral genome.  The 
numbers showing the actual nt position in the genome are based on the 
sequence of the Tabanan/87 sequence (Chadwick et al., 1995b).  
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Figure 3.8.  Alignment of Tat-1 amino acid sequence deduced from proviral DNA sequences.  The alignment was generated and 
displayed by PileUp and Pretty programs, respectively.  The sequence of Tabanan/87 is shown in capital letters.    Dashes and 
lower case letters indicate amino acid identity and substitution, respectively.  Variation was identified between the 3 JDV 
strains (Tab, Tabanan/87; Pul Pulukan/00; Kal, Kalimantan/00) , and the Kal strain was the most divergent.  There was 
conservation in the cysteine residues (bold) in the Cys-rich region, and of all residues in the core and basic regions.   74 
Pulukan/00 and Kal/00.  There was a high degree of conservation in the cysteine 
residues in Cys-rich region, and identity in the core and basic regions. 
Table 3.7.   Percentage of nucleotide and amino acid identities between 
JDV strains. 
                Tab/87                 Kal/00 
Virus strain
 
nt   aa  nt  aa 
Pul/00
  96.6 %  93.8 %  89.5 %  84.5 % 
Kal/00  89.1 %  83.5 %     
Discussion 
While limited studies of the transcriptional events involved in the replication of BIV 
have been undertaken (Fong et al., 1997; Liu et al., 1992) there have been no 
such studies involving the related JDV.  A major reason for this is the difficulty in 
gaining access to material for study: the virus has been recognised and detected 
in Indonesia only; the virus has not been successfully cultivated in vitro 
necessitating access to tissues of infected animals for analysis of transcriptional 
events.  This current study has therefore provided novel information in relation to 
the transcription of tat, potentially important with regard to the relationship of Tat 
to the acute pathogenicity of JDV, and the development of Tat proteins as 
immunogens for the induction of a protective immunity against Jembrana disease. 
Nucleotide sequence analysis of JDV tat cDNA clones showed that the tat gene 
was transcribed as at least 6 different mRNA transcripts predominated by types 
III–VI transcripts via multiple splicing events, a strategy typical of lentivirus 
transcription (Coffin et al., 1997; Tang et al., 1999).  The mRNA transcripts 
differed in the SA sites utilised upstream of the first coding exon, and by the 
presence/absence of non-coding exons between the major SD downstream from 
the LTR and the SA at tat-1.  Splicing between tat-1 and tat-2 was predominantly 
from the SD (nt 5335) downstream of tat-1 with the SA (nt 7032) of tat-2.  The 
presence of an in-frame stop codon of tat exon 1 before the splicing junction   75 
between tat-1 and tat-2 suggests tat-2 may not be translated.  This splicing 
pattern was similar to BIV (Fong et al., 1997; Liu et al., 1992) wherein, despite the 
occurrence of mRNAs derived by the joining of both tat exons, only Tat103  
encoded by tat-1 was detected (Fong et al., 1997), and evidence of stop codon 
read-through was not indicated. 
In the current study, the only material examined was from infections of the natural 
host during the acute phase disease of Jembrana disease.  This may have 
affected the results obtained as in HIV-1, of which two Tat proteins of different 
size were detected.  In the early stage of HIV-1replication where population of 
viral mRNAs is dominated by multiply spliced transcripts of ~2 kb encode for 
regulatory proteins, two-exon Tat was produced, whereas in the late stages one-
exon Tat was translated from singly spliced transcripts of ~4 kb whose 
cytoplasmic transport is Rev dependent in contrast to multiply spliced transcripts 
that can be exported easily to the cytoplasm for protein synthesis (Malim et al., 
1988; Purcell & Martin, 1993).  Sequence analysis of multiply spliced tat 
transcripts detected in this study suggested that a protein specified by tat-1, 
predicted to be 97 aa, was synthesised at least during the viraemic phase of 
Jembrana disease when there is maximal virus replication and plasma virus titres 
of 10
8 ID50/mLor higher has been reported (Soeharsono et al., 1990).  These 
conclusions are supported by 2 additional observations.  First, a protein band 
recognised by anti-Tat antibody was detected in PBMCs of experimentally 
infected cattle which size suggested as one-exon Tat (Presented in Chapter 4).  
Second, previous studies have demonstrated that the protein encoded from tat-1 
only was fully functional and strong trans-activator (Chen et al., 1999; 2000) 
suggesting tat-2 may not be essential for trans-activation.  Whether or not a 
different pattern is operating prior to viraemia cannot be elucidated in this study 
as attempts to detect tat mRNA in PBMCs collected prior the febrile phase was 
unsuccessful.  As lymphoreticular organs have been shown to be the main JDV 
target, lymphonode biopsies may provide a good source of transcripts. 
While Tat encoded by tat-1 of JDV has been shown to generate sufficient trans-
activation for efficient and high level replication, in HIV-1 the Tat encoded by the   76 
spliced product of both tat exons is required to produce efficient upregulation 
(Bieniasz et al., 1999a; Chen et al., 1999; Fong et al., 1997; Jeang et al., 1999).  
The second coding exon of HIV-1 has been associated with increased viral 
infectivity, TAR-independent trans-activation of env, and cellular internalisation 
(Kameoka et al., 2002; Kim & Panganiban, 1993; Ma & Nath, 1997; Tong-
Starksen et al., 1993; Verhoef et al., 1998).  Further study is required to examine 
the possible expression and function, if any, of the second tat exon JDV Tat. 
Although it was detected only in one occasion on Kal/00 strain and appeared to 
be unusual, a shorter transcript type VII (Figure 3.5, Panel B) utilised a SD 
upstream the 3’ end of tat exon 1 and was spliced to a SA in env.  The splicing 
site(s) between the common transcription start site in the LTR and tat-1 exon; 
however, were unsuccessfully detected due to the high similarity between the 
junction primer and an area in the gag region.  This mRNA transcript might 
encode a truncated Tat protein 10 aa less than the predicted normal Tat of 97 aa, 
and possibly fused with the protein encoded by the 5’ end of env in frame with 
Rev.  Patterns smilar to this was also detected in HIV-1 and EIAV which resulted 
in new chimeric proteins, such as Tev and Ttm (Benko et al., 1990; Salfeld et al., 
1990; Solomin et al., 1990). 
Mutation was evident in tat-1 but not tat-2 of the three JDV strains examined, and 
dominated by G to A substitution consistent with that described for most of
 the 
lentiviruses (Borman et al., 1995; Fitzgibbon et al., 1993; Perry et al., 1992; 
Vartanian et al., 1994; Wain-Hobson et al., 1995).  There was evidence of 
geographical variation in tat but further study of other geographically different 
samples is needed to clarify this observation, and to determine the significance of 
the variation.  Jembrana disease has been dispersed throughout some islands of 
Indonesia over a more than 30 year period, apparently originating in Bali in 1964, 
then occurring in East Java, then Lampung Province in Sumatra, then in the mid 
1990s in West Sumatra, then also in the mid 1990s it was detected in South 
Kalimantan.  While the origin of the South Kalimantan strain is unknown, the 
limited sequence data obtained in this study suggests that the Bali and 
Kalimantan strains were different.  Direct transmission from Bali to Kalimantan is   77 
unlikely due to quarantine restrictions on the movement of cattle between these 
provinces.  Possibly the virus may have been introduced into Kalimantan from 
Sumatra, from strains originally transmitted to Lampung province in Sumatra in 
the 1970s, and then subsequently to Kalimantan in the late 1990s.  Further 
sequence analysis of strains from all these areas, which is in progress, may help 
to determine the origin of the various strains in different islands of Indonesia. 
The nucleotide variation of JDV tat-1 was reflected in a similar variation of the 
amino acid sequence (Table 3.7).  However, it was observed in Figure 3.8 that 
the core and basic regions of the putative protein encoded by tat-1 exhibited only 
limited variation and the cysteine residues in the Cys-rich region were completely 
conserved similar to that of HIV-1 (Chakrabarti et al., 2001; Gregoire & Loret, 
1996; Husain et al., 2001; Reza et al., 2003; Scriba et al., 2002).  Nucleotide 
sequence of the core region was highly conserved among the three strains, while 
considerable substitutions in the basic region of Kalimantan strain were mostly 
synonimus (Figure 3.7).  The limited variation in tat would be consistent with an 
important role of the Tat protein in virus replication, especially in the regions that 
are critical in RNA-binding and transcription activation (Carvalho & Derse, 1991; 
Cullen & Garrett, 1992; Frankel, 1992; Jones & Peterlin, 1994; Jones, 1997; 
Ruben et al., 1989).  Substitution of any cys residues except C31 has an adverse 
effect on trans-activation activity of Tat, while conservative substitution C31G or 
C31S has a minimal consequence (Jeang et al., 1999). 
In conclusion, the results suggest that a Tat protein specified by coding exon 1 of 
tat was the predominant if not the only Tat protein produced during the acute 
phase of Jembrana disease, and was conserved in different strains of JDV 
strains.  The critical dependence of JDV replication on Tat, and its high 
conservation within strains from widely divergent areas of Indonesia, suggests it 
is a potential target for the control of JDV infection and warrants further study as 
a possible vaccine candidate.  The detection of the Tat protein in vivo and 
production of this protein using recombinant DNA technology for the purpose of 
immunisation are described in the Chapter 4.    78 
Chapter 4   
Production of recombinant proteins and 
immunogenicity examination in vivo 
Summary  
The expression and purification of recombinant JDV Tat was investigated utilising 
different vectors in bacterial and eukaryotic expression systems.  The tat exon 1 
DNA was cloned in frame to glutathione S-transferase (GST) or hexa-histidine 
(His6) genes, for expression in E. coli under the regulatable tac promoter.  Tat 
was also expressed constitutively as a His6 fusion protein in mammalian cells 
driven by the CMV promoter.  Tat was expressed in E. coli mostly within inclusion 
bodies either as a ~38-kDa GST fusion protein (GST-Tat) or a ~17-kDa His-Tat 
fusion protein.  Purification of GST-Tat was achieved by extensive detergent 
washing or urea-mediated solubilisation of inclusion bodies, while His-Tat was 
purified using nickel affinity chromatography.  The immunogenicity of GST-Tat in 
sheep and Bali cattle was demonstrated by induction of a specific antibody 
response in inoculated animals.  The specific antibody response was determined 
by Western immunoblotting utilising recombinant Tat produced in the eukaryotic 
expression system, so avoiding cross-reactivity with E. coli proteins.  Antibodies 
to Tat was also detected in cattle recovered from natural JDV infection, and in 
cattle immunised with a whole virus vaccine derived from spleen tissue of JDV-
infected cattle although the frequency and level of antibodies to Tat in these cattle 
were less than those to the JDV capsid protein.  Affinity purified sheep anti-Tat 
was able to detect the native Tat protein with an apparent molecular size of ~14 
kDa in PBMCs of JDV-infected Bali cattle.     79 
Introduction 
Within Indonesia where Jembrana disease is endemic, an inactivated vaccine is 
used for the control of the disease.  Although there are no published reports on 
the efficacy of this procedure, experimentally the vaccine has been shown to 
ameliorate the clinical signs of disease following challenge with virulent virus, and 
there is considerable anecdotal evidence that it is effective and has been 
favourably received by cattle owners in these areas (Dr Nining Hartaningsih, 
Personal Communication).  This Jembrana disease vaccine is prepared from 
spleen tissue of experimentally infected cattle, collected during the acute febrile 
phase of the induced disease when there is a high titre of infectious virus in 
spleen tissue (Hartaningsih et al., 2001).  There are a number of safety concerns 
regarding this vaccine: the virus in the vaccine is inactivated with detergent and 
this would not inactivate non-enveloped adventitious virus present in the donor 
animal; there is no method of standardisation of the quality of the vaccine in 
different batches; it is expensive to prepare, requiring the use of donor animals 
from disease-free areas; the current method of production of the vaccine is not 
applicable for commercial production techniques. 
In an attempt to develop a safe and effective JDV vaccine, the studies on the 
potential of using JDV Tat protein, produced by recombinant DNA technology, as 
an alternative vaccine, was explored.  Previous studies toward the control of HIV-
1 infection have considered Tat an attractive target immunogen for several 
reasons: first, Tat protein is produced
 early during the virus infection (Wu & 
Marsh, 2001); second, it is indispensable for efficient
 virus replication (Arya et al., 
1985; Dayton et al., 1986); third, Tat is immunogenic and Tat antibody correlated 
with low plasma viral load and delayed disease progression in HIV infected 
subjects (Re et al., 2001a; Reiss et al., 1990; Zagury et al., 1998b).  Vaccination 
experiments in animal models using active or inactive Tat have been shown to 
induce specific immune responses and confer protection against disease 
progression (Agwale et al., 2002; Barillari et al., 1999; Pauza et al., 2000).  
Antibodies from human volunteers immunised with Tat toxoid presented high   80 
antibody titres to Tat (1998; Gringeri et al., 1999) and inhibited Tat-mediated 
trans-activation (Noonan et al., 2003).  It was hypothesised that a similar 
approach would be applicable for Jembrana disease, and immunisation with 
recombinant Tat could overcome problems concerning the viral antigen 
production. 
In Chapter 3, mRNA transcripts potentially responsible for Tat protein production 
in infected cattle were identified.  These studies suggested that of the two tat 
coding exons of JDV, Tat of 97 aa encoded by exon 1 only is translated during 
the peak viraemia of the disease, in agreement with a previous report that the first 
tat exon (tat1) is sufficient to generate a functional Tat (Chen et al., 1999).  In the 
studies reported in this Chapter, therefore, we considered recombinant 
technology as a mean to produce JDV Tat from tat1, and to demonstrate the 
immunogenicity and antigenicity of the expressed products.  For the development 
of a potential immunogen that might be appropriate as a vaccine, attempts were 
made to express Tat in E. coli as either a glutathione-S-transferase (GST) and 
hexahistidine (His6) fusion protein, using plasmids pGEX-6P and pTrcHis vectors, 
respectively.  To increase the specificity of Western immunoblotting procedures 
for the detection of anti-Tat, an attempt was made to express JDV Tat in 
mammalian cells.  The immunogenicity of the purified GST-Tat fusion protein was 
investigated in sheep in Australia, and then Bali cattle in Indonesia.  For 
additional evidence of the immunogenicity of Tat in Bali cattle, the occurrence of 
anti-Tat antibody in JDV-vaccinated and recovered cattle was also investigated.   
Materials and methods 
Host cells, media and growth conditions.   
The E. coli Top10F’ [F´{lacI
q Tn10(Tet
R)} mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 deoR recA1 araD139 Δ(ara-leu)7697 galU galK rpsL 
(Str
R) endA1 nupG ] (Invitrogen) was used in this study.  Luria-Bertani broth 
supplemented with 100 μg/mLampicillin (LBA) was used for growth of bacteria at   81 
37°C with agitation.  For protein expression by bacteria, deficient M9 (Sambrook 
et al., 1989) and LB media, both containing 2 % glucose, 100 μg/mLampicillin and 
50 μg/mLtetracycline, were used.   
COS7 (African green monkey kidney) cell line was grown in 25 or 75 cm
2plastic 
flasks (Nalgene Nunc International) in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10 % foetal bovine serum, 100 U/mLpenicillin, 100 
µg/mLstreptomycin, and 2mM L-glutamine at 37°C in a 7 % CO2 atmosphere.  
When monolayers were confluent, cells were passaged by trypsinisation (0.25 % 
Bacto-trypsin; 1 mM EDTA; Hank’s balanced salt solution) using a split ratio of 
1:3, or maintained in DMEM with 2 % calf serum. 
Cloning vectors 
The TA-cloning vector pCR2.1 (Invitrogen) was used to clone PCR amplification 
products, and served as a holding vector for these products.  For bacterial 
expression studies, JDV tat1 was cloned in frame with glutathione-S-transferase 
(GST) in plasmids pGEX-6P-1 (Amersham Biosciences Biotech,) and a 
hexahistidine gene in plasmid pTrcHis A (Invitrogen).  These 2 vectors drive 
expression of heterologous gene products from a strong and regulatable tac 
promoter in E. coli.  For mammalian expression, pcDNA3.1/His C (Invitrogen) was 
used.  This plasmid contains a SV40 origin of replication, which enables it to 
replicate episomally in SV40 T antigen expressing cells, such as COS7 (Gluzman, 
1981; Kaufman, 1990; Makrides, 1999).  The neo
r under SV40 promoter conveys 
resistance to G-418 sulphate antibiotic (Southern & Berg, 1982).  The schematic 
diagrams of these expression vectors were depicted in Figure 4.1. 
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Figure 4.1.  Map of the expression vectors used in this study.  JDV tat DNA fragment was cloned into BamH1/EcoR1 
multiple cloning sites (MCS) of the vectors in frame with glutathione S-transferase (GST) or (His)6 N-terminal fusion 
partners in  pGEX (A, Amersham) or pTrcHis and pcDNA3.1/His (B and C, Invitrogen), respectively.   83 
Oligonucleotides 
The oligonucleotide primers shown in Table 4.1 were used during the course of 
these studies.  Primers were purchased from  Invitrogen and stocked as 200 µM 
solutions in sterile double-distilled water. 
Table 4.1.  Primers used for amplification and sequencing of JDV Tat 
constructs in different plasmid vectors. 
Primer  Sequence (5’ to 3’)  Genome  Nt. Position
 1) 
M13/F  GTAAAACGACGGCCAG  pCR2.1    205 – 221 
M13/R  CAGGAAACAGCTATGAC'  pCR2.1    404 – 389 
pGEX/5’  GGGCTGGCAAGCCACGTTTGGTG  pGEX-6P    869 – 891 
pGEX/3’  CCGGGAGCTGCATGTGTCAGAGG  pGEX-6P  1056 – 1034 
pTRC/5’  GAGGTATATATTAATGTATCG  pTrcHis    370 – 390 
pTRC/3’  GATTTAATCTGTATCAGG  pTrcHis    614 – 597 
pcDNA/T7   TAATACGACTCACTATAGGG  pcDNA3.1    863 – 882 
pcDNA/BGH   TAGAAGGCACAGTCGAGG  pcDNA3.1  1122 – 1105 
jTat4990 ATCAACCGGatccCCAGATATGCCTG  JDV  4990 – 5016 
jTat5328  TTCCAGGGTCCAACGATCTAGTGCCT  JDV  5328 – 5303 
1The nt numbering system adopted was according to GenBank accession No.  U21603.   
 
Restriction endonuclease digestion 
Restriction enzyme digestions were performed by incubating double-stranded 
DNA with an appropriate amount of endonucleases in their respective buffers as 
recommended by the supplier (NEB), at the optimal temperature for that specific 
enzyme, which was typically 37°C.  Standard digestions include 2–10 U enzyme 
per microgram of DNA in 50 μl reaction.  The reactions were usually incubated for 
1–3 hr to ensure complete digestion which was subsequently checked by gel 
electrophoresis.     84 
Construction of expression vectors 
DNA fragment containing the first coding exon of JDV tat (tat1) encompassing nt 
5010 to 5303 was generated by PCR from proviral DNA of the Tabanan/87-strain 
present in infected spleen tissue (Chapter 3) using synthetic oligonucleotides 
jTat4990 5’-ATCAACCGGatccCCAGATATGCCTG-3’ (nt 4990–5016) and 
jTat5328 5’-TTCCAGGGTCCAACGATCTAGTGCCT-3’ (nt 5328–5303).  To 
facilitate further cloning, the forward primer jTat/5’ was mutated (lowercase) to 
contain a BamH1 site (underlined) before the start codon.   
PCR was performed using the Expand™ high fidelity PCR system (Roche) with 
the following cycling conditions: initial denaturation at 95°C for 5 min, followed by 
30 cycles of denaturation (30 sec at 95°C), annealing (30 sec at 65°C) and 
elongation (1 min at 72°C), followed by a final elongation step at 72°C for 7 min.  
The predicted PCR product of 339 bp was TA-cloned.  By TA-cloning, the 
correctly amplified tat fragment, confirmed by sequencing, was then available for 
further cloning experiments, avoiding repeated amplification and introduction of 
sequence errors by polymerases.  DNA sequencing was performed as described 
in Chapter 3.   
The JDV tat fragment was released from pCR/tat by double digestion with BamHI 
and EcoRI restriction enzymes (NEB).  Following agarose gel electrophoresis, the 
fragment was excised and purified using a QIAquick Gel Extraction Kit (Qiagen).  
The fragment was then ligated into the corresponding site of digested plasmid 
vectors to generate pGEX/tat, pTrc/tat and pcDNA/tat.  Recombinant plasmids 
were screened by PCR and further confirmed by nucleotide sequencing using the 
respective vector-specific primers (Table 4.1).   
Expression of recombinant proteins 
E. coli transformation and induction 
E. coli TOP 10F’ cells were transformed with pGEX/tat or pTrc/tat by heat-shock 
treatment as previously described (Chapter 3).  A single colony of each 
transformant was inoculated in 5 mLLB broth supplemented with 100   85 
μg/mLampicillin, 50 μg/mLtetracycline and 2 % glucose as a starter culture and 
incubated at 37°C with agitation on a shaker (250 rpm) overnight.  The overnight 
culture was diluted 1:20 into 200 mLmedia in a 1,000 mLflask, and continuously 
agitated at 250 rpm for 1–2 h at 37°C until the OD600 measured 0.5.  For induction 
of expression, IPTG was added to a final concentration of 0.1mM for GST and 0.5 
mM for His6 fusion constructs, and the incubation continued for an additional 1.5 
h.  Comprehensive expression tests in small scale of 5 mLwere performed earlier 
to determine the optimum conditions with respect to IPTG concentration (0.1–1 
mM), length (1–4 h) and temperature (30 and 37°C) of induction, as well as the 
use of enrich and deficient media for high expression levels of soluble protein. 
Transfection and protein expression of eukaryotic cells 
The day before transfection, cells were seeded at 2 x 10
5 cells/cm
2 in 25 cm
2 
flasks, which developed to 80–90 % confluency the next day.  Following brief 
washing with DMEM, the cells were exposed for 3 h to a mixture containing 10 μg 
of pcDNA/tat plasmid DNA and 50 μl of Lipofectamine 2000 (Invitrogen) in 1 
mLserum free DMEM.  After incubation for 3 h at 37°C, the transfection medium 
was replaced with growth medium and the cells were incubated for further 72 h.  
The transfected cells were selected in growth medium containing 500 mg/mLG-
418 sulphate (GIBCO) which provides substrate for the selection marker 
aminoglycoside phosphotransferase (neo
r).  The resistant cells were serially 
diluted and propagated to produce an adequate amount of Tat-expressing cells.  
Cells transfected with control pcDNA3.1 were used as a negative control. 
The transfection efficiency was determined by transfecting triplicate cultures of 
COS7 cells in 24-well plates with pcDNA3.1/His/lacZ with a range of different 
DNA concentrations and volumes of lipofectant.  Transfected cells were washed 
with PBS, fixed with 0.05 % glutaraldehyde in PBS for 10 min, and stained with X-
gal and then incubated at 37°C for 2 h.  Transfection efficiency was determined 
by examining the cells with an inverted microscope and determining the 
percentage of galactosidase positive cells relative to the total cells.     86 
Purification of GST-fusion protein 
Purification of soluble fraction 
The E. coli cells from a 200 mLIPTG-induced culture were centrifuged (4,000 g, 
4°C, 10 min) following the addition of phenylmethylsulfonyl fluoride (PMSF) to a 
final 1 mM concentration.  The purification of soluble fusion was performed 
according to the GST gene fusion system protocol (Amersham Bioscience).  
Briefly, the pellet was resuspended in 4 mLice-cold phosphate buffer saline (PBS: 
137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.3) with 1 
mM PMSF, 1 mM EDTA, 5 mM 1,4-Dithiothreitol (DTT), 10 U/mLDNase I (Sigma) 
and 1 mg/mLlysozyme (Sigma)) and kept on ice for 30 min.  Cell extracts were 
prepared by several cycles of freezing in liquid N2 and thawing in a 42°C water 
bath until the solution was no longer viscous, and Triton-X was added to a final 
concentration of 2 %.  After incubation for 30 min on a rocking platform, the lysate 
was centrifuged (20,000 g, 30 min, 4°C) and the supernatant transferred to a 
chilled fresh tube.  To each 4 mLof prepared cell extract was added 400 μl of 50 
% slurry of Glutathione Sepharose 4B (Sigma) previously equilibrated with PBS.  
The suspension was gently mixed at 4°C for 2 h on a rotating wheel.  The 
Sepharose beads were pelleted by centrifugation (500 g, 5 min) and the 
supernatant carefully removed.  The pelleted matrix was mixed with 10 mLof cold 
PBS for 5 min and centrifuged (500 g, 5 min); this washing step was repeated 
twice.  The bound fusion protein was then eluted by the addition of 500 μl of 
glutathione elution buffer (20 mM reduced-glutathione; 50 mM Tris-HCl, pH 8.0).  
The tube was gently agitated by gentle inversion during the process (30 min, 
4°C).  Following centrifugation (500 g, 10 min) to sediment the beads, the eluant 
was removed and stored at –80°C until needed. 
Purification of inclusion bodies 
Cells and cellular debris from 200 mLcultures were washed repeatedly in 10 
mLvolumes of wash buffer (2 % Triton-X100, 50 mM Na2HPO4, 300 mM NaCl, 2 
mM EDTA, 10 % glycerol, pH 8.0) by centrifugation (13,000 g, 15 min, 4°C).  The 
washing process was repeated until the supernatant was clear (~6 cycles).  The   87 
washed inclusion bodies were then solubilised in 4 mLof 6 M guanidium HCl (Gu-
HCl) or 8 M urea, 50
 mM Na2HPO4, 20 % glycerol, 1 mM EDTA, 1 mM β-
mercaptoethanol, pH 8.0) and stirred for at least 5 h at room temperature, then 
centrifuged as above.  The supernatant containing solubilised inclusion bodies 
was stored at –80°C until further use.   
For injection into sheep or cattle, the solubilised inclusion bodies were first 
dialysed against PBS at 4°C for 24 h with 3 changes of PBS.  The solution was 
stirred at low speed during dialysis. 
Purification of His-tagged proteins 
High affinity of His-tagged proteins to a chelating resin charged with metal ions 
such as Ni
2+, Cu
2+ or Zn
2+, has been used for purification from proteins which 
have lower, or no, affinity for the resin (Hochuli et al., 1987; Porath et al., 1975).   
The advantage of histidine tagging is that it can be employed also under 
denaturing conditions (Holzinger et al., 1996). 
In this experiment, purification of His-Tat proteins was conducted under 
denaturing condition with a QIAexpressionist
® System Protein Purification
 kit 
(Qiagen) as described by the manufacturer.  Briefly, following 1.5 h of IPTG 
induction, PMSF was added to final concentration of 1 mM and the culture was 
centrifuged (4,000 g, 4°C, 10 min).  The pellet was resuspended and stirred for 30 
min on ice in 5 mLBuffer B (8 M urea, 100 mM NaH2PO4, 300 mM NaCl, 10 % 
glycerol, 1 % Triton-X100, 10 mM β-mercaptoethanol, pH.8.5) to lyse the cells.  
Cell debris was removed by centrifugation (20,000 g, 30 min, 4°C) and 0.5 mLof 
50 % Ni-NTA slurry (Qiagen) was added to 5 mLof the supernatant and incubated
 
for 1 h on a rotary wheel at room temperature.  The mixture was centrifuged and 
washed 3 times with buffer C (same as Buffer B but pH.  6.5).  The bound His-Tat 
was eluted with 0.4 mLbuffer D (same as Buffer B but pH.  5.8), followed by buffer 
E (same as Buffer B but pH 4.5).  All fractions were collected and stored at –80°C 
until further analysis was conducted.   88 
For His-Tat protein produced in eukaryotic system, purification was done under 
mild denaturing condition with the following modification.  Five 25 cm
2 flasks of 
stably transfected COS7 cells were washed twice with ice cold PBS and lysed in 
1 mLcold lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 % glycerol, 10 mM 
imidazole, 0.1 % SDS and EDTA-free protease inhibitor cocktail [Sigma]) for 30 
minutes at 4°C.  The soluble protein-containing supernatant was separated by 
centrifugation (14,000 g, 15 min, 4°C) and 250 µl of 50 % Ni-NTA slurry 
equilibrated with lysis buffer was added to 5 mLof the supernatant.  The process 
was continued as for the prokaryotic system, except wash buffer (lysis buffer with 
20 mM imidazole) replaced Buffer C, and elution buffer (lysis buffer with 300 mM 
imidazole) replaced Buffer D. 
Analysis of recombinant proteins  
Protein samples were separated by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and subsequently visualised by Coomasie brilliant 
blue (CBB) or silver staining.  The identity of the protein bands was confirmed by 
Western immunoblotting.  The yield of the purified protein was estimated 
densitomerically.   
SDS-PAGE 
Proteins were analysed by SDS-PAGE on discontinuous gels (Laemmli, 1970).  
One dimensional gel electrophoresis was performed in a Mini-Protean 3 
electrophoresis unit (BioRad) under reducing condition using a 15 % 
polyacrylamide gel with a 4 % stacking gel.  The molecular mass standards were 
purchased from BioRad and Pharmacia.  Immediately before electrophoreses, 
samples were boiled for 5 min in sample reducing buffer (0.5 M Tris-HCl, pH 6.8, 
2 % SDS, 0.1 % bromophenol blue, 10 % glycerol, 5 % β-mercaptoethanol).  The 
proteins were resolved at 150 V for 1.5–2 h at room temperature in running buffer 
containing 2.9 g/L Tris base, 14.4 g/L glycine, and 1g/L SDS. 
Following electrophoresis, the protein bands were visualised in Coomassie 
brilliant blue (0.1 % CBB [BioRad], 40 % methanol, 10 % acetic acid) for at least    89 
2 h at 37°C or overnight at room temperature.  The gel was destained for about   
2 h in solution containing 10 % acetic acid and 40 % methanol.   
For the detection of eukaryotic recombinant Tat, the bands were visualised on the 
gel with silver stain (BioRad) according to the procedure recommended by the 
manufacturer.  Briefly, gels were fixed for 10 min, washed with 50 % ethanol 3 
times, then washed 3 times in water, placed in a silver staining solution for 20 
min, washed in water for 2 min, then placed in a developing solution until bands 
appeared.  The gel was finally treated with “stop” solution and washed with 50 % 
ethanol. 
Western immunoblotting 
The separated proteins were transferred from gels onto Hybond
TM nitrocellulose 
membranes (BioRad,) in a Mini Trans-Blot Module (BioRad).  Transfer was 
performed in 25 mM Tris-HCl, 192 mM glycine, 20 % methanol for 2 h at 200 mA 
or overnight at 30V.  The membrane was blocked with TBST buffer containing 1 
% gelatin for 1 h at room temperature, and the blotted proteins were probed with 
primary antibodies for 1 h at room temperature or overnight at 4°C.  After washing 
4 times with TBST, the membrane was incubated with corresponding secondary 
antibodies for 1 h at room temperature.  Following washing, the reaction was 
visualised using freshly made colour development reagent (BioRad) as described 
by the manufacturer.  After the colour developed, the reaction was stopped by 
rinsing the membrane in water. 
Primary antibodies to detect GST-Tat or His-Tat fusion proteins were goat anti-
GST (Amersham Bioscience) and mouse anti-His6 (Sigma), respectively.  Both 
were used at 1:2,000 dilutions in TBST buffer (10 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 0.1 % Tween-20).  The secondary antibody (1:3,000) was either 
horseradish peroxidase (HRP) conjugated anti-sheep, anti-mouse (ICN), anti-goat 
(Amersham Bioscience) or anti-bovine (ICN) immunoglobulin, as appropriate.   90 
Concentration, molecular mass and pI estimation 
The CBB-stained gel image was captured using ProXPRESS™ ProFinder 
(PerkinElmer) followed by volume analysis with Proteome 1D Analyzer V1.10 
(PerkinElmer).  The concentration was calculated by comparison of densitometric 
scans with known amounts of bovine serum albumin, BSA and lysozyme (Sigma) 
run on the same gel.  Molecular mass and pI of proteins was calculated with 
ProtParam tool from the ExPASy molecular biology server accessible at 
http://au.expasy.org. 
Production of Tat-specific antiserum  
Polyclonal antibody was induced in sheep by injection of partially purified GST-
Tat inclusion bodies (above).  About 2 mg of GST-Tat was emulsified in 
incomplete Freund’s adjuvant and subcutaneously injected into a sheep.  Two 
booster injections were given intramuscularly at week 3 and 5 with the same 
preparations.  Serum samples were obtained before injection and 2 weeks after 
each injection, and stored at –20°C for further analysis.   
Due to the impurity of the Tat antigen used to produce specific antibodies, the 
serum was affinity purified by adsorption of antibody onto GST-Tat and then by 
removal of non-specific antibody by absorption against GST and bacterial 
proteins.  In brief, GST-Tat expressing E. coli lysates were subjected to 
preparative SDS-PAGE and blotted onto nitrocellulose membranes.  The 
membrane was stained with Ponceau solution (Sigma) and the GST-Tat band 
was excised and destained by washing with water.  The GST-Tat band from 4 
gels was incubated with 8 mLof a 1:5 dilution of the sheep serum in PBS, with 
gentle shaking at 4°C overnight.  The nitrocellulose strips were then extensively 
washed with PBS.  The adsorbed antibodies were eluted from the strips by 
placing them in 4 mL0.1 M glycine-HCl (pH 2.8) for 10 min and then immediately 
neutralised with 1 M Tris and subsequently brought up to 20 mLwith PBS.  Non-
specific antibodies were absorbed against total GST cell lysate blotted 
membranes overnight.  The remaining antibody solution was dialysed against   91 
PBS for 24 h at 4°C and 10 x concentrated by microfiltration (PAL).  The final 
antibody preparation was used for immunoblotting at a 1:200 dilution. 
Detection of native Tat protein 
Native Tat proteins were detected by WB using an enhanced chemiluminescent 
detection system (ECL™, Amersham
 Biotech).  Peripheral blood mononuclear 
cells (PBMCs) and spleen tissues were collected from experimentally infected 
cattle as described in Chapter 3.  Proteins were prepared by adding sample 
reducing buffer (above) directly to pelleted PBMCs or 50 % spleen homogenates 
in PBS.  Samples were subjected to SDS-PAGE using 17.5 % gel and blotted 
onto Hybond™ ECL™ membrane.  Non-specific binding was blocked with 5 % 
Blocking reagent in TBST.  Proteins were detected by subsequent
 incubation with 
the affinity-purified polyclonal sheep anti-Tat at 1:200 dilution in blocking solution 
followed by a 1:5,000 dilution of secondary horseradish
 peroxidase conjugated 
antibody (ICN) for 2 h and 30 min, respectively.  After extensive rinsing in TBST
 
the membrane was placed on Saran wrap with protein site up and a fresh mixture 
of detection solution ECL 1 and ECL 2 (3 mLeach) was poured.  After 1 min, the 
membrane was drained, wrapped and exposed to Hyperfilm™ ECL™ for 10–15 s 
in a film cassette.  The film was processed with a film developer machine (Fuji).  
All the development steps were done in a dark room. 
Immunogenicity of GST-Tat in Bali cattle 
Sera were obtained from 4 Bali cattle that had been injected 3 times (in 
Indonesia) with a preparation of GST-Tat emulsified in incomplete Freund’s 
adjuvant.  The injections were repeated twice at 2-week interval.  Sera were 
collected on day 0, 14, 28 and 42 after the initial injection.  Immune reactivity of 
the sera against GST and eukaryotic His-Tat by Western blotting was 
investigated.   92 
Detection of antibody to Tat in Bali cattle 
One hundred and forty three serum samples were obtained from the Disease 
Investigation Centre, Region VI, Bali, Indonesia.  Three sera were from cattle 
recovered from experimental infection (convalescent sera collected 1 month post 
infection), 81 were from cattle vaccinated with the crude spleen vaccine in Bali, 
26 were from similarly vaccinated cattle in South Kalimantan, 15 were from 
uninfected cattle in the Jembrana disease-free provinces Nusa Penida (5 sera) 
and Sulawesi (10 sera), and 10 sera with unknown vaccination history were 
collected from Bali.  Convalescent sera were collected monthly in 6-month period 
since the day of virus inoculation.  Sera from the vaccinated animals were 
collected 1 month after 3 injections at monthly intervals of the inactivated vaccine.  
Some of the sera had been tested with an ELISA using whole virus as the antigen 
(Hartaningsih et al., 1994).   
Recombinant His-Tatmam produced in mammalian cells and capsid protein fused 
to GST, GST-CA (Burkala et al., 1998) were used as antigens in western 
immunoblots.  GST-CA was produced in bacteria and affinity purified on 
glutathion sepharose as described earlier.  The purified proteins were resolved by 
15 % SDS-PAGE and transferred to nitrocellulose membranes, and subsequently 
cut into strips.  The antigen strips were incubated with 1:20 dilution of bovine 
sera, followed by anti-bovine conjugate (ICN) at 1:2000 and developed with 
Biorad colour development reagent.   
Results 
Construction of JDV Tat expression vectors 
The first coding exon of JDV tat was amplified from Tabanan/87 proviral DNA by 
PCR and cloned into pCR2.1 (Invitrogen), followed by subcloning in the correct 
orientation into the BamH1 and EcoR1 sites of pGEX and pTrc/His vectors for 
expression in E. coli (Figure 4.1A and B).  In addition, pcDNA3.1/His vector 
(Figure 4.1 C) was used to express Tat-1 in mammalian cells under the human   93 
cytomegalovirus (CMV) immediate-early promoter (PCMV) control.  Transformants 
containing Tat constructs were screened by PCR using primer combinations 
specific to vector and tat sequences (Table 4.1) which produced amplicons with 
the expected sizes (Table 4.2) are shown in Figure 4.2.  That the inserts were in 
the correct orientation and in-frame was confirmed by nucleotide sequencing. 
Figure 4.2.  Insert amplification and analysis of transformants.  JDV tat 
DNA was PCR amplified, TA cloned and further subcloned into pGEX6P, 
pTrcHis and pcDNA3.1/His expression vectors.  Following transformation 
into E. coli, positive transformants were identified by PCR using primer 
combinations complement to vector and tat sequences.  Lanes 1 & 2, 
water and JDV genomic DNA, respectively, amplified with primers 
jTat4990 and jTat5328; lanes 3, 6 & 9, and 4, 7 & 10, blank and tat 
containing vectors, respectively, amplified using appropriate vector-
specificprimers; lanes 5, 8 & 11tat vectors amplified with appropriate 
vector-specific forward primers in combination with jTat5328.  Marker 
was 1 kb Plus DNA marker (InVitrogen). 
Table 4.2.  Expected size of amplicons following PCR screening of Tat 
expression constructs. 
Expected size (bp)  Primer set 
pGEX pGEX/tat pTrc/His pTrc/tat pcDNA/His  pcDNA/tat
Vector specific  189  526  245  582  260  597 
Vector forward-
insert reverse  – 414  –  483  –  493 
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Expression in E. coli 
The tat gene exon 1 encoding 97 aa residues was expressed as a GST fusion 
protein with pGEX-6P and a His6 fusion protein with pTrcHis vectors in E. coli 
following IPTG induction.  Analysis of cell homogenates by SDS-PAGE showed a 
strong ~38 kDa and a weaker ~17 kDa band for GST- Tat and His-Tat fusion 
proteins, respectively (Figure 4.3A).  The size of GST-Tat concurs with values 
estimated from the deduced amino acid sequences of 37.7 kDa (Table 4.3), while 
His-Tat migrated slower than the estimated 15 kDa.  Their identity was confirmed 
by Western blotting analysis using anti-GST or anti-His6 antibodies (Figure 4.3B).  
Densitometric analysis of the electrophoresed cell lysates suggested that GST-
Tat was expressed at a higher level, about 17-20 % of total bacterial protein, 
compared to the His-Tat, which constituted about 5 % of total protein.  Separation 
of IPTG-induced bacterial cultures into soluble and insoluble fractions clearly 
demonstrated that the recombinant proteins were insoluble, despite attempts to 
optimise conditions for the production of soluble protein.  Several parameters 
were assessed including media for growth, temperature of growth, IPTG 
concentration, OD600 for induction and length of induction.  The optimum yield 
was achieved following induction at OD600= 0.5 with 0.1 and 0.5 mM IPTG for 
pGEX and pTrcHis, respectively, for 1.5 h at 37°C in either M9 or LB media.   
Table 4.3.  Predicted molecular weight and pI of recombinant and native 
Tat proteins.  Calculation was done using ProtParam tool from ExPAsy. 
Protein  Mw (kDa)  pI  No.  aa 
GST-Tat 37.7  8.8  330 
His6-Tat 15  9.7  135 
Tabanan Tat  10.7  10.3  97 
Pulukan Tat  10.7  10.2  97 
Kalimantan Tat  10.7  10.5  97 
 
When the induction was allowed for more than 2 h in the His-Tat system, the 
emergence of a lower sized protein band in the Western blots (Figure 4.4)   95 
suggested protein degradation occurred, but degradation of GST-Tat did not 
appear to occur even when the induction continued for 4 h (data not shown).   
 
Figure 4.3.  JDV Tat fusion proteins expressed in E. coli.  (A) Total protein 
extracted from transformed Top10F’ cells were fractionated on a 15 % 
polyacrylamide gel under reducing condition and visualised by Coomassie 
brillant blue staining.  The bacteria were harvested prior (lanes 1 and 3) 
and after 1.5 h induction with IPTG (lanes 2 and 4).  (B) Western-blot 
analysis using anti-GST and anti-His antibodies of the same preparation in 
A; higher level expression of 36-kDa GST-Tat (lane 2) was evident in 
comparison to the 17-kDa His-Tat (lane 4). 
 
Purification of GST fusion protein 
Only a small amount of soluble GST-Tat was recovered on the immobilised 
glutathione as demonstrated by Western bloting.  As expected, the expressed 
protein, migrating at approximately 38 kDa, was detected using GST antibody, in 
addition to a smaller band, presumably unbound GST  (lane 1, Fig 4.4).  Greater 
yields were obtained by sequential detergent washing of the insoluble inclusion 
bodies (lane 3, Figure 4.4) followed by solubilisation using 6 M guanidium   96 
chloride ((lane 4, Figure 4.4) or 8 M urea (lane 5, Figure 4.4).  Several smaller 
GST-staining bands were detected in addition to the 38-kDa fusion protein, 
presumably indicative of protein degradation of the fusion protein, perhaps 
associated with harsh solubilisation conditions.  There was no obvious difference 
in yield between these two denaturing agents.  The protein concentration was 
described below. 
 
Figure 4.4.  Western blot analysis of purified GST-Tat.  Protein 
purification was initially done using Glutathione-Sepharose 4B (Sigma).  
Lane 1 and 2, GST control plasmid and GST-Tat plasmid, respectively, 
expressed in bacterial cells, demonstrating soluble GST or GST-fusion 
proteins. The insoluble protein was partially purified by detergent 
washing (lane 3) and further solubilised with 6M guanidium chloride 
(lane 3) or 8M urea (lane 4).  The protein products were probed with 
anti-GST antibody to confirm identity and antigenicity. 
 
Purification of His6 fusion 
The Ni-NTA resin (Qiagen) enabled the purification of His-labelled Tat in the 
inclusion body material solubilised with 6 M Gu-HCl or 8 M urea.  Following 
recommended immobilisation, washing and elution protocols, the His-Tat protein 
of 17 kDa was detected from the eluates in considerable purity (Figure 4.5) in   97 
comparison to the purified GST-Tat (Figure 4.7).  Despite this apparent low 
impurity in CBB stained gel, several immunogenic bacterial protein contaminants 
produced high background reaction in WB assay using sheep Tat antiserum (data 
not shown). 
 
Figure 4.5.  Purification of His-Tat.  Following induction with 1 mM IPTG 
for 1.5 h at 37°C, the E. coli cells were lysed with buffer containing 8 M 
urea and centrifuged to pellet cell debris.  The supernatant was applied to 
a Ni-NTA column and the His-Tat was eluted with buffer containing 250 
mM imidazole.  Lane 1,: solubilised non-induced cells; lane 2, solubilised 
IPTG-induced cells; lane 3, flow through; lanes 4–6, 1st, 2nd and 3rd 
washes; lanes 7–8, 1st and 2nd eluates. 
Expression in mammalian cells 
To reduce background contamination of the Tat proteins by E. coli proteins, His-
Tat was expressed constitutively in mammalian cells using pcDNA/tat vector (His-
Tatmam).  Transfected COS7 cells, which survived routine passage in media 
containing G-418 sulphate for 6 to 8 weeks, were subjected to protein analysis.  
Initial analysis on whole cell extracts was unable to detect the predicted protein, 
indicating low level expression in this system.  After purification of the protein 
using Ni-NTA affinity chromatography, SDS-PAGE and subsequent silver staining   98 
detected a major protein product of approximately 17 kDa in size (Figure 4.6, 
Panel A, Lane 2) that was bigger than the calculated molecular mass of 15 kDa 
as noted with the prokaryotic version mentioned earlier.  The identity of the 
protein band migrating at 17 kDa was determined by Western blot using anti-His 
monoclonal antibody (Figure 4.6, Panel B, Lane 2) and sera from animals injected 
with GST-Tat (Figs.  4.9–11).  Furthermore, the antigenic reactivity of this protein 
was confirmed by Western blot with bovine sera collected from endemic area 
(Table 4.4).  JDV-negative bovine sera failed to recognize the protein, thereby 
showing the specificity of the assay. 
 
 
Figure 4.6.  Expression and purification of His-Tat produced in COS7 cells 
stably transfected with pcDNA/tat.  (A) The His6-tagged Tat was purified 
using Ni-NTA affinity chromatography.  Protein eluates from pcDNA3.1 
(lane 1) and pcDNA/tat (lane 2) transfected cells were resolved in 15 % 
SDS-PAGE.  Subsequent silver staining cells identified His-Tatmam as a 17 
kDa protein (arrow).  (B) Western blot analysis identical to that shown in 
panel A was done using monoclonal anti-His which recognised the 17-kDa 
band. 
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Estimation of the protein concentration 
As mentioned above, only a low yield of soluble GST-Tat was recovered on the 
immobilised glutathione after IPTG induction of the pGEX/tat transformed E. coli 
in contrast to the sequential detergent washing of the insoluble inclusion bodies 
followed by solubilisation using Gu-HCl or urea.  Proportional to the known 
concentrations of BSA and lysozyme and the harvest volume, densitometric 
analysis calculated an estimated 3.5 mg of purified GST-Tat was produced from 
200 mLculture with both denaturing agents compared to only 0.2 mg soluble 
protein (Lanes 6 and 7 Figure 4.7).  While the yield of His-Tat produced in E. coli 
was estimated about 1 mg/200 mLculture (Lane 8 Figure 4.7), less than obtained 
with the GST-Tat system and approximately 80 µg His-Tat was purified from 4 x 
75 cm
2 flasks of COS7 cells (Lane 9 Figure 4.7). 
 
Figure 4.7.  Concentration estimation of purified recombinant Tat proteins. 
Following SDS-PAGE of purified proteins and known concentrations of BSA 
(67 kDa) and lysozyme (14.3 kDa), concentration of Tat proteins was 
calculated densitometrically.  Lanes 1-5, BSA and lysozyme in various 
concentrations of 1,000, 500, 250, 125 and 50 ng, respectively; lane 6, 
GST-Tat purified from insoluble and lane 7, soluble fractions; lane 8, His-
Tat produced in E. coli and lane 9, His-Tatmam. 
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Induction of Tat antibody in sheep and cattle 
The immunogenicity of GST-Tat was confirmed by the induction of an antibody 
response following its injection in both sheep and cattle, detected by Western 
immunoblotting.  In sheep, weak reactivity against the immunising antigen 
appeared to be present at the time of the initial inoculation and 2 weeks after the 
first injection, and increased in intensity following subsequent booster injections 
(Figure 4.8, Panel A).  The weak signal given by pre-immune serum was 
presumably due to the presence of anti-GST antibody in the immunised animal.  
Since only partially purified GST-Tat antigen was used in this experiment, there 
was a high background due to contaminating E. coli proteins, which made the 
specificity of the antibody difficult to determine.  Using an antigen prepared with 
the eukaryotic expression system (His6-Tat in COS7 cells), which eliminated the 
background reaction associated with E. coli, the presence of Tat-specific antibody 
was evident (Figure 4.8, Panel B).  The sheep antiserum was shown to have a 
titre of ≥400 (Figure 4.8, Panel B). 
In 4 Bali cattle injected with a similar GST-Tat preparation, a strong specific 
antibody response was observed in 2 animals on day 28, 2 weeks after the 
second injection, and the intensity of the reaction increased at day 42 after an 
additional injection of the antigen (Figure 4.9).  Weak reactions against Tat were 
detected in sera of the other two animals at 28 and 42 d (Figure  4.9); in these 
two animals there was also a weak response against the GST component of the 
immunogen, suggesting these 2 animals were poor responders.  No reactivity to 
Tat was detected in animals immunised with GST only.  These results showed 
that the eukaryotic recombinant Tat protein can be used as a test antigen for the 
serodetection in Tat vaccinated animals. 
1
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Figure 4.8.  Detection of Tat-specific antibody following the injection of GST-Tat into sheep.  (Panel A) The detergent washed 
GST-Tat used for immunisation was blotted and incubated with sheep antisera collected at different days (d) after injection 
as indicated.  Lanes 1, 4, 7, 10; 3, 6, 12 and 2, 5, 8, 11, 1:100, 1:1,000 and 1:5,000 dilutions of serum, respectively.  The 
arrow indicates the expected size of GST-Tat.  (Panel B) Western immunoblot using a His-Tatmam antigen produced in stably 
transfected mammalian (COS7) cells, demonstrating the titration of Tat-specific antibodies induced in sheep against a crude 
GST-Tat antigen. 
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The serum sample from animal CB46 collected at day 42 (Figure 4.9) was serially 
diluted and reactivity to Tat was moderate in comparison to GST (Fig 4.10), 
suggesting that Tat was a relatively weaker immunogen than GST. 
 
 
 
 
Figure 4.9.  Western immunoblot demonstrating the antibody response in 
Bali cattle at days 0 (lane 1), 14 (lane 2), 28 (lane 3) and 42 (lane 4).  
Four animals were injected with a GST-Tat preparation at 0, 14 and 28 
days;.  Animal CB61 was injected with a control GST protein.  Serum 
samples were diluted 1:20 and the blot incorporated both purified GST 
antigen and a His-Tat antigen produced in stably transfected mammalian 
cells (COS7).  In 2 animals (CB46 and CB48), antibody against Tat was 
detected on day 28, 2 weeks after the second injection, and there was 
stronger reactivity 2 weeks after the third injection.  In animals CB45 and 
CB47 there was weak reactivity against Tat at day 28 and 42, and no 
reactivity was detected against Tat in animal CB61 injected with GST only.  
Lane C was reacted with sheep anti-GST-Tat serum.     103 
 
 
Figure 4.11.  Western blotting demonstrating His-Tat expression after 
varying induction times with 1 mM IPTG.  Cell lysates were prepared 
before (lane 1), 1 h (lane 2), 1.5 h (lane3) and 2 h (lane 4) after 
induction.  The proteins of 17 kDa were detected with an affinity purified 
sheep anti-Tat antibody. 
 
Figure 4.10.  Titration of antibodies from animal CB46 shown in Figure 
4.9.  Serum samples from animal CB46 were further diluted as indicated 
and reacted against GST and His-Tatmam.  A weak reaction to Tat was 
shown at a 1:400 dilution of the serum in comparison to the strong 
reaction to GST. 
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To eliminate non-Tat antibodies in the polyclonal sheep anti-Tat, the serum was 
affinity purified by adsorption of antibody onto GST-Tat and then by removal of 
non-specific antibody by absorption against GST and bacterial proteins.  This 
affinity-purified serum recognised only a single band of approximately 17 kDa 
when reacted with the whole cell lysate of His-Tat expressing E. coli as shown in 
Figure 4.11, which confirms its specificity. 
Detection of JDV Tat native protein 
PMBC and spleen lysates collected from Bali cattle during experimental infection 
with each of 3 different JDV strains were used as the protein sources.  Western 
blotting using affinity purified monospecific sheep anti-Tat detected protein bands 
with apparent mobility of 14 kDa primarily from PBMCs obtained prior to febrile 
period (Figure 4.12, panel A).  The seroreactivity of the 14 kDa protein was 
comparable with the eukaryotic His-Tatmam (Figure 4.12, panel B).  As noted with 
the His-Tat proteins, the native Tat proteins produced by Tabanan/87, Pulukan 
and Kalimantan JDV strains also migrated slower than 10.7 kDa predicted from 
the DNA sequences specifying 97 aa (Table 4.3).  This apparent mobility anomaly 
was also observed with Tat protein of BIV and HIV (Fong et al., 1997; Goh et al., 
1986). 
Seroreactivity of the Tat protein in different population of Bali 
cattle 
To further demonstrate the immunogenicity of JDV Tat, 147 serum samples were 
tested at a 1:20 dilution for the presence of anti-JDV antibodies by the 
recombinant protein-based Western blot using eukaryotic recombinant JDV Tat 
and GST-CA as test antigens.  Tat antibody was detected in animals that had 
recovered from experimental infection (Table 4.4).  As shown in Figure 4.13; 
however, the sera reacted weakly against Tat in contrast to the strong reactivity to 
capsid.  Apparent reaction was mainly demonstrated by sera collected 1-month pi 
which was evident in two animals (lanes A1 and B1 Figure 4.13) and weakened 
by the time, while in animal C the response was dubious (lane C2).  
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Figure 4.12.  Detection of native JDV Tat protein in JDV-infected cattle.  (A).  Affinity purified sheep anti-Tat recognised a 
band of approximately 14 kDa in PBMC lysates collected immediately preceding the development of fever in cattle 
infected with Tabanan/87 (lane1), Pulukan (lane 5) and Kalimantan (lane 6) strains of JDV.  No reactivity was shown by 
spleen (lanes 2, 4 and 8) and PBMC lysates (lanes 3, 7 and 9 representing Tabanan, Pulukan and Kalimantan strains, 
respectively) collected on the second day of the febrile reaction.  Immunoblots were developed using ECL detection 
system (Amersham).  (B).  High resolution 16 % Tricine-gel was used to for better protein separation, and the eukaryotic 
His-Tatmam was included (lane 1) as a comparison.  The native Tat (lane 3) migrated relatively faster (14.4 kDa) than the 
His-Tat (17 kDa); both of them migrated slower than the predicted molecular weight of 15 and 10.7 kDa, respectively.  
Lane 2 is PBMC lysate from an animal recovered from the acute phase disease as in panel A. 
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Table 4.4.  Prevalence of Tat antibodies in Bali cattle and correlation 
with ELISA and presence of antibodies to the JDV capsid protein.  
No.  (%) WB positive
b   JDV Status  No.  sera 
tested 
Absorbance 
reading of 
ELISA
a  Capsid Tat 
Recovered cattle  3  NA  3 (100)  2 (75) 
54  > 3.0  54 (100)  27 (50)  Vaccinated cattle
c (Bali and 
Kalimantan) 
61  1.1–3.0  61 (100)  1 (1.6) 
Unvaccinated cattle (Bali)  10  ND  10 (100)  2 (20) 
Jembrana disease-free area 
(South Sulawesi) 
10  ND  1 (10)  1 (10) 
Jembrana disease-free area 
(Nusa Penida) 
5  Neg  0 (0)  0 (0) 
aELISA was done by Disease Investigation Centre, Bali utilising whole virus pelleted 
from plasma as an antigen (Hartaningsih et al., 1994).   
bAntibody detected by Western blotting using a recombinant JDV capsid (Burkala et al., 
1998) and recombinant Tat blotted together in the same strip as shown in Figures 4.14 
and 15. 
cCattle were vaccinated with a crude spleen vaccine (Hartaningsih et al., 2001) 
 NA and ND denote not available and no done, respectively.  
 
Antibody was detected in 24 % of 115 vaccinated cattle in Bali and South 
Kalimantan; these had all tested positive by an ELISA utilising a whole virus 
antigen and were positive for antibody to recombinant capsid protein by Western 
immunoblots (Table 4.4).  In general, the seroreaction signal to Tat was weaker 
relative to capsid (Figure 4.14); relatively strong positive Tat results usually 
correlated with high ELISA titres (Table 4.4) and strong recognition to capsid 
antigen (lanes 1–5, Figure 4.14).  While sera with lower ELISA titre was less 
reactive to capsid and did not show reactivity with Tat (lanes 14–16, Figure 4.14).  
In cattle without vaccination history, Tat antibody was detected in 2 of 10 sera 
(Table 4.2) that were positive for antibody to the JDV capsid protein and were 
presumed to have been infected previously with JDV. 
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Figure 4.13.  Reactivity of bovine sera against capsid (CA ) and Tat 
proteins in experimentally infected cattle (A-C). Convalescent sera were 
collected monthly for 6 months (1-6) post infection. Weak reactivity to 
Tat was shown by sera collected 1-month post infection and reactivity 
decreased further with time, in contrast to the reactivity to CA. Sera were 
tested at a 1:20 dilution. 
 
Tat antibody was also detected in one serum from South Sulawesi where 
Jembrana disease has not been recognised; the serum was also reactive against 
capsid protein (Table 4.4).  Whereas Tat antibody was not detected in Bali cattle 
from the Jembrana disease-free island Nusa Penida (Table 4.2); these cattle 
were also negative for antibody to JDV capsid protein as represented in lane 16, 
Figure 4.14.   108 
 
Figure 4.14.  Reactivity of bovine sera against CA and Tat in vaccinated 
cattle.  Immunoreactivity was mostly demonstrated by cattle vaccinated 
with inactivated tissue-derived virus antigens (lanes 1-15) as shown in 
Table 4.2.  Tat reactivity was shown mostly by animals with high ELISA 
titre (Table 4.4) and strong reactivity to the JDV capsid protein. Lane 16, 
serum sample from disease-free area of Nusa Penida (Table 4.4). Sera 
were tested at 1:20 dilution. 
 
Discussion 
The methods selected for the production of recombinant proteins were partly 
based on their intended use.  There were three basic needs: first, a method for 
production of potential antigens that could be used in vaccines, that would 
provide a high level of protein expression and would be appropriate for use in 
Indonesia; second, potential vaccine proteins would need to be immunogenic and 
preferably soluble; third, proteins intended as antigens for serological tests would 
need to have minimal or no antigenic cross-reactivity with non-JDV proteins, so 
providing high specificity.  For the production of a JDV Tat antigen that might be 
incorporated into a vaccine and could be used in Indonesia, bacterial expression 
system were considered preferable because of relative simplicity of production   109 
methods and potential yields, thereby reducing costs.  Either a GST or His-tagged 
protein seemed appropriate for a vaccine.  For a serological antigen, where high 
level production was less important, two systems were considered appropriate: 
either a His-tagged (fusion) protein expressed in a bacterial system, or one that 
would enable expression in eukaryotic cells.  His-tags enable single-step affinity 
purification using nickel-chelating resin under denaturing condition, and the 
eukaryotic (COS7 cell) system eliminates the problem of cross-reactivity with 
contaminating E. coli proteins.   
High levels of expression were achieved with the pGEX system producing a GST-
Tat fusion protein.  The GST fusion partner is well known to increase the quantity 
and stability of expressed proteins (Hearn & Acosta, 2001).  This system was 
considered a potentially efficient way of producing JDV Tat antigen suitable for 
incorporation into a vaccine.  However, although yields were high in this 
prokaryotic system, the yield of soluble protein was low, too low for efficient large-
scale production.  The proteins were produced mainly as insoluble inclusion 
bodies.  Formation of inclusion bodies is known to be a common outcome in over-
expression of heterologous protein in E. coli cytoplasm (Hannig & Makrides, 
1998).  Findings similar to these have been reported with HIV-1 Tat expressed 
with different vectors in bacterial systems: the high cysteine content of Tat has 
been implicated in this aggregation as it causes misfolding of the protein through 
intra- and/or inter-molecular binding (Frankel et al., 1988a; Frankel et al., 1988b; 
Kirsch et al., 1996; Koken et al., 1994; Rhim et al., 1994).  Nine cysteine residues 
were predicted to occur in JDV Tat1 (Chadwick et al., 1995b).  Partial purification 
of inclusion bodies was eventually achieved following solubilisation with either 
Gu-HCl or urea, even though re-aggregation was evident after dialysis against 
PBS.  These procedures did not appear to affect the antigenicity and 
immunogenicity of the protein, and refolding was not attempted.  Urea provides a 
potentially low cost method for the large scale solubilisation of protein for 
preparation of a vaccine, should such a vaccine be shown efficacious against 
JDV.   110 
This aggregation propensity was anticipated using a His6 tag expression system, 
pTrc/His.  A strong and conformationally independent interaction between 6 
histidine tags and immobilized Ni
2+ ions has been the main advantage of this 
system, which allows protein purification under denaturing conditions (Hochuli et 
al., 1987; Holzinger et al., 1996).  Thus, proteins that have aggregated into 
inclusion bodies can be dissolved in a suitable agent such as urea before affinity 
purification.  Unfortunately, despite the relatively higher purity the yield obtained 
using this system was less than the GST system.  However, for future large scale 
production, further scale-up optimisation of this system is worth considering. 
To enable a confident assessment of antibody response induced by the 
bacterially expressed recombinant Tat, an unrelated expression system was 
employed to synthesise the JDV Tat in pcDNA3.1/His vector.  This vector 
contains the cytomegalovirus immediate early promoter (PCMV), which provides a 
high level constitutive expression in a range of mammalian cells (Boshart et al., 
1985), and a bovine growth hormone polyadenilation (BGHpA) signal for efficient 
transcription termination and polyadenylation of mRNA (Goodwin & Rottman, 
1992).  The advantages of mammalian cells over other expression systems are 
the ability to carry out proper protein folding, complex glycosylation, as well as a 
broad spectrum of post-translational modifications (Geisse et al., 1996).  As 
expected, the His-Tat protein expressed by this system (His-Tatmam) reacted 
specifically with serum antibodies collected from GST-Tat injected animals.  The 
clean background of the reaction may provide a diagnostic reagent for analysing 
antibody response to Tat vaccination unambiguously.   
The immunogenicity of the GST-Tat fusion protein was initially established by the 
ability of this preparation to induce specific antibody response in sheep, and 
subsequently in Bali cattle in Indonesia.  Comparable immunogenicity was 
observed in immunised animals, although a relatively greater immunological 
response to the GST rather than the Tat moiety was noted (Figures 4.8-4.10), 
perhaps due to the insoluble nature of the immunizing antigen (Rothel et al., 
1997) or simply because JDV Tat was relatively less immunogenic than the GST.  
In all 4 cattle immunised with GST-Tat, antibody was detected (Figure 4.9)   111 
although the level of antibody seemed to vary markedly between the animals.  
This could be significant if the GST-Tat was trialled as a vaccine in Bali cattle.  
However, the level of Tat antibody induced using this GST-Tat preparation was 
higher than using the conventional vaccine.  The result, therefore, indicates that 
the insolubility of the immunising GST-Tat did not affect its final immunogenicity.   
The antigenicity of GST-Tat was confirmed by the demonstration that the sheep 
anti-Tat antibodies were reactive with native JDV Tat produced in cattle infected 
with each of Tabanan/87, Pulukan and Kalimantan strains which indicates the 
conservation of the immunogenic/antigenic domain in support to genetic studies 
in Chapter 3.  The native JDV Tat was shown to have an apparent molecular 
weight of approximately 14 kDa, which was greater than that (10.7 kDa) 
calculated from the deduced 97 aa sequence (Table 4.3).  Similar findings to this 
were described for BIV and HIV-1 Tat proteins, both were identified as 14 kDa as 
opposed to the predicted 12.7 and 10.7 kDa, respectively.  These discrepancies 
thought to be associated with high pI or number of positively charged (basic) 
residues such as arginine and lysine (Aldovini et al., 1986; Ensoli et al., 1993; 
Fong et al., 1997; Goh et al., 1986; Jeang et al., 1988; Wright et al., 1986).  
Protein with high basic residues may be analysed to have an apparent molecular 
weight greater than the actual molecular weight because basic amino acids 
attract more negatively charged SDS, resulting in the increase of the mass to 
charge ratio of the SDS-protein complex, thus lowering electrophoretic mobility 
(Hames, 1998).  This effect was also observed in His-Tat proteins, but not in 
GST-Tat probably due to the greater mass and lower pI of the latter protein 
(Table 4.3).   
The prevalence of Tat antibody in seropositive cattle was low (Table 4.4).  The 
weaker signal to Tat protein observed in this study indicates the low titre of 
naturally occurring Tat antibody as a result of infection or immunisation with the 
crude tissue vaccine.  Tat antibody was only weakly detected in convalescent 
sera from experimentally infected cattle despite the strong reactivity to JDV 
capsid protein in these animals, and 2 out of 10 sera from unvaccinated cattle in 
endemic areas were reactive; presumably these cattle had recovered from natural   112 
infection.  One serum sample from the Jembrana disease free area of South 
Sulawesi reacted with Tat and CA proteins suggesting that an antigenically-
related non-pathogenic bovine lentivirus is circulating in this area.  Results from 
experimental infection suggest that antibody response to Tat is transient in 
contrast to CA.  This discrepancy might be due to the different abundance of the 
2 proteins during the course of infection and possibly the immunological status of 
the infected animals.  These results suggested that Tat protein was expressed 
early in the infection and appeared to be a minor protein similar to what was 
previously reported in HIV-1 infection (Chang et al., 1997; Ensoli et al., 1993).  
Possibly, therefore, only small amount of JDV Tat was presented to the humoral 
immune system during viral infection or in vaccination with inactivated vaccine.  
This conclusion; however, needs to be confirmed. 
Like the pathogenesis of disease associated with many lentivirus infections, in 
both man and animals (Haffer et al., 1990; Newman et al., 1991; Zhang et al., 
1997), the immune system in JDV-infected cattle is severely damaged; there is a 
marked lymphopenia (Soesanto et al., 1990) and generalised atrophy of follicular 
(B cell) areas of lymphoid tissues (Dharma et al., 1991) which would account for 
the delayed immunological response.  The antibody response to JDV in infected 
animals is delayed (Hartaningsih et al., 1994; Wareing et al., 1999), usually not 
occurring for several weeks after infection and recovery.   
Despite evidence suggesting a strong correlation between anti-Tat antibody and 
delayed AIDS progression (Agwale et al., 2002; Barillari et al., 1999; Pauza et al., 
2000; Reiss et al., 1991), it remains to be confirmed whether the development of 
Tat antibody in cattle is associated with protection against infection.  There is no 
clear evidence from the serological results of vaccinated and recovered cattle that 
this is true.  Cattle recovered from JDV infection have been shown to resist 
further challenge with virulent virus (Soeharsono et al., 1990) but Tat antibody 
appeared to be transient and was detected in only some cattle that were 
recovered from experimental or natural infection and were all positive for antibody 
to the immunodominant capsid protein.  Tat was certainly less immunogenic than 
the capsid protein but possibly, low levels of Tat antibody were present, beyond   113 
the limit of detection, but sufficient to provide a protective immunity.  The use of 
epitope peptide in ELISA test would be expected to increase sensitivity and 
specificity of serological detection in clarifying this question.  The low 
seroprevalence and antigenicity of JDV Tat was not unexpected;  similar findings 
in HIV-1 have been reported (Butto et al., 2003; Krone et al., 1988). 
In conclusion, given that Tat antibody has inhibited HIV 1 replication in vitro, and 
lowered viral load and delayed disease progression in seropositive patients 
(Mhashilkar et al., 1995; Re et al., 1995; 2001b; Reiss et al., 1990; Zagury et al., 
1998b), it seems worthwhile to investigate the role of Tat antibody in the 
development of protective immunity against JDV infection.  The studies reported 
in this Chapter have paved the way for such studies.  It was clearly demonstrated 
that recombinant Tat proteins could be produced that were immunogenic in cattle.  
The evaluation of Tat vaccines in the induction of a protective immunity seems a 
logical extension of these studies.  Application of different adjuvants and 
vaccination dosage are warranted to modulate the immune responses for a better 
outcome.  Such studies are currently under investigation in Indonesia.  114 
Chapter 5   
Construction and in vitro evaluation of a 
DNA plasmid encoding JDV tat  
Summary 
Preliminary studies towards the development of a potential JDV tat DNA vaccine 
are described.  A plasmid encoding the Tat protein was constructed based on the 
mammalian expression vector pVAX1.  The performance of this construct was 
evaluated via transfection into COS7 and primary bovine lung cells.  Transcription 
of the encoded gene was confirmed through the detection of tat mRNA by RT-
PCR.  The presence of Tat protein in the transfected cells was detected by 
immunofluorescence staining; the protein was shown to localise primarily in the 
nuclear pheriphery.  Further verification of the functional performance of this 
construct was established using a trans-activation assay.  The results 
demonstrate that the tat DNA plasmid is functional in vitro and further evaluation 
in animals is warranted.     115 
Introduction  
In Bali cattle, JDV infection results in a transient high titre of infectious virus (virus 
load) coincident with the febrile period and acute disease syndrome.  The virus 
load declines after the fever has dissipated (Soeharsono et al., 1990).  An 
antibody response is not detected for several weeks after infection (Hartaningsih 
et al., 1994), presumably associated with lesions in the lymphoid system and 
particularly with depletion of follicular (B cell) areas (Dharma et al., 1994).  The 
delayed antibody response suggests the potential importance of cell-mediated 
immunity (CMI) in recovery from infection and perhaps in the suppression of JDV 
infection in naïve animals.  There is evidence that strongly suggests the essential 
role of this arm of the immune responses in containing lentivirus infections 
including HIV-1 (Borrow et al., 1994; Koup et al., 1994), SIV (Kuroda et al., 1999; 
Schmitz et al., 1999), EIA (Hammond et al., 1997; McGuire et al., 1994; 1997) 
and FIV (Flynn et al., 1996; 2000).  In addition, there
 is evidence that cytotoxic T 
lymphocyte (CTL) response against Tat may be more efficacious
 in controlling 
infection than comparable responses to viral
 structural proteins (Addo et al., 2001; 
Allen et al., 2000; Stittelaar et al., 2002; van Baalen et al., 1997).  Relevant to 
these notions, there has been increasing interest in AIDS vaccine approaches 
that elicit CTLs, which recognize and eliminate cells infected with HIV (McMichael 
& Hanke, 2003).  Unlike antibodies, effective CTL responses can be directed 
against epitopes derived from any viral protein, raising the possibility that CTLs 
can be targeted to regions that are more conserved than the viral envelope. 
A novel vaccination strategy involving the direct inoculation of a plasmid DNA 
containing appropriate genes encoding protein antigens involved in the induction 
of a protective immunity has been demonstrated to be an effective method of 
vaccination (Tang et al., 1992).  This DNA enables endogenous antigen 
processing mimicking that which might occur in natural infections and leading to 
the induction of antibody and a cell-mediated immune response (An & Whitton, 
1999; Arulkanthan et al., 1999; Bagarazzi et al., 1998; Deng et al., 2000).  
Protection as a consequence of the inoculation of the appropriate DNA has been   116 
observed in many different infectious disease models (Ulmer et al., 1993; Wang 
et al., 1993), in native animals such as dogs and cats (Cherpillod et al., 2000; 
Jallet et al., 1999; Kwang et al., 1999), pigs (Gerdts et al., 1997; Hong et al., 
2002; Markowska-Daniel et al., 2001), horses (Cantlon et al., 2000; Lunn et al., 
1999) and cattle (Braun et al., 1998; Harpin et al., 1999; Loehr et al., 2001; 
Schrijver et al., 1997).   
Tat has been used with success as a DNA vaccine component for the 
suppression of HIV infection in mice and cynomolgus monkeys (Billaut-Mulot et 
al., 2001; Cafaro et al., 2001; Caselli et al., 1999) and CAEV infection (Beyer et 
al., 2001; Harmache et al., 1998).  In this Chapter a JDV Tat-encoding plasmid 
was constructed and its function was evaluated in mammalian cell cultures.   
Materials and methods 
Vectors and cells 
pVAX1 (Invitrogen) shown schematically in Figure 5.1, was used to drive 
expression of the inserted gene from the CMV immediate early promoter in 
mammalian cells.  pVAX1/lacZ (Invitrogen) as shown in Figure 5.1, expresses the 
bacterial β-galactosidase gene and was used to determine the transfection 
efficiency and to generate a reporter plasmid for trans-activation assays. 
The expression of an inserted gene in pVAX1 is driven by the CMV immediate 
early promoter (Boshart et al., 1985; Nelson et al., 1987) and terminated by BGH 
pA signal for efficient polyadenylation of mRNA (Goodwin & Rottman, 1992).   
Plasmid constructs 
Construction of pVAX/tat 
The first coding exon of JDV tat was synthesized by PCR using the forward 
primer jtatV1 5’-ACCGGCTAGCCaAATATGgCTG-3’ (JDV nt.4994–5016) and the 
reverse primer jtatV2 5’-TTCCAGGGTCCAACGATCTAGTG-3’ (nt.5306–5329)   117 
from spleen DNA (Chapter 3).  An NheI restriction endonuclease cleavage site 
(underlined) outside the coding sequence was included to facilitate further 
cloning.  Two mutations (lowercase) were also introduced into the forward primer 
to form a strong ribosome-binding site AnnATGG (Kozak, 1997). 
The PCR reaction was done using Expand™ high fidelity PCR system (Roche) 
and was prepared as detailed in Chapter 3.  After initial incubation at 95°C for 5 
min, the reaction was allowed to proceed for 30 cycles (95° for 40 s, 69°C for 30 s 
and 72°C for 1 min), followed by a final incubation at 72°C for 7 min.  The 
amplified product was gel purified,TA-cloned and subsequently sequenced.  To 
generate a DNA vaccine that expresses the JDV Tat, pVAX/tat, the tat fragment 
was cleaved from the TA-vector with NheI and EcoRI restriction endonucleases 
and fused to the respective sites of pVAX1 vector downstream of the CMV 
promoter (Figure 5.1A).  Positive constructs were initially screened by PCR using 
 
Figure 5.1.  Schematic representation of mammalian expression vectors 
pVAX1 and pVAX1/lacZ.  (A) pVax1 was used to generate a DNA vaccine 
by inserting JDV tat into NheI/EcoRI restriction sites.  (B) pVAX1 
encoding the 3.1 kb lacZ was used in transfection efficiency 
determination and reporter plasmid construction.  To construct a reporter 
plasmid pLTR/lacZ, the CMV promoter was excised by AseI/NheI 
restriction digestion and replaced by the JDV LTR promoter fragment. 
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primers T7 in combination with BGH or jtatV1 (Table 5.1) followed by restriction 
enzyme digestion and subsequently confirmed by sequencing. 
Table 5.1  Oligonucleotide primers specific to pVax1 DNA vaccine vector 
or JDV regions.  
Genomic positions  Primer  Sequence (5’ to 3’) 
Nucleotide   Region 
T7 TAATACGACTCACTATAGGG      664–683 pVAX1 
BGH   TAGAAGGCACAGTCGAGG    823–840  pVAX1 
VAX  ACTCTTCGCGATGTACGG        2–19         pVAX1 
jLTR1   AGCaTTaatCGGAGCTGGAATATCTGATTG 7424–7453  JDV 
jLTR2   GTGCCTTACAGGCTAgCAGCTGGG  7678–7655 JDV 
jtatV1 ACCGGCTAGCCaAATATGgCTG  4994–5016  JDV 
jtatV2 TTCCAGGGTCCAACGATCTAGTG  5329–5306 JDV 
 Lowercase letters indicate nt modification introduced to create restriction enzyme 
cleavage sites (underlined) and ribosome-binding site 
 
Construction of a reporter plasmid pLTR/lacZ 
The JDV LTR containing basal promoter, enhancer elements and TAR region 
excluding the inhibitory element reported earlier (Chen et al., 1999) was isolated 
by PCR from Tabanan/87 infected spleen DNA.  Primers jLTR1 5’-
AGCaTTaatCGGAGCTGGAATATCTGATTG-3’ and jLTR2 5’-
GTGCCTTACAGGCTAgCAGCTGGG-3’ modified (lowercase) to contain AseI and 
NheI sites (underlined) respectively were used to generate a 255 bp (nt 7424–
7678) fragment with the same conditions as for tat except an annealing 
temperature of 65°C was used.  The product was then TA-cloned and sequenced. 
Following confirmation by sequencing, AseI and NheI restriction enzymes were 
used to excise a 639-bp fragment containing the CMV promoter from pVAX1/lacZ 
(Figure 5.1B).  The LTR promoter of 243 bp in size was cleaved with the same 
enzymes and fused to replace the PCMV to generate pLTR/lacZ.  An 
oligonucleotide VAX 5’-ACTCTTCGCGATGTACGG-3’ corresponding to the 
pVAX1/lacZ region upstream of the AseI site was used, in conjunction with the   119 
BGH primer, for PCR screening using the conditions described in Chapter 3 
except that the extension step was at 72°C for 3 min due to the larger size of the 
product and for sequencing. 
Isolation of plasmid DNA 
To obtain sufficient amounts of plasmid DNA for transfection experiments, the 
plasmid was purified using a Quantum Prep
TM Midiprep (BioRad) according to the 
manufacturer’s instructions.  First, each plasmid construct (described above) was 
transformed into E. coli Top10 as detailed in Chapter 3.  A single colony was 
selected and inoculated into 50 mLLB broth and incubated overnight at 37°C with 
vigorous shaking.  The cells were pelleted by centrifugation (4,000 g, 10 min) and 
resuspended in 5 mLCell Resuspension Solution.  Five mLof Cell Lysis Solution 
was added to lyse the cells, and then an equal amount of Neutralisation Solution 
was added.  The mixture was centrifuged (8,000 g, 30 min) and the supernatant 
transferred into a new tube and mixed with 1 mLof matrix.  After centrifugation 
(8,000 g, 2 min), the matrix was washed with 10 mLWash Buffer, centrifuged and 
resuspended in 600 µl Wash Buffer, subsequently transferred into a spin column.  
The column was centrifuged (14,000 g, 30 seconds) and washed once more with 
500 µl Wash Buffer, followed by centrifugation (14,000 g, 2 min) to remove 
residual ethanol.  Finally, 600 µl of warm deionised H2O was added to the 
column, it was centrifuged (14,000 g, 2 min) to elute the DNA stored at –20°C.  
The DNA concentration was determined as previously described (Chapter 3).   
Transient transfection  
The ability of pVAX/tat to express Tat in vitro was determined in primary foetal 
bovine lung (FBL) cells and African COS7 cells.  Both cell types were maintained 
and passaged as described previously (Chapter 4).   
The detailed protocol for transfection was as previously described for 
pcDNA3.1/tat (Chapter 4) except that G-418 sulphate step for selection of 
transfected cells was omitted.  Briefly, cells were seeded into either 6-well plates 
containing glass coverslips or 25 cm
2 flasks the day before lipid-mediated   120 
transfection (Felgner et al., 1987) was attempted.  Transfection mixtures were 
prepared containing 5 µg pVAX1/lacZ, or 5 µg pVAX1, or 4 µg pVAX/tat plasmid 
DNA in serum-free DMEM with an additional 25 µl Lipofectamine
TM 2000 reagent 
(Invitrogen) per ml.  Volumes of 200 µL or 1 mLwere applied to approximately 80 
% confluent monolayers per well or per 25 cm
2 flask, respectively, and incubated 
at 37°C for 3h.  The transfection medium was replaced with growth medium and 
the cells were incubated for an additional 48 h.  Transfection experiments were 
performed in triplicate with each plasmid construct.   
pVAX1/lacZ transfected cells were trypsinised and collected into a 1.5 
mLeppendorf tube, washed twice with PBS and fixed with 0.5 % glutaraldehyde in 
PBS for 15 min at room temperature.  The fixed cells were washed 2 times with 
PBS and the cells stained with 5 mLX-gal mixture (1 mg/mLX-Gal, 5 mM 
potassium ferricyanate, 5 mM potassium ferrocyanate, 2 mM MgCl2 in PBS) 
followed by incubation on a rotating wheel at room temperature for 2 h.  The 
transfection efficiency was determined by counting the number of galactosidase 
positive cells relative to the total cells using a haemocytometer.   
Detection of tat transcripts  
RNA extraction  
Total RNA was extracted from transfected cells grown over a 2 day period in 25 
cm
2 flasks using the RNA 4 PCR kit (Ambion) as suggested by the manufacturer.  
Briefly, after 2 washes with PBS the cells were lysed with 500 µL Lysis/Binding 
Solution, scrapped and transferred into an eppendorf tube, homogenised by 
vortexing, then cleared by centrifugation (14,000 g, 3 min).  The lysate was 
precipitated with 500 µl of 64 % ethanol and transferred into a filter column.  
Following centrifugation (14,000 g, 1 min) the column was washed with 700 µl 
Wash Solution and centrifuged again.  The washing step was repeated twice with 
500 µl volumes of Wash Solution and finally eluted with 30 µl of Elution Solution.  
The RNA solution was stored at –70°C.     121 
cDNA synthesis and PCR analysis 
cDNA synthesis was as previously detailed in Chapter3.  SuperScript II 
(Invitrogen) was used to reverse transcribe 2 µg of total RNA using 100 ng of 
BGH primer incubated at 47°C for 45 min. 
Vector-specific T7 and insert-specific jtatV2 were used as sense and antisense 
primers to amplify the tat cDNA in conjunction with Expand
TM system (Roche) and 
set up as detailed in Chapter 3.  The PCR cycle progression was an initial 4 min 
at 94°C, followed by 30 cycles at 94°C for 25 seconds (denaturation), 60°C for 30 
seconds (annealing) and 72°C for 1 min (extension), followed by 5 min at 72°C for 
final extension.  For a negative control, the reaction was performed with RNA that 
had not been reverse transcribed.  The amplified products were separated by 
agarose gel electrophoresis, stained with ethidium bromide and visualised by UV 
transillumination. 
Protein analysis 
Immunofluorescence staining 
Cos7 cells stably transfected with pcDNA/tat or transiently transfected with 
pVAX/tat grown on glass coverslips were used.  The cells were washed with cold 
PBS and then fixed in methanol:acetone for 10 min.  After fixation, the cells were 
washed 3 times with PBS, and incubated with a blocking solution (PBS containing 
0.2 % Triton-X100 and 1 % bovine serum albumin) for 5 min on ice to 
permeabilise the cells and reduce non-specific staining.  Primary antibody was 
added and incubated for 1 h at 37°C in a humidified chamber.  Following 
extensive rinsing with PBS, the cells were reacted with FITC-conjugated antibody 
(ICN Biomedical) for 1 h at room temperature.  After extensive washing with PBS, 
the coverslips were mounted on a microscope slide with a PBS:glycerol mountant 
and examined by fluorescence microscopy using a laser confocal microscope 
(BioRad).  Cos7 cells transfected with blank vectors were used as negative 
control.  Where appropriate, the primary antibodies were a monoclonal anti- His6, 
of 1:200 dilution in a 1 % bovine serum albumin solution in PBS and a sheep 
polyclonal anti-Tat (Chapter 4) absorbed with COS7 cells transfected with blank   122 
vector to remove non-specific antibody and then used at a dilution of 1:50.  The 
secondary antibodies were FITC-labelled rabbit anti-sheep and goat anti-mouse 
IgGs (ICN Biomedical) and used in 1:200 dilution. 
Trans-activation assay 
The assay was based on the ability of Tat protein to accelerate the LTR-directed 
gene transcription in trans fashion and is
 required for viral replication and a high 
viral load (Taube et al., 1999).  Tat was expected to interact with the trans-
activating responsive (TAR) element of the LTR and increase gene transcription 
elongation efficiency associated with the LTR promoter (Berkhout et al., 1989; 
Feinberg et al., 1991; Rana & Jeang, 1999; Xiao et al., 2000).  In the absence of 
Tat, the LTR-directed transcription should prematurely terminated (Kao et al., 
1987) and the protein product would not be expressed. 
Transfection was carried out in COS7 and FBL cells with the combination of 3 µg 
of pLTR/lacZ and 1 to 2 µg of pVAX/tat or 1 to 2 µg of pVAX1.  The transfection 
procedure was as for pcDNA3.1/tat detailed in Chapter 4.  The expression of β-
Galactosidase from the reporter plasmid was detected 48 h after transfection.  
The monolayer cells were subjected to X-Gal staining (as described above) for 1 
h before rinsing in PBS.  The stained cells were examined with an inverted 
microscope.   
Results 
Cloning of tat in pVAX1 
Oligonucleotide primers jtatV1 and 2 were used to amplify a 336 bp fragment 
(Figure 5.2A) containing the JDV tat exon 1 coding sequence from a cDNA library 
(Chadwick et al., 1995b) and cloned into pCR2.1 to generate pCR2.1/tat.  
Following plasmid amplification, the fragment was excised by digestion with 
NheI/EcoRI and inserted into the respective sites of pVAX1 (Figure 5.1A) to 
generate pVAX/tat.  Following transformation into E. coli Top10, plasmids from 
several colonies were screened by PCR and restriction digestion to detect the   123 
presence of the tat insert.  As shown in Figure 5.2B, 2 constructs slightly different 
in size containing NheI/EcoRI or EcoRI tat fragments designated pVAX/tat-N/E or 
-E, respectively, were identified.  The latter resulted from incomplete restriction 
enzyme digestion during attempts to excise the insert from pCR2.1/tat and 
linearise the expression vector pVAX1 as a consequence of the lower activity of 
NheI in comparison to EcoRI used in the double digestion reaction.  The two 
constructs differed by 65 bp in length between the tat coding sequence and the 
CMV promoter.  However, both constructs were equally functional and expressed 
Tat (as described below). 
 
Figure 5.2.  PCR amplification and colony screening of tat constructs.  A 336 
bp DNA fragment containing JDV tat exon 1 was amplified by PCR from JDV 
genomic DNA (Panel A) and cloned into pVAX1 to create pVAX/tat.  Two 
constructs containing JDV tat were identified (pVAX/tat-E and pVAX/tat-
N/E) by PCR with 2 sets of primers: vector forward-insert reverse (lanes 1 
and 2) and vector forward-reverse (lanes 3 and 4).  These 2 constructs 
were subjected to restriction enzyme analysis by digestion with EcoRI (lane 
5) and NheI/EcoRI (lane 6) to confirm their identity.  The marker (lane M) 
was a 100 bp DNA Ladder (Invitrogen). 
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Detection of tat-specific transcripts by RT-PCR 
Transcription of JDV tat mRNA was detected by RT-PCR in COS7 cells 
transfected with pVAX/tat.  Two days after transfection of COS7 cells, total RNA 
was extracted and reverse transcribed to synthesise cDNA and PCR analysis 
using T7 and jtatV1 primers identified the correct products depending on the 
pVAX/tat constructs tested (pVAX/tat-E or pVAX/tat-N/E) as shown in Figure 5.3.  
No significant differences in the level of transcription by the two pVAX/tat 
constructs, judged by the amount of product detected in agarose gels, was 
detected even though there were differences in the distance between coding 
sequences and the promoter in the 2 constructs. 
 
Figure 5.3.  Detection of tat transcripts by RT-PCR.  Two days after 
transfection with pVAX/tat, total cellular RNA was extracted and reverse-
transcribed.  Primers T7 and jtatV2 were used to detect the mRNA 
transcript.  Lane 1, non-transcribed RNA; lane 2, pVAX; lane 3 and 4, 
pVAX/tat-E and pVAX/tat-N/E, respectively; M, 100 bp DNA Ladder. 
Immunofluorescence detection of Tat in transfected cells 
The presence of Tat protein in transfected cells was detected serologically by 
indirect immunofluorescence assays using polyclonal sheep anti-Tat serum.  
Confocal laser microscopy of COS7 cells transiently transfected with either  
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Figure 5.4.  Detection of Tat in transfected COS7 cells.  The presence of Tat protein expressed in Cos7 cells transiently (A) 
and stably (B) transfected with pVAX/tat and pcDNA/tat, respectively, was detected using appropriate primary antibodies.  
Both transfections show fluorescence detected predominantly in a perinuclear location (Panel A and insert, magnification 
x400 and x1,000, respectively) with some protein in an intranuclear location (Panel B, magnification x1,600).     126 
pVAX/tat-E or pVAX/tat-N/E showed Tat accumulated in a predominantly 
perinuclear location and some in an apparently intranuclear location (Figure 5.4).  
To ensure that the localisation preference is independent from methods of 
transfection, COS7 stably transfected with pcDNA/tat developed in Chapter 4 was 
included and similar localisation was detected.   
Functional detection  
Expression of a biologically active Tat protein was verified by co-transfection with 
a reporter plasmid.  A plasmid expressing β-galactosidase under the control of 
JDV promoter was successfully constructed by inserting the LTR fragment (Figure 
5.5A) to replace the CMV promoter in pVAX1/lacZ.  PCR amplification and 
restriction enzyme digestion identified the correct constructs (Figure 5.5B and C, 
respectively).  Nucleotide sequence analysis confirmed the integrity of the 
reporter plasmid which was 396-bp shorter than the parent plasmid.   
The reporter plasmid pLTR/lacZ was co-transfected into COS7 and FBL cells with 
pVAX1 or pVAX1/tat.  In COS7 cells transfected with pLTR/lacZ and pVAX1, β-
galactosidase expression was absent (Figure 5.6, Panel A) whereas when the 
cells were co-transfected with pVAX/tat and pLTR/lacZ cells, intracellular β-
galactosidase activity was demonstrated (Figure 5.6 Panel B) indicating efficient 
trans-activation of the JDV promoter by a biologically active Tat protein.  When 
FBL cells were transfected, a transfection efficiency with pVAX1/lacZ of about 40 
% was detected, less than the 55–60 % obtained in COS7 cells (Figure 5.7, Panel 
A).  A relatively high basal LTR activity demonstrated in previous study utilising a 
chloramphenicol acetyltransferase (CAT) reporter plasmid (Chen et al., 1999) was 
not detected following pLTR/lacZ and pVAX1 transfection.  However, when 
pVAX/tat and pLTR/lacZ were co-transfected, JDV LTR was able to stimulate β-
galactosidase expression as cells expressing β-galactosidase were detected 
(Figure 5.7, Panels B and C) although most of the β-galactosidase-containing 
cells had abnormal shapes, suggesting perhaps a detrimental effect of Tat in 
these cells.  
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Figure 5.5.  PCR amplification and colony screening of the reporter plasmid.  Panel A.  The amplified LTR promoter of 257 bp 
(lane 2) was cloned in pVAX1/lacZ to replace the CMV promoter to create a reporter plasmid pLTR/lacZ. Lane 1, water 
control.  Panel B.  four clones were PCR amplified using primers VAX and BGH (Table 5.1) to screen for constructs of the 
appropriate size as shown by the approximately 3.5 Kb amplification product (lanes 2, 3 and 5). Lane 1, water control; lane 
4, incorrect clone.  Panel C.  Undigested and NheI digested pVAX1/lacZ (lanes 1 and 2) and undigested and NheI digested 
pLTR/lacZ (lanes 3 and 4) indicating the smaller size of the pLTR/lacZ construct relative to pVAX1/lacZ.  Lane M, 100 bp and 
1 Kb Plus DNA Ladders used as marker  
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Figure 5.6.  Trans-activation assay in COS7 cells.  The JDV LTR is a weak promoter; minimal expression of β-galactosidase 
was demonstrated in cells transfected with the reporter plasmid pLTR/lacZ (Panel A), in contrast to the enhanced β-
galactosidase expression in cells co- transfected with pLTR/lacZ and pVAX/tat (Panel B ) demonstrating the trans-activating 
effect of Tat in the JDV LTR.  
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Figure 5.7.  Transfection and trans-activation in FBL cells.  Panel A, FBL cells transfected with pVAX1/lacZ demonstrating 
excellent β-galactosidase production in cells and a transfection efficiency of about 40 %.  Panels B and C, enhanced 
expression of β-galactosidase in cells co-transfected with pLTR/lacZ and pVAX/tat demonstrating the effect of Tat in 
activating the normally weak JDV promoter.   130 
Discussion 
The results obtained clearly demonstrated that it was possible to generate a 
functional DNA plasmid expressing the first exon of JDV tat.  It was demonstrated 
that the tat gene was transcribed and Tat protein was produced in cells 
transfected with the construct.   
In immunofluorescence assay to detect Tat expression in transfected cell, it was 
demonstrated for the first time the cellular localisation of JDV Tat.  Both transient 
and stable transfection revealed the concentration of Tat in nuclear periphery and 
only partially intra-nucleus.  Perinuclear localisation of JDV Tat was in contrast to 
the intranuclear confinement of BIV Tat (Fong et al., 1997).  A nuclear location of 
Tat is thought to be associated with its transcriptional regulatory activity and is 
linked to the transduction domain in the basic residues (Hauber et al., 1987; 
1989; Mann & Frankel, 1991; Vives et al., 1997).  Transcriptional activation in 
HIV-1 is a resultant of multiple interactions of Tat
 with cellular proteins and the 
LTR promoter, particularly TAR (reviewed in Rana & Jeang, 1999).  The 
observations made in this current study with JDV Tat suggest there was only a 
low level of Tat in the nucleus but that this low level was sufficient for its 
functional activity; extensive nuclear accumulation of Tat did not seem to be 
essential for Tat function.  This situation is similar to that reported for HIV-1 Tat, 
whose subcellular localisation is a dynamic process which reflects viral 
pathogenesis (Marasco et al., 1994);(Marcello et al., 2001; Orsini & Debouck, 
1996; Ranki et al., 1994; Rohr et al., 2003; Stauber & Pavlakis, 1998).  The 
predominant localisation of JDV Tat in nucleus periphery rather than nucleus 
observed in these current studies, together with previous findings of its ability to 
functionally substitutes HIV-1 Tat in partially TAR-dependent fashion (Chen et al., 
2000) suggest a possible unique molecular mechanism of trans-activation which 
merits further study.   
During trans-activation study in COS7 and primary FBL cells, 3 differences were 
noted.  Firstly, a high basal level of JDV LTR activity in FBL cells demonstrated in   131 
the previous study (Chen et al., 1999) was not detected in this experiment; the 
reasons are unclear but the different reporter systems may be partly responsible.  
The larger size of β-Gal relative to the CAT gene used by Chen et al. (1999) 
might have contributed to this discrepancy.  Second, cytopathic effects as a 
consequence of transfection of pVAX/tat in FBL were greater than in COS7 cells.  
The reason for this is not known but possibilities include an apoptotic effect (Li et 
al., 1995a; McCloskey et al., 1997; Zauli et al., 1995a), cell death (Adams et al., 
1999; Conant et al., 1996) and activation of cellular genes (Badou et al., 2000; Ott 
et al., 1997) as a consequence of Tat production.  In addition, given the broad 
trans-activating capability of JDV Tat (Chen et al., 1999; 2000; Smith et al., 
2000), it could have been due to other virus infection in the FBL cells used in the 
experiments.  Third, greater enhancement of β-galactosidase production was 
observed in pLTR/lacZ and pVAX1/tat co-transfected COS7 cells than in FBL 
cells.  This finding is conceivable as COS7 cells express the SV40 large T-
antigen which allows plasmid replication to a high copy number (Harvey et al., 
1997). 
In contrast to the apparent cell species specificity of HIV-1 Tat (Alonso et al., 
1992; Bieniasz et al., 1998; Luo et al., 1993), JDV Tat appears to be functional in 
cells of non-bovine origin: JDV Tat was functional in both COS7 cells of non-
human primate origin and bovine lung cells.  The functional activity of JDV Tat in 
cells of different animal origin is consistent with previous findings for JDV Tat by 
(Chen et al., 1999) and similar to that reported for the other bovine lentivirus, 
Bovine immunodeficiency virus (Bogerd et al., 2000).   
Reports that detergent-inactivated virus preparations derived from tissues of 
infected animals can be used to induce a protective immunity suggests that the 
immunological response resulting in this protective immunity may be antibody-
mediated, as such vaccines are normally stronger inducers of an antibody 
response than a cell-mediated response (Ada, 2001).  However, the protection 
induced by immunisation with this crude vaccine preparation provides only partial 
protection and it only ameliorates and partially inhibits subsequent JDV infection 
(Hartaningsih et al., 2001) suggesting methods that induce a cell-mediated   132 
immunity may be more effective methods of inducing a protective immunity.  The 
recovery from acute phase disease also appears to occur prior to the 
development of an antibody response (Hartaningsih et al., 1994), and although 
definitive evidence of the early development of cell-mediated coincident with 
recovery from the acute phase disease is not available, it is possible.  It is 
generally accepted that DNA vaccines are potential inducers of a cell-mediated 
immune response (Boyle et al., 1997; Donnelly et al., 2000) and the value of 
investigating such DNA vaccines as a potential means of control of Jembrana 
disease seems worthwhile.  DNA vaccine would be safer vaccines than the 
current inactive vaccine and could be used in areas of Indonesia where Bali cattle 
population is high and Jembrana disease has not been detected.  
Animal experimentation to further evaluate the in vivo activity of the construct was 
not attemped. If DNA vaccination against Jembrana disease is considered in the 
future, this construct should be evaluated as a candidate vaccinevaccine, alone 
or in combination with a recombinant virus protein vaccine.  A prime-boost 
vaccination strategy using a DNA priming inoculation, followed by recombinant 
viral boost has been used to achieve long term and enhanced cellular and 
humoral immune responses (Billaut-Mulot et al., 2001; Cantlon et al., 2000; 
Markowska-Daniel et al., 2001; Putkonen et al., 1998; Ruitenberg et al., 2000; 
Zhang et al., 1997). 
Assays to detect the protein antigen and trans-activation activity of JDV Tat 
developed during this study may provide tools for monitoring quality of the 
construct if large-scale production was undertaken.  Although vaccination with 
biologically active HIV-1 Tat in healthy animals was safe (Barillari et al., 1999; 
Cafaro et al., 2001), concerns regarding the detrimental effects of this protein on 
cells have led to research to generate an alternative functionally inactive but 
immunogenic Tat for prophylactic and therapeutic purposes (Betti et al., 2001; 
Caselli et al., 1999; Gallo, 1999; Gringeri et al., 1998; Pauza et al., 2000).  
Therefore, the techniques would be useful for the development of a functionally 
attenuated Tat construct.   133 
Chapter 6   
General Discussion 
Attempts to control lentivirus infections in a number of animal species and 
particularly HIV-1 in man have utilised a variety of strategies.  These have 
included attempts to stimulate humoral and cellular immune responses to a 
variety of virus components, including Tat.  Tat is particularly essential for virus 
replication (Cullen, 1998; Jeang et al., 1999) and is expressed early in the 
replicative cycle of the virus preceding the integration of the RNA genome (Wu & 
Marsh, 2001).  Thus, the induction of an immune response against Tat allows the 
elimination of infected cells before progeny virus is released.  There is evidence 
suggesting that an immune response against Tat correlates with low viral load 
and delayed progression to AIDS (Addo et al., 2001; Re et al., 2001a; van Baalen 
et al., 1997; Zagury et al., 1998b) and immunisation with Tat may be more 
efficacious
 in controlling infection than a comparable response to the viral
 
structural proteins (Poznansky et al., 1998; Stittelaar et al., 2002).  Tat delivered 
either as subunit protein or naked DNA has shown promising results in macaque 
models (Cafaro et al., 1999; Cafaro et al., 2001; Goldstein et al., 2000; Pauza et 
al., 2000).   
JDV infection in Bali cattle produces an acute and severe lymphoproliferative 
syndrome; the acute nature of Jembrana disease is not unique but uncommon in 
the lentiviruses.  About 80 % of cattle recover from the acute infection, almost 
complete recovery occurs over about a 6-week period following the end of the 
febrile phase that coincides with virus clearance (Soeharsono et al., 1990).  It was 
previously shown by Chen et al. (1999) that JDV Tat encoded by exon 1 was a 
strong and ubiquitous trans-activator and it was hypothesised that this strong 
trans-activating ability might be associated with the high level of virus replication 
and acute and severe nature of the virus infection in Bali cattle.  This was one   134 
reason for the selection of Tat as a potential immunogen in this current study, it 
was hypothesised that an immune response against this essential regulatory 
protein could be induced and consequently prevent or reduce the viral burden and 
ameliorate the acute clinical disease.  Investigation of this hypothesis 
necessitated further examination of the characteristics of JDV Tat, as at the 
commencement of the studies very little was known. 
This thesis reports for the first time the transcription pattern of JDV tat gene in 
infected cattle, the sequence variation, the detection of native JDV Tat, the 
expression of JDV Tat encoded by tat exon 1 in bacterial and mammalian cell 
systems, the characteristics of the antigenicity and immunogenicity of the 
expressed proteins, and the production of a potential DNA vaccine based on the 
tat exon 1.  It provides novel information on the characteristics of JDV tat that will 
be significant in future attempts to produce a vaccine for the control of Jembrana 
disease in Indonesia. 
The studies showed that JDV tat transcription in viraemic cattle was characterised 
by four major transcript variants generated by double or multiple splicing events 
involving the two separate tat coding exons.  This was common to all JDV strains 
studied: Tabanan/87, Pulukan/00 and Kalimantan/01.  Sequence analysis of the 
transcripts suggested that only the first coding exon was translated, at least 
during the febrile phase of the disease.  Interestingly, an immunoreactive protein 
product with an apparent molecular mass of 14 kDa was detected in PBMCs 
collected prior to fever, which could probably either one- or two-exon Tat; but 
further characterisation such as aa sequencing is required to confirm the identity 
of the protein.   
In the course of HIV-1 infection, 2 Tat proteins and the respective mRNA 
transcripts have been detected: a full length two-exon Tat (86 or 101-amino acid) 
produced early from multiply spliced transcripts, and a one-exon Tat (72-amino 
acid) produced later from singly spliced transcripts that requires Rev for 
cytoplasmic transport (Malim et al., 1988; Powell et al., 1997; Purcell & Martin, 
1993).  The full length Tat has been suggested to enhance HIV-1 replication in   135 
vitro (Verhoef et al., 1998) especially in macrophages (Neuveut et al., 2003).  In 
experimentally infected macaques, and HIV-1 positive individuals, dynamic 
changes in Tat formation similar to the in vitro effects observed by Malim et al. 
(1988) were also observed (Smith et al., 2003): acute viraemia was associated 
with the two-exon Tat, the subsequent asymptomatic period was associated with 
the smaller one-exon Tat, and the progression to clinical disease was associated 
with a shift from one-exon to two-exon Tat form.  In JDV infection there may also 
be variation in tat transcription and translation and it would be of great interest to 
examine the splicing pattern of JDV in the early phase of infection and in 
recovered animals that are resistant to re-infection and have a persistent low level 
viraemia (Soeharsono et al., 1990), when it is possible that exon 2 might also be 
translated. 
The sequence of both tat exons in three strains of JDV from two quite different 
regions of Indonesia was determined, as variation could have a significant effect 
on the antigenicity of the expressed product.  It has been reported in HIV-1 that 
Tat mutation preserves the trans-activation activity, but affects antigenic cross-
recognition between variants (Butto et al., 2003; Opi et al., 2002; Tikhonov et al., 
2003).  In this study of JDV, variation was detected in exon 1, solely caused by 
nucleotide substitutions which resulted in alteration of encoded amino acids, and 
particularly evident when comparing strains from geographically-different regions 
(Bali compared to Kalimantan).  The mutations occurred mainly in the N- and C- 
terminal domains, and did not affect the cysteine residues in the Cys-rich, the 
whole core and basic domains.  Indeed, epitope mapping of HIV-1 Tat has 
demonstrated that the major immunodominant epitope is contained within the 
basic region (Tosi et al., 2000).  It would be unlikely, therefore, that the 
immunogenicity of the essential functional domains of JDV Tat would vary, and it 
could be expected that if Tat was used for immunisation to effect a protective 
immunity, that a single Tat encoded by any strain would be effective. 
Rapid genetic variation during in vivo HIV-1 infection is driven by immunological 
and/or therapeutic pressures, and facilitated by the error-prone reverse 
transcriptase, recombination and high virus replication (Coffin, 1995; Wain-  136 
Hobson, 1993).  It could be possible that JDV tat sequence variation observed in 
exon 1 in this study reflects
 immune selection or the consequent evolution
 of virus 
escape variants.  The absence of sequence variation, interestingly, was evident in 
the second tat coding exon that may not be translated, and conservation 
generally reflects functional importance.  Being untranslated as a Tat protein 
might be a way of maintaining the sequence conservation of this segment that 
could possibly bear a functional significance as part of other ORFs, such as Rev 
or Tmx.  Further studies will have to be performed to explore these hypotheses.   
Substantiation of the antigenicity and immunogenicity of Tat encoded by exon 1 
was achieved via the production of recombinant Tabanan/87 JDV Tat.  The 
recombinant Tat was expressed in E. coli and the protein was shown to induce a 
specific antibody response in both sheep and cattle.  The Tabanan/87 strain is an 
unofficial type strain, and at the time the studies reported in this thesis were 
commenced, it was the only strain that had been fully sequenced.  It is the strain 
that was used by others in Indonesia for the production of a crude whole virus 
vaccine (Hartaningsih et al., 2001).  The pGEX expression vector produced a high 
yield of protein and there is the potential for this system to be used for the 
production of vaccine within Indonesia, if it was proved to be an effective 
immunogen for stimulating a protective immunity against Jembrana disease.  
Specific antibodies against JDV Tat were elicited following the injection of the 
recombinant Tat into sheep; the antibodies were reactive with native Tat detected 
in cattle infected with the homologous Tabanan/87 strain.  Importantly, they were 
also reactive with the heterologous Pulukan/00 and Kalimantan/01 strains, 
indicating conservation of the reactive antigenic domains in these three strains 
consistence with the sequence conservation.  Indeed, monoclonal antibodies 
against the basic region of HIV-1 Tat has been shown to inhibit the trans-
activation activity of exogenous Tat by preventing its uptake by the cell (Tosi et 
al., 2000) and recognise Tat proteins from the geographically diverse strains of 
HIV-1 (Goldstein et al., 2001; Moreau et al., 2004; Tikhonov et al., 2003). 
Antibody reactive with the recombinant Tabanan/87 Tat was detected in Bali 
cattle that had recovered from experimental infection with the homologous strain   137 
and in cattle vaccinated with the crude whole virus vaccine preparation prepared 
from tissues of cattle infected with the homologous Tabanan/87 strain 
(Hartaningsih et al., 2001).  JDV Tat antibody was detected in only 24 % of JDV 
ELISA-positive animals tested, which probably detects mainly capsid antibody 
(Hartaningsih et al., 1994).  In comparison to antibody levels induced in cattle by 
the recombinant Tat, the levels of Tat antibody in naturally-infected and 
vaccinated cattle appeared relatively less as determined by the weak reactivity in 
Western blots (Chapter 4).  Native JDV Tat appears to be a weaker immunogen, 
possibly due to differences in the conformational epitopes (Moreau et al., 2004) of 
the native and recombinant proteins.   
The low prevalence of antibody to Tat in recovered and vaccinated animals is 
similar to that which has been noted in HIV-1 infected individuals (Butto et al., 
2003; Krone et al., 1988).  The presence of this low level of HIV Tat antibody 
seems significant; however, as it has been associated with non-progression to 
clinical disease (Re et al., 2001b; Zagury et al., 1998b).  In Chapter 4, 
observation of Tat antibody responses in three experimentally infected cattle over 
6-month period demonstrated that the strongest response was achieved 1 month 
after infection and decreased with time relative to the response against capsid, 
suggesting the possibility that down-regulation of virus replication was associated 
with Tat antibody.  Although CTL responses during JDV infection have not been 
determined, it was possible that CTLs are induced prior to the antibody 
production and might therefore control the infection. 
Studies to determine the ability of the recombinant Tat to induce a protective 
immunity are currently in progress in Indonesia.  Initial observations (Dr Moira 
Desport, Personal Communication) suggest that immunisation with 1 mg of the 
protein on 3 occasions at 2-week intervals was able to effect a reduction in the  
severity of the disease induced by challenge with homologous strains of virus 
after an interval of 2–3 weeks.  Such a recombinant protein preparation would be 
a safer vaccine than the crude whole virus preparation currently being used in 
Indonesia.  Future studies to enhance the immunogenicity of the recombinant Tat 
antigen, perhaps by careful selection of adjuvants and other immunomodulators,   138 
perhaps by use of alternative methods of solubilisation and refolding of the 
protein, are warranted. 
It is recognised that the studies reported in this thesis concentrated on the 
determination of immunogenicity and antigenicity based on the production of an 
antibody (B cell)-mediated immune response, and no attempt was made to 
examine if the recombinant Tat could induce a T cell-mediated immunity, or if 
such cell-mediated immunity is induced to Tat in JDV-infected cattle.  This could 
be extremely important: cell-mediated immune responses play a major part in 
reducing pathogenic events in many viral infections including HIV (Klein & Horejs, 
1997).   Virus-specific CTL responses control HIV-1 replication (Mackewicz et al., 
1995; Toso et al., 1995) and are thought to be associated with a reduction in the 
viraemia during the acute phase of infection (Borrow et al., 1994; Koup et al., 
1994; Musey et al., 1997)  This arm of the immune response appears to be 
important in maintaining the prolonged asymptomatic stage in HIV-infected 
persons (Klein et al., 1995; Pantaleo et al., 1997; Rinaldo et al., 1995) and high 
levels of  HIV Tat-specific CTL activity associated with a low viral load are thought 
to contribute to a lack of disease in HIV-1-infected long-term non-progressors 
(van Baalen et al., 1997). 
It can not be assumed that a recombinant protein would be an effective means if 
induction of a cell-mediated immune response.  It has been generally accepted 
that endogenous antigen synthesis and processing likely to be achieved through 
DNA vaccination would result in a more effective means of inducing a protective 
immune response than immunisation with subunit protein vaccines (Cichutek, 
2000; Donnelly et al., 1997; 2000).  In this thesis, the studies undertaken 
(Chapter 5) to develop a candidate JDV tat DNA vaccine could be very important 
in future attempts to induce a protective CTL-mediated immunity against JDV 
infection.  A DNA plasmid encoding JDV tat was produced (Chapter 5) and it was 
demonstrated by immunofluorescence and trans-activation assays that the 
construct was able to induce protein expression in culture of mammalian cells 
including primary bovine lung cells.  The next logical phase of experimentation is 
to demonstrate if the construct is able to induce a protective immunity in Bali   139 
cattle.  The use of naked plasmid constructs for immunisation (DNA vaccination) 
is an attractive option especially in Indonesia, as it could enable the production of 
vaccine at a reasonably low cost, which should be stable at room temperature 
and perhaps avoiding dependence on a cold chain (Finn & Bell, 1998; Giese, 
1998).  Future research would need to consider details such as the method of 
administration of the vaccine, the dose and frequency of administration, and the 
effect of immunomodulators such as cytokines.  In conjunction with the 
recombinant Tat, a prime-boost immunisation approach to achieve a beter 
immune response is also warranted.   
In conclusion, characteristics of JDV Tat during the acute stages of Jembrana 
disease have been determined.  These studies enabled the development of 
recombinant Tat proteins that were immunogenic and reacted with antibody 
developed in some recovered cattle.  It is considered likely that this recombinant 
protein has potential application as a vaccine for the control of Jembrana disease 
in Indonesia, and it is currently being evaluated for this in Indonesia.  A potential 
tat DNA vaccine was also produced and shown to express JDV Tat in vitro and is 
now being further evaluated in cattle. 
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